APPROVED DRUG PRODUCTS
With Therapeutic Equivalence Evaluations

The "Orange Book"

FDA data supplied by DrugPatentWatch.com

CUMULATIVE SUPPLEMENT 12
JAN'98-DEC'98



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

18TH EDITION

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF INFORMATION TECHNOLOGY
DIVISION OF DATA MANAGEMENT AND SERVICES

1998

SUBSCRIBE NOW!

Available in March 1999

New 19th Edition



APPROVED DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

19TH EDITION
1999

CONTENTS

- Prescription Drug Product List
- OTC Drug Product List
- Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List
- Discontinued Drug Product List
- Orphan Drug Product Designations
- Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution
- Patent and Exclusivity Information

See Subscription Form Inside Back Cover

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

18TH EDITION

Cumulative Supplement 12

DECEMBER 1998

CONTENTS

		PAGE
1.0	INTRODUCTION	iii
1.1	How to Use the Cumulative Supplement	iii
1.2	Applicant Name Changes	iv
1.3	Acyclovir 200 mg Tablet-Reference Listed Drug	vi
1.4	Diclofenac Sodium Ophthalmic Solution	vi
1.5	Ribavirin 200 mg Oral Capsule	vi
1.6	Follitropin Alfa and Beta	vi
1.7	Availability of the Publication and Updating Procedures	vii
1.8	Report of Counts for the Prescription Drug Product List	viii
2.0	DRUG PRODUCT LISTS	
2.1	Prescription Drug Product List	1
2.2	OTC Drug Product List	79
2.3	Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List	82
2.4	Orphan Product Designations and Approvals List	83
2.5	Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution	98
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM		
A.	Patent and Exclusivity Terms	99
B.	Patent and Exclusivity Lists	103

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

18TH EDITION

CUMULATIVE SUPPLEMENT 12
DECEMBER 1998

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 18th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Patent and Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the patent and/or exclusivity expires. Refer to the Patent and Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Information regarding drug patents and exclusivity for an approved product will appear in this addendum as it is received and may not correspond with the month the drug product is approved and published in the Rx/OTC sections of the Cumulative Supplement.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

New additions to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol **>ADD>** to the left of the line on which new information exists. The **>ADD>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol **>DLT>** (DELETE) to the left of the line. The **>DLT>** symbol is dropped in subsequent Cumulative Supplements for that item. The shaded print remains in the Prescription Drug Product List and OTC Drug Product Lists in all Cumulative Supplements (hard copy only) for this edition. However, the overstruck data in the Patent and Exclusivity Data is dropped in subsequent Cumulative Supplements (hard copy).

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 18th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 19th Edition.

1.2 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will automatically reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. However, when the applicant name change is one which may not be easily recognized or located in the listing (e.g., White Towne Paulsen [Former Abbreviated Name] is changed to Whiteworth Towne PLSN [New Abbreviated Name], the name change will appear in this section and will be identified with an asterisk.

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
ASTRA MERCK INC (ASTRA MERCK)	ASTRA PHARMACEUTICALS LP (ASTRA PHARMS)
ASTRA USA INC (ASTRA)	ASTRA PHARMACEUTICALS LP (ASTRA PHARMS)
DUPONT RADIOPHARMACEUTICALS DIV (DUPONT)	DUPONT PHARMACEUTICALS COMPANY (DUPONT PHARMS)
FUJISAWA USA INC (FUJISAWA)	AMERICAN PHARMACEUTICAL PARTNERS INC (AM PHARM PARTNERS)
GENSIA INC (GENSIA)	GENSIA SICOR PHARMACEUTICALS INC (GENSIA SICOR PHARMS)
GENSIA LABORATORIES LTD (GENSIA)	GENSIA SICOR PHARMACEUTICALS INC (GENSIA SICOR PHARMS)
JONES MEDICAL INDUSTRIES INC (JONES MEDCL INDS)	JONES PHARMA INC (JONES PHARMA)
MERCK RESEARCH LABORATORIES DIV MERCK AND CO INC (MERCK)	MERCK AND CO INC (MERCK)
MERCK SHARP AND DOHME DIV MERCK AND CO INC (MERCK)	MERCK AND CO INC (MERCK)
ZENITH LABORATORIES (ZENITH LABS)	ZENITH GOLDLINE PHARMACEUTICALS (ZENITH GOLDLINE)

1.3 ACYCLOVIR 200MG TABLET-REFERENCE LISTED DRUG

Novopharm's single source acyclovir tablets have been declared to be a reference listed drug for the 200 mg tablet in addition to the acylcovir (Zovirax) 800 mg tablet of the innovator. A generic firm wishing to submit an ANDA for a duplicate of the 200 mg acyclovir tablet will be eligible for a waiver of the *in vivo* determination of bioequivalence (1) if their product is proportionally similar in its active and inactive ingredients to their own 800 mg acyclovir tablet and (2) by doing an acceptable comparative dissolution test (dissolution profile) against Novopharm's 200 mg acyclovir reference listed drug.

Before a waiver of the *in vivo* determination of bioequivalence can be granted for the 200 mg acyclovir tablet, the generic firm must have completed an acceptable fasting and fed study comparing their acyclovir 800 mg tablet against the Zovirax 800 mg tablet.

For further information on the study designs, you should contact the Division of Bioequivalence, Office of Generic Drugs.

1.4 DICLOFENAC SODIUM OPHTHALMIC SOLUTION 0.1%

Two NDAs have been approved for diclofenac sodium ophthalmic solution 0.1% (DSOS), (1) Ciba's NDA 20-037 for Voltaren and (2) Alcon's NDA 20-809 for DSOS. Alcon was required to do a study comparing their DSOS to Voltaren and to a placebo control in post cataract surgical inflammation. This study was necessary to demonstrate that the different formulation of the Alcon drug product did not affect the safety and/or effectiveness of the proposed drug product for this indication. Prior to the approval of Alcon's DSOS Ciba did clinical studies and was approved for two additional indications for the temporary relief of pain and photophobia in patients undergoing corneal refractive surgery. Three years of Waxman-Hatch marketing exclusivity was granted to Ciba for these two new uses.

Since the treatment of pain has a different site of action than the anti-inflammatory or photophobia indications the Agency did not have information to support a recommendation that the Alcon and Ciba DSOS are therapeutically equivalent for the treatment of pain. The designation of therapeutic equivalence at this time applies only to the anti-inflammatory indication. The therapeutic equivalence designation will apply to the photophobia indication upon expiration of Ciba's marketing exclusivity.

1.5 RIBAVIRIN 200MG ORAL CAPSULE

Indicated for use and comarketed with interferon alfa-2b, recombinant (Intron A), as Rebetron Combination Therapy.

1.6 FOLLITROPIN ALFA AND BETA

Based on available data derived from physico-chemical tests and bioassay, follitropin alfa and follitropin beta are indistinguishable.

1.7 AVAILABILITY OF THE PUBLICATION AND UPDATING PROCEDURES

The *Approved Drug Products with Therapeutic Equivalence Evaluations* files are available on Internet. There is more than one media users may select to access these files.

Preface and ASCII Text Files:
The Preface may be accessed using this URL: http://www.fda.gov/cder/orange/adp.htm. Users who wish to download the Prescription Drug Product List; OTC Drug Products and Discontinued Drug Products lists may access the ASCII text files using this URL: htttp://www.fda.gov/cder/orange/obreadme.htm. The drug product lists and the zipobtxt.exe files are updated concurrently with the publication of the annual edition or monthly cumulative supplements. Appendix A and B are updated twice a year.

Preface and Searchable Query Database:
The Preface may be accessed using this URL: http://www.fda.gov/cder/ob/docs/preface/ectablec18.htm. Users who wish to query on a specific drug product may access the database using this URL: http://www.fda.gov/cder/ob. The Query enables searching of the database by active ingredient, proprietary name, applicant holder or applicant number. The data is updated concurrently with the publication of the annual edition or monthly cumulative supplements.

1.8 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 1997) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 1997	JUN 1998	SEP 1998	DEC 1998
DRUG PRODUCTS LISTED	9624	9768	9798	9923
SINGLE SOURCE	2462 (25.6%)	2494 (25.6%)	2479 (25.3%)	2504 (25.2%)
MULTISOURCE	7052 (73.3%)	7164 (73.3%)	7208 (73.6%)	7308 (73.6%)
THERAPEUTICALLY EQUIVALENT	6673 (69.3%)	6790 (69.5%)	6829 (69.7%)	6934 (69.9%)
NOT THERAPEUTICALLY EQUIVALENT	379 (4.0%)	374 (3.8%)	379 (3.9%)	374 (3.8%)
EXCEPTIONS[1]	110 (1.1%)	110 (1.1%)	111 (1.1%)	111 (1.1%)
NEW MOLECULAR ENTITIES APPROVED	--	9	4	10
NUMBER OF APPLICANTS	551	538	551	563

[1]Amino acid-containing products of varying composition (see Introduction, page xx of the List).

> ADD > ABACAVIR SULFATE

> ADD > SOLUTION; ORAL
> ADD > ZIAGEN
> ADD > + GLAXO WELLCOME EQ 20MG BASE/ML N20978 001 DEC 17, 1998
> ADD >

> ADD > TABLET; ORAL
> ADD > ZIAGEN
> ADD > + GLAXO WELLCOME EQ 300MG BASE N20977 001 DEC 17, 1998
> ADD >

ACARBOSE

TABLET; ORAL
PRECOSE
@ BAYER 25MG N20482 004 MAY 29, 1997

25MG N20482 004 MAY 29, 1997

ACETAMINOPHEN; BUTALBITAL

TABLET; ORAL
BUTALBITAL AND ACETAMINOPHEN
AB DANBURY PHARMA 325MG;50MG N87550 001 OCT 19, 1984

@ 325MG;50MG N87550 001 OCT 19, 1984

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE
AB WEST WARD 500MG;50MG;40MG N40261 001 OCT 28, 1998

ESGIC-PLUS
AB + MIKART 500MG;50MG;40MG N40085 001 MAR 28, 1996

TABLET; ORAL
ACETAMINOPHEN, BUTALBITAL AND CAFFEINE
AB GILBERT LABS 325MG;50MG;40MG N87629 001 NOV 13, 1984

@ 325MG;50MG;40MG N87629 001 NOV 13, 1984

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET; ORAL
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE
AB MALLINCKRODT 325MG;50MG;40MG N87804 001 JAN 24, 1985
AB + MIKART 500MG;50MG;40MG N89451 001 MAY 23, 1988
AB WATSON LABS 500MG;50MG;40MG N40267 001 JUL 30, 1998

REPAN
AB MALLINCKRODT 325MG;50MG;40MG N87804 001 JAN 24, 1985

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL
ACETAMINOPHEN AND CODEINE PHOSPHATE
AA ROYCE LABS 300MG;15MG N89997 001 DEC 28, 1994
AA 300MG;30MG N89998 001 DEC 28, 1994
AA 300MG;60MG N89999 001 DEC 28, 1994
AA WATSON LABS 300MG;15MG N89997 001 DEC 28, 1994
AA 300MG;30MG N89998 001 DEC 28, 1994
AA 300MG;60MG N89999 001 DEC 28, 1994

ACETAMINOPHEN AND CODEINE PHOSPHATE #3
AA PUREPAC PHARM 300MG;30MG N89080 001 JUL 17, 1986

@ 300MG;30MG N89080 001 JUL 17, 1986

ACETAMINOPHEN; HYDROCODONE BITARTRATE

ELIXIR; ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN
AA + MIKART 500MG/15ML;7.5MG/15ML N81051 001 AUG 28, 1992
AA PHARM ASSOC 500MG/15ML;7.5MG/15ML N40182 001 MAR 13, 1998

TABLET; ORAL
CO-GESIC
> DLT > AA CENT PHARMS 500MG;5MG N87757 001 MAY 03, 1982
> DLT >

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

CO-GESIC

> ADD >	AA	SCHWARZ PHARMA	500MG;5MG	N87757 001
> ADD				MAY 03, 1982

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

	AA	ENDO PHARMS	500MG;5MG	N40281 001
				SEP 30, 1998
	AA		500MG;7.5MG	N40280 001
				SEP 30, 1998
	AA		650MG;7.5MG	N40280 002
				SEP 30, 1998
	AA		650MG;10MG	N40280 003
				SEP 30, 1998
	AA		750MG;7.5MG	N40281 002
				SEP 30, 1998
			400MG;5MG	N40288 001
				NOV 27, 1998
			400MG;7.5MG	N40288 002
				NOV 27, 1998
			400MG;10MG	N40288 003
				NOV 27, 1998
	AA	MALLINCKRODT	500MG;7.5MG	N40201 001
				FEB 27, 1998
	AA		500MG;10MG	N40201 002
				FEB 27, 1998
	AA	ROYCE LABS	500MG;2.5MG	N40123 003
				MAR 04, 1996
	AA		500MG;5MG	N40122 001
				MAR 04, 1996
	AA		500MG;7.5MG	N40123 004
				MAR 04, 1996
	AA		650MG;7.5MG	N40123 001
				MAR 04, 1996
	AA		650MG;10MG	N40123 002
				MAR 04, 1996
	AA		750MG;7.5MG	N40122 002
				MAR 04, 1996
	AA	WATSON LABS	500MG;2.5MG	N40123 003
				MAR 04, 1996
	AA		500MG;5MG	N40122 001
				MAR 04, 1996
	AA		500MG;7.5MG	N40123 004
				MAR 04, 1996
	AA		650MG;7.5MG	N40123 001
				MAR 04, 1996
	AA		650MG;10MG	N40123 002
				MAR 04, 1996

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

	AA	WATSON LABS	750MG;7.5MG	N40122 002
				MAR 04, 1996

ACETAMINOPHEN; OXYCODONE

CAPSULE; ORAL

OXYCODONE AND ACETAMINOPHEN

	AA	HALSEY	500MG;5MG	N40219 001
				JAN 22, 1998

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

OXYCODONE AND ACETAMINOPHEN

> ADD >	AA	AMIDE PHARM	500MG;5MG	N40199 001
> ADD >				DEC 30, 1998
	AA	MALLINCKRODT	500MG;5MG	N40257 001
				AUG 04, 1998
	AA	ROYCE LABS	500MG;5MG	N40234 001
				OCT 30, 1997
	AA	WATSON LABS	500MG;5MG	N40234 001
				OCT 30, 1997

TABLET; ORAL

OXYCODONE AND ACETAMINOPHEN

	AA	DURAMED	325MG;5MG	N40272 001
				JUN 30, 1998
	AA	ROYCE LABS	325MG;5MG	N40171 001
				OCT 10, 1997
	AA	WATSON LABS	325MG;5MG	N40171 001
				OCT 30, 1997

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

TABLET; ORAL

PROPOXYPHENE HCL AND ACETAMINOPHEN

	AA	ROYCE LABS	650MG;65MG	N40139 001
				DEC 16, 1996
	AA	WATSON LABS	650MG;65MG	N40139 001
				DEC 16, 1996

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

> DLT >	**AB**	TEVA	**650MG;100MG**	**N70732 001** JAN 03, 1986
> DLT >				
> ADD >		@	650MG;100MG	N70732 001 JAN 03, 1986
> ADD >				

ACETIC ACID, GLACIAL

SOLUTION; IRRIGATION, URETHRAL
ACETIC ACID 0.25% IN PLASTIC CONTAINER

AT	B BRAUN	**250MG/100ML**	**N18161 001**
AT	MCGAW	**250MG/100ML**	**N18161 001**

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS; OTIC
HYDROCORTISONE AND ACETIC ACID

AT	BAUSCH AND LOMB	**2%;1%**	**N40097 001** OCT 31, 1994
	@	2%;1%	N40097 001 OCT 31, 1994

ACYCLOVIR

CAPSULE; ORAL
ACYCLOVIR

AB	CHELSEA LABS	**200MG**	**N75101 001** APR 15, 1998
AB	GENPHARM	**200MG**	**N74977 001** APR 13, 1998
AB	RANBAXY	**200MG**	**N74975 001** SEP 30, 1998

TABLET; ORAL
ACYCLOVIR

AB	COPLEY PHARM	**400MG**	**N75021 001** MAR 18, 1998
AB		**800MG**	**N75021 002** MAR 18, 1998
AB	GENPHARM	**400MG**	**N74976 001** APR 13, 1998
AB		**800MG**	**N74976 002** APR 13, 1998

ACYCLOVIR

TABLET; ORAL
ACYCLOVIR

AB	MYLAN	**400MG**	**N75211 001** SEP 28, 1998
AB		**800MG**	**N75211 002** SEP 28, 1998
	+ NOVOPHARM	200MG	N74556 001 APR 22, 1997
	@	200MG	N74556 001 APR 22, 1997
AB	RANBAXY	**400MG**	**N74980 001** SEP 30, 1998
AB		**800MG**	**N74980 002** SEP 30, 1998

ACYCLOVIR SODIUM

INJECTABLE; INJECTION
ACYCLOVIR SODIUM

AP	AESGEN	**EQ 500MG BASE/VIAL**	**N75015 001** APR 30, 1998
	+ AM PHARM PARTNERS	EQ 50MG BASE/ML	N74930 001 MAY 13, 1998
AP	APOTHECON	**EQ 500MG BASE/VIAL**	**N74897 001** FEB 27, 1998
AP		**EQ 1GM BASE/VIAL**	**N74897 002** FEB 27, 1998
AP	FUJISAWA	**EQ 500MG BASE/VIAL**	**N74930 001** MAY 13, 1998

ADENOSINE

INJECTABLE; INJECTION
ADENOCARD

	+ FUJISAWA HLTHCARE	3MG/ML	N19937 002 OCT 30, 1989
	+ MEDCO RES	3MG/ML	N19937 002 OCT 30, 1989

ADENOSCAN

	+ FUJISAWA HLTHCARE	3MG/ML	N20059 001 MAY 18, 1995
	+ MEDCO RES	3MG/ML	N20059 001 MAY 18, 1995

ALBUTEROL SULFATE

SOLUTION; INHALATION
ALBUTEROL SULFATE

AN	BAUSCH AND LOMB	EQ 0.5% BASE	N75050 001	JUN 18, 1998
> DLT > AN	COPLEY PHARM	EQ 0.083% BASE	N73495 001	MAY 28, 1993
> DLT > AN		EQ 0.5% BASE	N73307 001	NOV 27, 1991
> DLT >				
> ADD > @		EQ 0.083% BASE	N73495 001	MAY 28, 1993
> ADD >				
> ADD > @		EQ 0.5% BASE	N73307 001	NOV 27, 1991
> ADD >				
AN	HI TECH PHARMA	EQ 0.5% BASE	N74543 001	JAN 15, 1998

SYRUP; ORAL
ALBUTEROL SULFATE

AA	HI TECH PHARMA	EQ 2MG BASE/5ML	N74749 001	JAN 30, 1998
AA	MOVA	EQ 2MG BASE/5ML	N74302 001	SEP 30, 1994
@		EQ 2MG BASE/5ML	N74302 001	SEP 30, 1994

TABLET; ORAL
ALBUTEROL SULFATE

AB	COPLEY PHARM	EQ 2MG BASE	N72966 001	NOV 22, 1991
AB		EQ 4MG BASE	N72967 001	NOV 22, 1991
@		EQ 2MG BASE	N72966 001	NOV 22, 1991
@		EQ 4MG BASE	N72967 001	NOV 22, 1991

ALFENTANIL HYDROCHLORIDE

INJECTABLE; INJECTION
ALFENTA

+	AKORN	EQ 0.5MG BASE/ML	N19353 001	DEC 29, 1986
+	JANSSEN	EQ 0.5MG BASE/ML	N19353 001	DEC 29, 1986

ALLOPURINOL SODIUM

INJECTABLE; INJECTION
ZYLOPRIM

+	CATALYTICA PHARMS	EQ 500MG BASE/VIAL	N20298 001	MAY 17, 1996
+	GLAXO WELLCOME	EQ 500MG BASE/VIAL	N20298 001	MAY 17, 1996

ALPRAZOLAM

TABLET; ORAL
ALPRAZOLAM

AB	GENEVA PHARMS	2MG	N74909 001	MAR 25, 1998
AB	ROYCE LABS	0.25MG	N74479 001	JAN 21, 1997
AB		0.5MG	N74479 002	JAN 21, 1997
AB		1MG	N74479 003	JAN 21, 1997
AB	WATSON LABS	0.25MG	N74479 001	JAN 21, 1997
AB		0.5MG	N74479 002	JAN 21, 1997
AB		1MG	N74479 003	JAN 21, 1997

ALPROSTADIL

INJECTABLE; INJECTION
ALPROSTADIL

AP	BEDFORD	0.5MG/ML	N74815 001	JAN 20, 1998
	CAVERJECT			
> DLT >	PHARMACIA AND UPJOHN	0.005MG/ML	N20755 001	OCT 31, 1997
> DLT >				
> ADD > @		0.005MG/ML	N20755 001	OCT 31, 1997
> ADD >				
	PROSTIN VR PEDIATRIC			
AP +	PHARMACIA AND UPJOHN	0.5MG/ML	N18484 001	
+		0.5MG/ML	N18484 001	

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

		AMANTADINE HCL			
AB		ROSEMONT	100MG	N70589 001	AUG 05, 1986
AB	+		100MG	N70589 001	AUG 05, 1986
		SYMMETREL			
	+	ENDO PHARMS	100MG	N16020 001	
	@		100MG	N16020 001	

SYRUP; ORAL

		AMANTADINE HCL			
> ADD > AA		MORTON GROVE	50MG/5ML	N75060 001	DEC 24, 1998
> ADD >					
		SYMMETREL			
AA	+	DUPONT MERCK	50MG/5ML	N16023 002	
AA	+	ENDO PHARMS	50MG/5ML	N16023 002	

TABLET; ORAL

		SYMMETREL			
	@	ENDO PHARMS	100MG	N18101 001	
	+		100MG	N18101 001	

AMCINONIDE

OINTMENT; TOPICAL

		CYCLOCORT			
	+	LEDERLE	0.1%	N18498 001	
	+	WYETH AYERST	0.1%	N18498 001	

AMILORIDE HYDROCHLORIDE

TABLET; ORAL

		MIDAMOR			
AB	+	MERCK	5MG	N18200 001	
AB	+	MERCK SHARP DOHME	5MG	N18200 001	

AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

		AMILORIDE HCL AND HYDROCHLOROTHIAZIDE			
AB		ROYCE LABS	EQ 5MG ANHYDROUS;50MG	N73334 001	JUL 19, 1991
AB		WATSON LABS	EQ 5MG ANHYDROUS;50MG	N73334 001	JUL 19, 1991
		MODURETIC 5-50			
AB	+	MERCK	EQ 5MG ANHYDROUS;50MG	N18201 001	
AB	+	MERCK SHARP DOHME	EQ 5MG ANHYDROUS;50MG	N18201 001	

AMINO ACIDS

INJECTABLE; INJECTION

		PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER			
	+	BAXTER HLTHCARE	20%	N20849 001	AUG 26, 1998

AMINOCAPROIC ACID

SYRUP; ORAL

		AMICAR			
AA	+	IMMUNEX	1.25GM/5ML	N15230 002	
AA	+		1.25GM/5ML	N15230 002	
		AMINOCAPROIC ACID			
AA		MIKART	1.25GM/5ML	N74759 001	SEP 02, 1998

AMIODARONE HYDROCHLORIDE

TABLET; ORAL

		AMIODARONE HCL			
AB		COPLEY PHARM	200MG	N74739 001	NOV 30, 1998
> ADD > AB		EON	200MG	N75315 001	DEC 23, 1998
> ADD >					
		CORDARONE			
AB	+	WYETH AYERST	200MG	N18972 001	DEC 24, 1985
		PACERONE			
AB		UPSHER SMITH	200MG	N75135 001	APR 30, 1998

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL
AMITRIPTYLINE HCL

AB	DANBURY PHARMA	10MG	N88620 001 MAR 02, 1984
AB		25MG	N88621 001 MAR 02, 1984
AB		50MG	N88622 001 MAR 02, 1984
AB		75MG	N88633 001 MAR 02, 1984
AB		100MG	N88634 001 MAR 02, 1984
AB		150MG	N88635 001 MAR 02, 1984
@		10MG	N88620 001 MAR 02, 1984
@		25MG	N88621 001 MAR 02, 1984
@		50MG	N88622 001 MAR 02, 1984
@		75MG	N88633 001 MAR 02, 1984
@		100MG	N88634 001 MAR 02, 1984
@		150MG	N88635 001 MAR 02, 1984

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL
PERPHENAZINE AND AMITRIPTYLINE HCL

AB	DANBURY PHARMA	10MG;2MG	N72539 001 FEB 15, 1989
AB		10MG;4MG	N72540 001 FEB 15, 1989
AB		25MG;2MG	N72541 001 FEB 15, 1989
AB		25MG;4MG	N72134 001 FEB 15, 1989
AB		50MG;4MG	N72135 001 FEB 15, 1989
@		10MG;2MG	N72539 001 FEB 15, 1989
@		10MG;4MG	N72540 001 FEB 15, 1989

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL
PERPHENAZINE AND AMITRIPTYLINE HCL

@	DANBURY PHARMA	25MG;2MG	N72541 001 FEB 15, 1989
@		25MG;4MG	N72134 001 FEB 15, 1989
@		50MG;4MG	N72135 001 FEB 15, 1989
AB	ROYCE LABS	10MG;2MG	N73007 001 OCT 17, 1991
AB		10MG;4MG	N73009 001 OCT 17, 1991
AB		25MG;2MG	N73008 001 OCT 17, 1991
AB		25MG;4MG	N73010 001 OCT 17, 1991
AB	WATSON LABS	10MG;2MG	N73007 001 OCT 17, 1991
AB		10MG;4MG	N73009 001 OCT 17, 1991
AB		25MG;2MG	N73008 001 OCT 17, 1991
AB		25MG;4MG	N73010 001 OCT 17, 1991

AMMONIUM CHLORIDE

INJECTABLE; INJECTION
AMMONIUM CHLORIDE 2.14%

@	B BRAUN	40MEQ/100ML	N85734 001
@	MCGAW	40MEQ/100ML	N85734 001

AMMONIUM LACTATE

CREAM; TOPICAL
LAC-HYDRIN

	WESTWOOD SQUIBB	EQ 12% BASE	N20508 001 AUG 29, 1996
+		EQ 12% BASE	N20508 001 AUG 29, 1996

AMOXICILLIN

TABLET; ORAL
AMOXIL
+ SMITHKLINE BEECHAM 500MG N50754 002 JUL 10, 1998
+ 875MG N50754 001 JUL 10, 1998

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

CAPSULE, TABLET, CAPSULE, EXTENDED RELEASE; ORAL
PREVPAC
> DLT > # TAP HOLDINGS 500MG,30MG
> DLT > N50757 001 DEC 02, 1997
> ADD > + 500MG;500MG;30MG
> ADD > N50757 001 DEC 02, 1997

AMRINONE LACTATE

INJECTABLE; INJECTION
AMRINONE
AP ABBOTT **EQ 5MG BASE/ML** **N74616 001** AUG 03, 1998

INOCOR
AP + SANOFI **EQ 5MG BASE/ML** **N18700 001** JUL 31, 1984

ARBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
GENESA
GENSIA 0.05MG/ML N20420 001 SEP 12, 1997
+ GENSIA AUTOMEDICS 0.05MG/ML N20420 001 SEP 12, 1997

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL
BUTALBITAL,ASPIRIN,CAFFEINE AND CODEINE PHOSPHATE
AB STEVENS J **325MG;50MG;40MG;30MG** **N74951 001** AUG 31, 1998

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL
ORPHENGESIC
AB PAR PHARM **385MG;30MG;25MG** **N75141 001** MAY 29, 1998

ORPHENGESIC FORTE
AB PAR PHARM **770MG;60MG;50MG** **N75141 002** MAY 29, 1998

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET; ORAL
CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE
> ADD > **AB** AMIDE PHARM **325MG;200MG;16MG** **N40283 001** DEC 29, 1998
> ADD >

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL
OXYCODONE AND ASPIRIN
AA HALSEY **325MG;4.5MG;0.38MG** **N40260 001** JUL 17, 1998
AA WATSON LABS **325MG;4.5MG;0.38MG** **N40255 001** FEB 27, 1998

ATENOLOL

TABLET; ORAL
ATENOLOL
AB GENPHARM **25MG** **N74126 003** AUG 26, 1998

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL
ATENOLOL AND CHLORTHALIDONE
AB MARTEC **50MG;25MG** **N74404 001** MAY 14, 1998
AB **100MG;25MG** **N74404 002** MAY 14, 1998

ATORVASTATIN CALCIUM

TABLET; ORAL
LIPITOR

	PARKE DAVIS	EQ 10MG BASE	N20702 001	DEC 17, 1996
		EQ 20MG BASE	N20702 002	DEC 17, 1996
#		EQ 40MG BASE	N20702 003	DEC 17, 1996
	WARNER LAMBERT EXPOR	EQ 10MG BASE	N20702 001	DEC 17, 1996
		EQ 20MG BASE	N20702 002	DEC 17, 1996
+		EQ 40MG BASE	N20702 003	DEC 17, 1996

ATRACURIUM BESYLATE

INJECTABLE; INJECTION
ATRACURIUM BESYLATE

AP	MARSAM	**10MG/ML**	**N74945 001**	JUL 28, 1998

ATRACURIUM BESYLATE PRESERVATIVE FREE

AP	MARSAM	**10MG/ML**	**N74944 001**	JUL 28, 1998

>ADD> AZITHROMYCIN DIHYDRATE; TROVAFLOXACIN MESYLATE

>ADD> POWDER FOR RECONSTITUTION, TABLET; ORAL
>ADD> TROVAN/ZITHROMAX COMPLIANCE PAK

>ADD> +	PFIZER	EQ 1GM BASE; EQ 100MG BASE	N50762 001	DEC 18, 1998

BACITRACIN

POWDER; FOR RX COMPOUNDING
BACITRACIN

	PADDOCK	5,000,000 UNITS/BOT	N62456 001	JUL 27, 1983
@		5,000,000 UNITS/BOT	N62456 001	JUL 27, 1983

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
CORTISPORIN

AT +	GLAXO WELLCOME	**400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM**	**N50416 002**	
AT +	MONARCH PHARMS	**400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM**	**N50416 002**	

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
NEOSPORIN

AT +	GLAXO WELLCOME	**400 UNITS/GM;EQ 3.5MG BASE/GM; 10,000 UNITS/GM**	**N50417 001**	
AT +	MONARCH PHARMS	**400 UNITS/GM;EQ 3.5MG BASE/GM; 10,000 UNITS/GM**	**N50417 001**	

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
BACITRACIN ZINC AND POLYMYXIN B SULFATE

AT	ADV REMEDIES	**500 UNITS/GM; 10,000 UNITS/GM**	**N64028 001**	JAN 30, 1995
AT	AKORN	**500 UNITS/GM; 10,000 UNITS/GM**	**N64028 001**	JAN 30, 1995

POLYSPORIN

AT +	GLAXO WELLCOME	**500 UNITS/GM; 10,000 UNITS/GM**	**N61229 001**	
AT +	MONARCH PHARMS	**500 UNITS/GM; 10,000 UNITS/GM**	**N61229 001**	

BACLOFEN

TABLET; ORAL
BACLOFEN

AB	ROYCE LABS	**10MG**	**N73092 001**	JAN 28, 1994
AB		**20MG**	**N73093 001**	JAN 28, 1994
AB	WATSON LABS	**10MG**	**N73092 001**	JAN 28, 1994

BACLOFEN

TABLET; ORAL
BACLOFEN

AB	WATSON LABS	20MG	N73093 001	JAN 28, 1994

BENZYL PENICILLOYL-POLYLYSINE

INJECTABLE; INJECTION
PRE-PEN

+	BAYER	60 UMOLAR	N50114 001	
+	SCHWARZ PHARMA	60 UMOLAR	N50114 001	

BEPRIDIL HYDROCHLORIDE

TABLET; ORAL
VASCOR

	JOHNSON RW	300MG	N19002 002	>ADD>	
			DEC 28, 1990	>ADD>	
+		400MG	N19002 003		
			DEC 28, 1990	>ADD>	
+		300MG	N19002 002	>ADD>	
			DEC 28, 1990		
@		400MG	N19002 003		
			DEC 28, 1990		

BETAMETHASONE VALERATE

CREAM; TOPICAL
BETAMETHASONE VALERATE

AB	CLAY PARK	EQ 0.1% BASE	N70053 001	JUN 10, 1986
@		EQ 0.1% BASE	N70053 001	JUN 10, 1986

BETHANECHOL CHLORIDE

TABLET; ORAL
BETHANECHOL CHLORIDE

AA	DANBURY PHARMA	5MG	N84402 001	
@		5MG	N84402 001	

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION
BRETYLOL

AP	+ FAULDING	50MG/ML	N17954 001	
@		50MG/ML	N17954 001	

BRINZOLAMIDE

SUSPENSION/DROPS; OPHTHALMIC
AZOPT

+	ALCON	1%	N20816 001	APR 01, 1998

BROMOCRIPTINE MESYLATE

CAPSULE; ORAL
BROMOCRIPTINE MESYLATE

AB	LEK PHARM	EQ 5MG BASE	N75100 001	DEC 10, 1998

PARLODEL

AB	+ NOVARTIS	EQ 5MG BASE	N17962 002	MAR 01, 1982

TABLET; ORAL
BROMOCRIPTINE MESYLATE

AB	LEK PHARM	EQ 2.5MG BASE	N74631 001	JAN 13, 1998

PARLODEL

AB	+ NOVARTIS	EQ 2.5MG BASE	N17962 001	

BROMPHENIRAMINE MALEATE

TABLET; ORAL
BROMPHENIRAMINE MALEATE

AA	DANBURY PHARMA	4MG	N83123 001	
@		4MG	N83123 001	

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
ZYBAN

+	GLAXO WELLCOME	100MG	N20711 002	MAY 14, 1997

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
ZYBAN
@ GLAXO WELLCOME 100MG N20711 002
MAY 14, 1997

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION
BUTORPHANOL TARTRATE
AP BEDFORD **2MG/ML** **N75046 001**
AUG 12, 1998

BUTORPHANOL TARTRATE PRESERVATIVE FREE
AP BEDFORD **1MG/ML** **N75045 001**
AUG 12, 1998
AP **2MG/ML** **N75045 002**
AUG 12, 1998
AP FAULDING **1MG/ML** **N75170 001**
SEP 28, 1998
AP **2MG/ML** **N75170 002**
SEP 28, 1998

CALCITRIOL

SOLUTION; ORAL
ROCALTROL
+ ROCHE 1 UGM/ML N21068 001
NOV 20, 1998

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER
B BRAUN 37MG/100ML;5GM/100ML;31MG/100ML;
120MG/100ML;330MG/100ML;
88MG/100ML N19864 001
JUN 10, 1993
MCGAW 37MG/100ML;5GM/100ML;31MG/100ML;
120MG/100ML;330MG/100ML;
88MG/100ML N19864 001
JUN 10, 1993

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION
ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER
B BRAUN 35MG/100ML;5GM/100ML;30MG/100ML;
74MG/100ML;640MG/100ML;500MG/100ML;
74MG/100ML N19867 001
DEC 20, 1993
MCGAW 35MG/100ML;5GM/100ML;30MG/100ML;
74MG/100ML;640MG/100ML;500MG/100ML;
74MG/100ML N19867 001
DEC 20, 1993

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION
DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER
AP B BRAUN **33MG/100ML;5GM/100ML;30MG/100ML;**
860MG/100ML **N18256 001**
AP **33MG/100ML;5GM/100ML;30MG/100ML;**
860MG/100ML **N20000 001**
APR 17, 1992
AP MCGAW 33MG/100ML;5GM/100ML;30MG/100ML;
860MG/100ML N18256 001
AP 33MG/100ML;5GM/100ML;30MG/100ML;
860MG/100ML N20000 001
APR 17, 1992

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION
DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER
@ B BRAUN 20MG/100ML;5GM/100ML;30MG/100ML;
600MG/100ML;310MG/100ML N17510 001
@ MCGAW 20MG/100ML;5GM/100ML;30MG/100ML;
600MG/100ML;310MG/100ML N17510 001

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION
ISOLYTE E IN PLASTIC CONTAINER

	B BRAUN	35MG/100ML;30MG/100ML;74MG/100ML; 640MG/100ML;500MG/100ML; 74MG/100ML	N19718 001 SEP 29, 1989
	MCGAW	35MG/100ML;30MG/100ML;74MG/100ML; 640MG/100ML;500MG/100ML; 74MG/100ML	N19718 001 SEP 29, 1989

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SOLUTION; PERFUSION, CARDIAC
PLEGISOL IN PLASTIC CONTAINER

	ABBOTT	17.6MG/100ML;325.3MG/100ML; 119.3MG/100ML;643MG/100ML	N18608 001 FEB 26, 1982
+		17.6MG/100ML;325.3MG/100ML; 119.3MG/100ML;643MG/100ML	N18608 001 FEB 26, 1982

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION
RINGER'S IN PLASTIC CONTAINER

AP	B BRAUN	**33MG/100ML;30MG/100ML; 860MG/100ML**	**N18721 001** NOV 09, 1982
AP		**33MG/100ML;30MG/100ML; 860MG/100ML**	**N20002 001** APR 17, 1992
AP	MCGAW	**33MG/100ML;30MG/100ML; 860MG/100ML**	**N18721 001** NOV 09, 1982
AP		**33MG/100ML;30MG/100ML; 860MG/100ML**	**N20002 001** APR 17, 1992

SOLUTION; IRRIGATION
RINGER'S IN PLASTIC CONTAINER

AT	B BRAUN	**33MG/100ML;30MG/100ML; 860MG/100ML**	**N18156 001**

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SOLUTION; IRRIGATION
RINGER'S IN PLASTIC CONTAINER

AT	MCGAW	**33MG/100ML;30MG/100ML; 860MG/100ML**	**N18156 001**

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION
LACTATED RINGER'S IN PLASTIC CONTAINER

AP	B BRAUN	**20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML**	**N19632 001** FEB 29, 1988
	@	20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML	N18023 001
AP	MCGAW	**20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML**	**N19632 001** FEB 29, 1988
	@	20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML	N18023 001

SOLUTION; IRRIGATION
LACTATED RINGER'S IN PLASTIC CONTAINER

AT	B BRAUN	**20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML**	**N18681 001** DEC 27, 1982
AT	MCGAW	**20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML**	**N18681 001** DEC 27, 1982

CALFACTANT

INJECTABLE; INJECTION
INFASURF PRESERVATIVE FREE

+	ONY	35MG/ML	N20521 001 JUL 01, 1998

CANDESARTAN CILEXETIL

TABLET; ORAL
ATACAND

	ASTRA MERCK	4MG	N20838 001 JUN 04, 1998

CANDESARTAN CILEXETIL

TABLET; ORAL

	ATACAND			
	ASTRA MERCK	8MG	N20838 002	JUN 04, 1998
		16MG	N20838 003	JUN 04, 1998
	+	32MG	N20838 004	JUN 04, 1998
	ASTRA PHARMS	4MG	N20838 001	JUN 04, 1998
		8MG	N20838 002	JUN 04, 1998
		16MG	N20838 003	JUN 04, 1998
	+	32MG	N20838 004	JUN 04, 1998

CAPECITABINE

TABLET; ORAL

	XELODA			
	ROCHE	150MG	N20896 001	APR 30, 1998
	+	500MG	N20896 002	APR 30, 1998

CAPTOPRIL

TABLET; ORAL

	CAPTOPRIL			
AB	PUREPAC PHARM	12.5MG	N74640 001	MAR 31, 1997
AB		25MG	N74640 002	MAR 31, 1997
AB		50MG	N74640 003	MAR 31, 1997
AB		100MG	N74640 004	MAR 31, 1997
	@	12.5MG	N74640 001	MAR 31, 1997
	@	25MG	N74640 002	MAR 31, 1997
	@	50MG	N74640 003	MAR 31, 1997

CAPTOPRIL

TABLET; ORAL

	CAPTOPRIL			
	@ PUREPAC PHARM	100MG	N74640 004	MAR 31, 1997
AB	ROYCE LABS	12.5MG	N74451 001	FEB 13, 1996
AB		25MG	N74451 002	FEB 13, 1996
AB		50MG	N74451 003	FEB 13, 1996
AB		100MG	N74451 004	FEB 13, 1996
AB	TORPHARM	12.5MG	N74737 001	OCT 28, 1998
AB		25MG	N74737 002	OCT 28, 1998
AB		50MG	N74737 003	OCT 28, 1998
AB		100MG	N74737 004	OCT 28, 1998
AB	WATSON LABS	12.5MG	N74451 001	FEB 13, 1996
AB		25MG	N74451 002	FEB 13, 1996
AB		50MG	N74451 003	FEB 13, 1996
AB		100MG	N74451 004	FEB 13, 1996

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

		CAPOZIDE 25/15			
AB		BRISTOL MYERS SQUIBB	25MG;15MG	N18709 001	OCT 12, 1984
AB		SQUIBB	25MG;15MG	N18709 001	OCT 12, 1984
		CAPOZIDE 25/25			
AB	+	BRISTOL MYERS SQUIBB	25MG;25MG	N18709 002	OCT 12, 1984
AB	+	SQUIBB	25MG;25MG	N18709 002	OCT 12, 1984
		CAPOZIDE 50/15			
AB	+	BRISTOL MYERS SQUIBB	50MG;15MG	N18709 004	OCT 12, 1984

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

		CAPOZIDE 50/15		
AB	+	SQUIBB	50MG;15MG	N18709 004 OCT 12, 1984
		CAPOZIDE 50/25		
AB		BRISTOL MYERS SQUIBB	50MG;25MG	N18709 003 OCT 12, 1984
AB		SQUIBB	50MG;25MG	N18709 003 OCT 12, 1984
		CAPTOPRIL AND HYDROCHLOROTHIAZIDE		
AB		ZENITH GOLDLINE	25MG;15MG	N75055 001 JUN 18, 1998
AB			25MG;25MG	N75055 002 JUN 18, 1998
AB			50MG;15MG	N75055 004 JUN 18, 1998
AB			50MG;25MG	N75055 003 JUN 18, 1998

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL

		CARBATROL		
	+	ATHENA	200MG	N20712 001 SEP 30, 1997
	+		300MG	N20712 002 SEP 30, 1997
	+	SHIRE LABS	200MG	N20712 001 SEP 30, 1997
	+		300MG	N20712 002 SEP 30, 1997

CARBIDOPA

TABLET; ORAL

		LODOSYN		
	+	DUPONT MERCK	25MG	N17830 001
	+	DUPONT PHARMS	25MG	N17830 001

CARBIDOPA; LEVODOPA

TABLET; ORAL

		SINEMET		
AB		DUPONT MERCK	10MG;100MG	N17555 001

CARBIDOPA; LEVODOPA

TABLET; ORAL

		SINEMET		
AB		DUPONT MERCK	25MG;100MG	N17555 003
AB	+		25MG;250MG	N17555 002
AB		DUPONT PHARMS	10MG;100MG	N17555 001
AB			25MG;100MG	N17555 003
AB	+		25MG;250MG	N17555 002

TABLET, EXTENDED RELEASE; ORAL

		SINEMET CR		
		DUPONT MERCK	25MG;100MG	N19856 002 DEC 24, 1992
	+		50MG;200MG	N19856 001 MAY 30, 1991
		DUPONT PHARMS	25MG;100MG	N19856 002 DEC 24, 1992
	+		50MG;200MG	N19856 001 MAY 30, 1991

CARISOPRODOL

TABLET; ORAL

		CARISOPRODOL		
AA		ROYCE LABS	350MG	N40152 001 DEC 03, 1996
AA		WATSON LABS	350MG	N40152 001 DEC 03, 1996

CEFACLOR

POWDER FOR RECONSTITUTION; ORAL

		CEFACLOR		
AB		MARSAM	EQ 125MG BASE/5ML	N64204 001 FEB 18, 1998
AB			EQ 187MG BASE/5ML	N64205 001 FEB 18, 1998
AB			EQ 250MG BASE/5ML	N64206 001 FEB 18, 1998
AB			EQ 375MG BASE/5ML	N64207 001 FEB 18, 1998

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

	CEFAZOLIN SODIUM			
AP	AM PHARM PARTNERS	**EQ 1MG BASE/VIAL**	**N64169 002**	AUG 14, 1998
AP		**EQ 500MG BASE/VIAL**	**N64169 001**	AUG 14, 1998
AP		**EQ 10GM BASE/VIAL**	**N64170 001**	MAR 18, 1998
AP		**EQ 20GM BASE/VIAL**	**N64170 002**	MAR 18, 1998

CEFTIZOXIME SODIUM

INJECTABLE; INJECTION

	CEFIZOX			
+	FUJISAWA	EQ 500MG BASE/VIAL	N50560 001	SEP 15, 1983
+		EQ 1GM BASE/VIAL	N50560 002	SEP 15, 1983
+		EQ 2GM BASE/VIAL	N50560 003	SEP 15, 1983
		EQ 10GM BASE/VIAL	N50560 005	MAR 19, 1991
+	FUJISAWA HLTHCARE	EQ 500MG BASE/VIAL	N50560 001	SEP 15, 1983
+		EQ 1GM BASE/VIAL	N50560 002	SEP 15, 1983
+		EQ 2GM BASE/VIAL	N50560 003	SEP 15, 1983
		EQ 10GM BASE/VIAL	N50560 005	MAR 19, 1993
	CEFIZOX IN DEXTROSE 5%	IN PLASTIC CONTAINER		
@	FUJISAWA	EQ 40MG BASE/ML	N50589 002	OCT 03, 1984
@	FUJISAWA HLTHCARE	EQ 40MG BASE/ML	N50589 002	OCT 03, 1984
	CEFIZOX IN PLASTIC CONTAINER			
+	FUJISAWA	EQ 20MG BASE/ML	N50589 003	APR 13, 1995
+		EQ 40MG BASE/ML	N50589 004	APR 13, 1995
+	FUJISAWA HLTHCARE	EQ 20MG BASE/ML	N50589 003	APR 13, 1995
+		EQ 40MG BASE/ML	N50589 004	APR 13, 1995

CEFUROXIME SODIUM

INJECTABLE; INJECTION

	CEFUROXIME			
AB	ASTRA PHARMS	**EQ 750MG BASE/VIAL**	**N64192 002**	APR 16, 1998
AP		**EQ 1.5GM BASE/VIAL**	**N64192 001**	APR 16, 1998
AP		**EQ 7.5GM BASE/VIAL**	**N64191 001**	APR 16, 1998
	CEFUROXIME SODIUM			
AP	AM PHARM PARTNERS	**EQ 7.5GM BASE/VIAL**	**N65002 001**	SEP 28, 1998

> ADD >

CELECOXIB

> ADD >

CAPSULE; ORAL

> ADD >

	CELEBREX		
	SEARLE	100MG	N20998 001
			DEC 31, 1998
+		200MG	N20998 002
			DEC 31, 1998

> ADD >

CEPHALEXIN

CAPSULE; ORAL

	CEPHALEXIN			
AB	ZENITH GOLDLINE	**EQ 250MG BASE**	**N61969 001**	
AB		**EQ 500MG BASE**	**N61969 002**	
AB	ZENITH LABS	**EQ 250MG BASE**	**N61969 001**	
AB		**EQ 500MG BASE**	**N61969 002**	

POWDER FOR RECONSTITUTION; ORAL

	KEFLEX		
+	LILLY	EQ 100MG BASE/ML	N50406 003
		EQ 100MG BASE/ML	N62117 001
@		EQ 100MG BASE/ML	N50406 003
+		EQ 100MG BASE/ML	N62117 001

CHLORAMPHENICOL

CAPSULE; ORAL

	CHLOROMYCETIN			
AB	+ PARKE DAVIS	**250MG**	**N60591 002**	
		50MG	N60591 001	
+		100MG	N60591 003	

CHLORAMPHENICOL

CAPSULE; ORAL
CHLOROMYCETIN

AB	+	PARKEDALE	250MG	N60591 002	
			50MG	N60591 001	
	+		100MG	N60591 003	

OINTMENT; OPHTHALMIC
CHLOROMYCETIN

AT	+	PARKE DAVIS	1%	N50156 001	> DLT >
AT	+	PARKEDALE	1%	N50156 001	> DLT >
					> DLT >
					> ADD >

POWDER FOR RECONSTITUTION; OPHTHALMIC
CHLOROMYCETIN

	+	PARKE DAVIS	25MG/VIAL	N50143 001
	+	PARKEDALE	25MG/VIAL	N50143 001

SOLUTION/DROPS; OPHTHALMIC
OPHTHOCHLOR

AT		PARKE DAVIS	0.5%	N61220 001
AT		PARKEDALE	0.5%	N61220 001

SOLUTION/DROPS; OTIC
CHLOROMYCETIN

	+	PARKE DAVIS	0.5%	N50205 001
	+	PARKEDALE	0.5%	N50205 001

CHLORAMPHENICOL; HYDROCORTISONE ACETATE

POWDER FOR RECONSTITUTION; OPHTHALMIC
CHLOROMYCETIN HYDROCORTISONE

	+	PARKE DAVIS	12.5MG/VIAL;25MG/VIAL	N50202 001
	+	PARKEDALE	12.5MG/VIAL;25MG/VIAL	N50202 001

CHLORAMPHENICOL; HYDROCORTISONE ACETATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
OPHTHOCORT

	@	PARKE DAVIS	10MG/GM;5MG/GM; 10,000 UNITS/GM	N50201 002
	@	PARKEDALE	10MG/GM;5MG/GM; 10,000 UNITS/GM	N50201 002

CHLORAMPHENICOL SODIUM SUCCINATE

INJECTABLE; INJECTION
CHLOROMYCETIN

AP	+	PARKE DAVIS	EQ 1GM BASE/VIAL	N50155 001
AP	+	PARKEDALE	EQ 1GM BASE/VIAL	N50155 001

CHLORDIAZEPOXIDE

TABLET; ORAL
LIBRITABS

	+	ICN	5MG	N85482 001
	@		5MG	N85482 001
	@		10MG	N85481 001
	@		25MG	N85488 001
	@	ROCHE	10MG	N85481 001
	@		25MG	N85488 001

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL
LIBRIUM

AB		ICN	5MG	N85461 001
AB			10MG	N85472 001
AB	+		25MG	N85475 001
AB		ROCHE	5MG	N85461 001
AB			10MG	N85472 001
AB	+		25MG	N85475 001

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL
PERIDEX

AT	+	PROCTER AND GAMBLE	0.12%	N19028 001 AUG 13, 1986
AT	+	ZILA	0.12%	N19028 001 AUG 13, 1986

TABLET; DENTAL
PERIOCHIP

	+	PERIO PRODS	2.5MG	N20774 001 MAY 15, 1998

CHLOROPROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
CHLOROPROCAINE HCL

AP	BEDFORD	2%	N40273 001	
			SEP 09, 1998	
AP		3%	N40273 002	
			SEP 09, 1998	

CHLOROQUINE PHOSPHATE

TABLET; ORAL
CHLOROQUINE PHOSPHATE

AA	WEST WARD	EQ 150MG BASE	N83082 001	
@		EQ 150MG BASE	N83082 001	

CHLOROTHIAZIDE

SUSPENSION; ORAL
DIURIL

+	MERCK	250MG/5ML	N11870 001	
+	MERCK SHARP DOHME	250MG/5ML	N11870 001	

TABLET; ORAL
DIURIL

AB	MERCK	250MG	N11145 004	
AB +		500MG	N11145 002	
AB	MERCK SHARP DOHME	250MG	N11145 004	
AB +		500MG	N11145 002	> DLT >
				> DLT >
				> DLT >
				> DLT >
				> DLT >
				> DLT >

CHLOROTHIAZIDE; RESERPINE

TABLET; ORAL
DIUPRES-250

BP	MERCK	250MG;0.125MG	N11635 003	> ADD >
			AUG 26, 1987	> ADD >
BP	MERCK SHARP DOHME	250MG;0.125MG	N11635 003	> ADD >
			AUG 26, 1987	> ADD >
				> ADD >
	DIUPRES-500			
BP +	MERCK	500MG;0.125MG	N11635 006	> ADD >
			AUG 26, 1987	
BP +	MERCK SHARP DOHME	500MG;0.125MG	N11635 006	
			AUG 26, 1987	

CHLOROTHIAZIDE SODIUM

INJECTABLE; INJECTION
DIURIL

+	MERCK	EQ 500MG BASE/VIAL	N11145 005
+	MERCK SHARP DOHME	EQ 500MG BASE/VIAL	N11145 005

CHLORPHENIRAMINE MALEATE

TABLET; ORAL
CHLORPHENIRAMINE MALEATE

AA	DANBURY PHARMA	4MG	N80696 001
@		4MG	N80696 001

CHLORPROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
CHLORPROMAZINE HCL

AP	MARSAM	25MG/ML	N89563 001
			APR 15, 1988
@		25MG/ML	N89563 001
			APR 15, 1988

CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE

TABLET; ORAL
CLONIDINE HCL AND CHLORTHALIDONE

AB	MYLAN	15MG;0.1MG	N71323 001
			FEB 09, 1987
AB		15MG;0.2MG	N71324 001
			FEB 09, 1987
AB		15MG;0.3MG	N71325 001
			FEB 09, 1987
	CLORPRES		
AB	MYLAN	15MG;0.1MG	N71323 001
			FEB 09, 1987
AB		15MG;0.2MG	N71324 001
			FEB 09, 1987
AB		15MG;0.3MG	N71325 001
			FEB 09, 1987

CHLORZOXAZONE

TABLET; ORAL
CHLORZOXAZONE

AA	DANBURY PHARMA	250MG	N86901 001

CHLORZOXAZONE

TABLET; ORAL

	CHLORZOXAZONE		
	@ DANBURY PHARMA	250MG	N86901 001
AA	ROYCE LABS	500MG	N81040 001 AUG 22, 1989
AA	WATSON LABS	500MG	N81040 001 AUG 22, 1989

CHOLESTYRAMINE

POWDER; ORAL

	CHOLESTYRAMINE			
AB	NOVOPHARM	EQ 4GM RESIN/PACKET	N74347 001 MAY 28, 1998	
AB		EQ 4GM RESIN/SCOOPFUL	N74347 002 MAY 28, 1998	> ADD > > ADD >
	CHOLESTYRAMINE LIGHT			> ADD >
AB	COPLEY PHARM	EQ 4GM RESIN/PACKET	N74555 001 SEP 30, 1998	> ADD > > ADD >
AB	NOVOPHARM	EQ 4GM RESIN/PACKET	N74348 001 MAY 28, 1998	> ADD > > ADD >
AB		EQ 4GM RESIN/SCOOPFUL	N74348 002 MAY 28, 1998	> ADD >
	LOCHOLEST			
AB	EON	EQ 4GM RESIN/PACKET	N74561 001 AUG 15, 1996	
AB		EQ 4GM RESIN/SCOOPFUL	N74561 002 AUG 15, 1996	
	@	EQ 4GM RESIN/PACKET	N74561 001 AUG 15, 1996	
	@	EQ 4GM RESIN/SCOOPFUL	N74561 002 AUG 15, 1996	
	LOCHOLEST LIGHT			
AB	EON	EQ 4GM RESIN/PACKET	N74562 001 AUG 15, 1996	
AB		EQ 4GM RESIN/SCOOPFUL	N74562 002 AUG 15, 1996	
	@	EQ 4GM RESIN/PACKET	N74562 001 AUG 15, 1996	
	@	EQ 4GM RESIN/SCOOPFUL	N74562 002 AUG 15, 1996	

CIMETIDINE

SOLUTION; ORAL

	CIMETIDINE HCL		
AA	DURAMED	300MG/5ML	N75110 001 JUN 18, 1998

TABLET; ORAL

	CIMETIDINE		
AB	BAKER NORTON	200MG	N74424 001 JUL 28, 1995
AB		300MG	N74424 002 JUL 28, 1995
AB		400MG	N74424 003 JUL 28, 1995
AB		800MG	N74424 004 JUL 28, 1995
AB	TORPHARM	200MG	N74890 001 DEC 18, 1998
AB		300MG	N74890 002 DEC 18, 1998
AB		400MG	N74890 003 DEC 18, 1998
AB		800MG	N74890 004 DEC 18, 1998
AB	ZENITH LABS	200MG	N74424 001 JUL 28, 1995
AB		300MG	N74424 002 JUL 28, 1995
AB		400MG	N74424 003 JUL 28, 1995
AB		800MG	N74424 004 JUL 28, 1995

CIMETIDINE HYDROCHLORIDE

SOLUTION; ORAL

	CIMETIDINE HCL		
AA	COPLEY PHARM	EQ 300MG BASE/5ML	N74859 001 JUL 09, 1998

CIPROFLOXACIN HYDROCHLORIDE

OINTMENT; OPHTHALMIC

	CILOXAN		
	+ ALCON	EQ 0.3% BASE	N20369 001 MAR 30, 1998

CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE

SUSPENSION/DROPS; OTIC
CIPRO HC

>ADD>	+	ALCON	EQ 0.2% BASE;1%	N20805 001 FEB 10, 1998
>ADD>				
>DLT>	+	BAYER	EQ 0.2% BASE;1%	N20805 001 FEB 10, 1998
>DLT>				

CISAPRIDE MONOHYDRATE

TABLET; ORAL
PROPULSID QUICKSOLV

+	JANSSEN	EQ 20MG BASE	N20767 001 NOV 07, 1997

TABLET, ORALLY DISINTEGRATING; ORAL
PROPULSID QUICKSOLV

+	JANSSEN	EQ 20MG BASE	N20767 001 NOV 07, 1997

CITALOPRAM HYDROBROMIDE

TABLET; ORAL
CELEXA

	FOREST LABS	EQ 20MG BASE	N20822 002 JUL 17, 1998	
		EQ 40MG BASE	N20822 003 JUL 17, 1998	
+		EQ 60MG BASE	N20822 004 JUL 17, 1998	>DLT> >DLT> >ADD> >ADD>

CLEMASTINE FUMARATE

SYRUP; ORAL
CLEMASTINE FUMARATE

AA	MORTON GROVE	**EQ 0.5MG BASE/5ML**	**N74863 001** MAR 13, 1998

CLIDINIUM BROMIDE

CAPSULE; ORAL
QUARZAN

ROCHE	2.5MG	N10355 001
	5MG	N10355 002

CLIDINIUM BROMIDE

CAPSULE; ORAL
QUARZAN

@	ROCHE	2.5MG	N10355 001
@		5MG	N10355 002

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL
CLINDAMYCIN HCL

AB	DANBURY PHARMA	**EQ 75MG BASE**	**N63082 001 JUL 31, 1991**
@		EQ 75MG BASE	N63082 001 JUL 31, 1991

CLINDAMYCIN PHOSPHATE

CREAM; VAGINAL
CLEOCIN

+	PHARMACIA AND UPJOHN	EQ 2% BASE	N50680 001 AUG 11, 1992
@		EQ 2% BASE	N50680 001 AUG 11, 1992
+		EQ 2% BASE	N50680 002 MAR 02, 1998

INJECTABLE; INJECTION
CLINDAMYCIN PHOSPHATE

AP	BEDFORD	**EQ 150MG BASE/ML**	**N63163 001 JUN 30, 1994**	>DLT> >DLT>
@		EQ 150MG BASE/ML	N63163 001 JUN 30, 1994	>ADD> >ADD>
AP	MARSAM	**EQ 150MG BASE/ML**	**N62913 001 OCT 20, 1988**	
@		EQ 150MG BASE/ML	N62913 001 OCT 20, 1988	

SOLUTION; TOPICAL
CLEOCIN T

AT	PHARMACIA AND UPJOHN	**EQ 1% BASE**	**N62363 001 FEB 08, 1982**
@		EQ 1% BASE	N62363 001 FEB 08, 1982

CLOBETASOL PROPIONATE

CREAM; TOPICAL

			CLOBETASOL PROPIONATE			
> DLT >	**AB**		COPLEY PHARM	**0.05%**	**N74087 001**	
> DLT >					FEB 16, 1994	
> ADD >	**AB1**			**0.05%**	**N74087 001**	
> ADD >					FEB 16, 1994	
> DLT >	**AB**		FOUGERA	**0.05%**	**N74392 001**	
> DLT >					SEP 30, 1996	
> ADD >	**AB1**			**0.05%**	**N74392 001**	
> ADD >					SEP 30, 1996	
> DLT >	**AB**		NMC	**0.05%**	**N74139 001**	
> DLT >					AUG 03, 1994	
> ADD >	**AB1**			**0.05%**	**N74139 001**	
> ADD >					AUG 03, 1994	
> DLT >	**AB**		TARO	**0.05%**	**N74249 001**	
> DLT >					JUL 08, 1996	
> ADD >	**AB1**			**0.05%**	**N74249 001**	
> ADD >					JUL 08, 1996	
			CORMAX			
> DLT >	**AB**		HEALTHPOINT	**0.05%**	**N74220 001**	
> DLT >					MAY 16, 1997	
> ADD >	**AB1**			**0.05%**	**N74220 001**	
> ADD >					MAY 16, 1997	
> ADD >			**EMBELINE E**			
> ADD >	**AB2**		HEALTHPOINT	**0.05%**	**N75325 001**	
> ADD >					DEC 24, 1998	
			TEMOVATE			
> DLT >	**AB**	+	GLAXO WELLCOME	**0.05%**	**N19322 001**	
> DLT >					DEC 27, 1985	
> ADD >	**AB1**	+		**0.05%**	**N19322 001**	
> ADD >					DEC 27, 1985	
			TEMOVATE E			
> ADD >	**AB2**	+	GLAXO WELLCOME	**0.05%**	**N20340 001**	
> ADD >					JUN 17, 1994	
> DLT >	**BX**	+		**0.05%**	**N20340 001**	
> DLT >					JUN 17, 1994	

OINTMENT; TOPICAL

		CLOBETASOL PROPIONATE			
AB		STIEFEL	**0.05%**	**N75057 001**	
				AUG 12, 1998	
		EMBELINE			
AB		DPT	**0.05%**	**N74221 001**	
				MAR 31, 1995	
AB		HEALTHPOINT	**0.05%**	**N74221 001**	
				MAR 31, 1995	

CLOBETASOL PROPIONATE

SOLUTION; TOPICAL

	CLOBETASOL PROPIONATE			
AT	MORTON GROVE	**0.05%**	**N75205 001**	
			NOV 13, 1998	
AT	TARO	**0.05%**	**N75224 001**	
			NOV 16, 1998	

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

	CLOMIPRAMINE HCL			
AB	CHELSEA LABS	**25MG**	**N74751 001**	
			SEP 30, 1998	
AB		**50MG**	**N74751 002**	
			SEP 30, 1998	
AB		**75MG**	**N74751 003**	
			SEP 30, 1998	
AB	MYLAN	**25MG**	**N74947 001**	
			APR 30, 1998	
AB		**50MG**	**N74947 002**	
			APR 30, 1998	
AB		**75MG**	**N74947 003**	
			APR 30, 1998	

CLONAZEPAM

TABLET; ORAL

	CLONAZEPAM			
AB	MYLAN	**0.5MG**	**N75150 001**	
			OCT 05, 1998	
AB		**1MG**	**N75150 002**	
			OCT 05, 1998	
AB		**2MG**	**N75150 003**	
			OCT 05, 1998	
AB	NOVOPHARM	**0.5MG**	**N74920 001**	
			AUG 04, 1998	
AB		**1MG**	**N74920 002**	
			AUG 04, 1998	
AB		**2MG**	**N74920 003**	
			AUG 04, 1998	
	KLONOPIN			
AB	ROCHE	**1MG**	**N17533 002**	
AB	+	**1MG**	**N17533 002**	
AB	+	**2MG**	**N17533 003**	
AB		**2MG**	**N17533 003**	

CLONAZEPAM

TABLET; ORAL
KLONOPIN RAPIDLY DISINTEGRATING

+	ROCHE	0.125MG	N20813 001 DEC 23, 1997
		0.25MG	N20813 002 DEC 23, 1997
		0.5MG	N20813 003 DEC 23, 1997

TABLET, ORALLY DISINTEGRATING; ORAL
KLONOPIN RAPIDLY DISINTEGRATING

	ROCHE	1MG	N20813 004 DEC 23, 1997
+		2MG	N20813 005 DEC 23, 1997
+		0.125MG	N20813 001 DEC 23, 1997
		0.25MG	N20813 002 DEC 23, 1997
		0.5MG	N20813 003 DEC 23, 1997
+		1MG	N20813 004 DEC 23, 1997
		2MG	N20813 005 DEC 23, 1997

CLONIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
DURACLON

+	FUJISAWA	0.1MG/ML	N20615 001 OCT 02, 1996
+	ROXANE	0.1MG/ML	N20615 001 OCT 02, 1996

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL
ACTIFED W/ CODEINE

AA	+	GLAXO WELLCOME	10MG/5ML;30MG/5ML; 1.25MG/5ML	N12575 003 APR 04, 1984

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL
ACTIFED W/ CODEINE

	@ GLAXO WELLCOME	10MG/5ML;30MG/5ML; 1.25MG/5ML	N12575 003 APR 04, 1984

TRIPROLIDINE HCL, PSEUDOEPHEDRINE HCL AND CODEINE PHOSPHATE

AA	MORTON GROVE	10MG/5ML;30MG/5ML; 1.25MG/5ML	N88833 001 NOV 16, 1984
AA	+	10MG/5ML;30MG/5ML; 1.25MG/5ML	N88833 001 NOV 16, 1984

COLISTIMETHATE SODIUM

INJECTABLE; INJECTION
COLY-MYCIN M

+	PARKE DAVIS	EQ 150MG BASE/VIAL	N50108 002
+	PARKEDALE	EQ 150MG BASE/VIAL	N50108 002

COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDE

SUSPENSION/DROPS; OTIC
COLY-MYCIN S

+	PARKE DAVIS	EQ 3MG BASE/ML;10MG/ML; EQ 3.3MG BASE/ML;0.5MG/ML	N50356 001
+	PARKEDALE	EQ 3MG BASE/ML;10MG/ML; EQ 3.3MG BASE/ML;0.5MG/ML	N50356 001

CORTICOTROPIN

INJECTABLE; INJECTION
ACTH

@	PARKE DAVIS	25 UNITS/VIAL	N08317 002
@		40 UNITS/VIAL	N08317 004
@	PARKEDALE	25 UNITS/VIAL	N08317 002
@		40 UNITS/VIAL	N08317 004

CROMOLYN SODIUM

CAPSULE; INHALATION
INTAL

	+	RHONE POULENC RORER	20MG	N16990 001
	@		20MG	N16990 001

SOLUTION/DROPS; OPHTHALMIC
CROLOM

AT		BAUSCH AND LOMB	**4%**	**N74443 001** JAN 30, 1995
	+		4%	N74443 001 JAN 30, 1995

CROMOLYN SODIUM

AT		ADV REMEDIES	**4%**	**N74706 001** APR 29, 1998
AT		AKORN	**4%**	**N74706 001** APR 29, 1998

OPTICROM

AT	+	ALLERGAN	**4%**	**N18155 001** OCT 03, 1984
	@	RHONE POULENC RORER	4%	N18155 001 OCT 03, 1984

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL
CYCLOBENZAPRINE HCL

AB		ROYCE LABS	**10MG**	**N74436 001** NOV 30, 1994
AB		WATSON LABS	**10MG**	**N74436 001** NOV 30, 1994

CYCLOSPORINE

CAPSULE; ORAL
NEORAL

BX		NOVARTIS	25MG	N50715 001 JUL 14, 1995
BX			50MG	N50715 003 JUL 14, 1995
BX	+		100MG	N50715 002 JUL 14, 1995

SANDIMMUNE

BX		NOVARTIS	25MG	N50625 001 MAR 02, 1990

CYCLOSPORINE

CAPSULE; ORAL
SANDIMMUNE

BX		NOVARTIS	50MG	N50625 003 NOV 23, 1992
BX	+		100MG	N50625 002 MAR 02, 1990
			25MG	N50625 001 MAR 02, 1990
			50MG	N50625 003 NOV 23, 1992
	+		100MG	N50625 002 MAR 02, 1990

CAPSULE, MICROEMULSION, ORAL
NEORAL

		NOVARTIS	25MG	N50715 001 JUL 14, 1995
			50MG	N50715 003 JUL 14, 1995
	+		100MG	N50715 002 JUL 14, 1995

SOLUTION; ORAL
NEORAL

AB	+	NOVARTIS	**100MG/ML**	**N50716 001** JUL 14, 1995
BX	+		100MG/ML	N50716 001 JUL 14, 1995

SANDIMMUNE

BX	+	NOVARTIS	100MG/ML	N50574 001 NOV 14, 1983
	+		100MG/ML	N50574 001 NOV 14, 1983

SANGCYA

AB		SANGSTAT	**100MG/ML**	**N64195 001** OCT 31, 1998

CYPROHEPTADINE HYDROCHLORIDE

TABLET; ORAL
CYPROHEPTADINE HCL

AA		DANBURY PHARMA	**4MG**	**N86580 001**
	@		4MG	N86580 001

CYTARABINE

INJECTABLE; INJECTION

CYTARABINE

> ADD >	**AP**	GENSIA SICOR PHARMS	**100MG/VIAL**	**N75206 001**	
> ADD >				DEC 30, 1998	
> ADD >	**AP**		**500MG/VIAL**	**N75206 002**	
> ADD >				DEC 30, 1998	
> ADD >	**AP**		**1GM/VIAL**	**N75206 004**	
> ADD >				DEC 30, 1998	
> ADD >	**AP**		**2GM/VIAL**	**N75206 003**	
> ADD >				DEC 30, 1998	

DACARBAZINE

INJECTABLE; INJECTION

DACARBAZINE

AP		GENSIA SICOR PHARMS	**200MG/VIAL**	**N75259 002**
				AUG 27, 1998

DTIC-DOME

AP	+	BAYER	**200MG/VIAL**	**N17575 002**

DACTINOMYCIN

INJECTABLE; INJECTION

COSMEGEN

	+	MERCK	0.5MG/VIAL	N50682 001
	#	MERCK SHARP DOHME	0.5MG/VIAL	N50682 001

DALTEPARIN SODIUM

INJECTABLE; INJECTION

FRAGMIN

	#	PHARMACIA AND UPJOHN	10,000 IU/9.5ML	N20287 004
				JAN 30, 1998
	+		10,000 IU/ML	N20287 004
				JAN 30, 1998

DANAZOL

CAPSULE; ORAL

DANAZOL

AB		BARR	**50MG**	**N74582 003**
				MAY 29, 1998

DANAZOL

CAPSULE; ORAL

DANAZOL

AB		BARR	**100MG**	**N74582 002**
				MAY 29, 1998

DANOCRINE

AB		SANOFI	**50MG**	**N17557 003**
AB			**100MG**	**N17557 004**

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

CERUBIDINE

	+	BEDFORD	EQ 20MG BASE/VIAL	N64103 001
				FEB 03, 1995

DAUNORUBICIN HCL

	#	BEDFORD	EQ 20MG BASE/VIAL	N64103 001
				FEB 03, 1995

DAUNORUBICIN HCL PRESERVATIVE FREE

AP	+	BEDFORD	**EQ 20MG BASE/VIAL**	**N50731 001**
				JAN 30, 1998
AP		GENSIA SICOR PHARMS	**EQ 20MG BASE/VIAL**	**N64212 001**
				JUN 23, 1998

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28

MIRCETTE

	+	ORGANON	0.15MG;0.02MG	N20713 001
				APR 22, 1998

DESOXIMETASONE

GEL; TOPICAL

DESOXIMETASONE

AB		TARO	**0.05%**	**N74904 001**
				JUL 14, 1998

TOPICORT

AB	+	HOECHST MARION RSSL	**0.05%**	**N18586 001**
				MAR 29, 1982

OINTMENT; TOPICAL

DESOXIMETASONE

AB		ALTANA	**0.25%**	**N73440 001**
				APR 01, 1998

DEXAMETHASONE

AEROSOL; TOPICAL
AEROSEB-DEX

>DLT>	+	ALLERGAN HERBERT	0.01%	N83296 002
>ADD>	@		0.01%	N83296 002

DEXAMETHASONE SODIUM PHOSPHATE

AEROSOL, NASAL
DEXACORT

	+	MEDEVA	EQ 0.1MG PHOSPHATE/INH	N14242 001
	@		EQ 0.1MG PHOSPHATE/INH	N14242 001

AEROSOL, METERED; INHALATION
DEXACORT

	+	MEDEVA	EQ 0.1MG PHOSPHATE/INH	N13413 001
	@		EQ 0.1MG PHOSPHATE/INH	N13413 001

DEXAMETHASONE SODIUM PHOSPHATE; NEOMYCIN SULFATE

OINTMENT; OPHTHALMIC
NEODECADRON

>ADD>	@	MERCK	EQ 0.05% PHOSPHATE; EQ 3.5MG BASE/GM	N50324 001
>DLT>	+	MERCK SHARP DOHME	EQ 0.05% PHOSPHATE; EQ 3.5MG BASE/GM	N50324 001

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL
DEXEDRINE

AA	+	SMITHKLINE BEECHAM	5MG	N84935 001
AA			5MG	N84935 001

DEXTROSTAT

AA		SHIRE RICHWOOD	5MG	N84051 001
AA	+		5MG	N84051 001

DEXTROSE

INJECTABLE; INJECTION
DEXTROSE 10% IN PLASTIC CONTAINER

AP		B BRAUN	10GM/100ML	N18046 001
AP		MCGAW	10GM/100ML	N18046 001

DEXTROSE 5% IN PLASTIC CONTAINER

AP		B BRAUN	5GM/100ML	N16730 001

DEXTROSE

INJECTABLE; INJECTION
DEXTROSE 5% IN PLASTIC CONTAINER

AP		B BRAUN	50MG/ML	N16730 002
AP		MCGAW	5GM/100ML	N16730 001
AP			50MG/ML	N16730 002

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE

INJECTABLE; INJECTION
ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER

		B BRAUN	5GM/100ML;31MG/100ML;130MG/100ML; 26MG/100ML;320MG/100ML	N19873 001 JUN 10, 1993
		MCGAW	5GM/100ML;31MG/100ML;130MG/100ML; 26MG/100ML;320MG/100ML	N19873 001 JUN 10, 1993

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER

		B BRAUN	5GM/100ML;30MG/100ML;97MG/100ML; 220MG/100ML;140MG/100ML	N19844 001 JUN 10, 1993
		MCGAW	5GM/100ML;30MG/100ML;97MG/100ML; 220MG/100ML;140MG/100ML	N19844 001 JUN 10, 1993

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION
ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER

AP		B BRAUN	5GM/100ML;30MG/100ML;37MG/100ML; 370MG/100ML;530MG/100ML; 500MG/100ML	N19843 001 AUG 09, 1993
AP		MCGAW	5GM/100ML;30MG/100ML;37MG/100ML; 370MG/100ML;530MG/100ML; 500MG/100ML	N19843 001 AUG 09, 1993

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

ISOLYTE S W/ DEXTROSE 5% IN PLASTIC CONTAINER

AP	B BRAUN	5GM/100ML;30MG/100ML;37MG/100ML; 370MG/100ML;530MG/100ML; 500MG/100ML	N18274 001	
AP	MCGAW	5GM/100ML;30MG/100ML;37MG/100ML; 370MG/100ML;530MG/100ML; 500MG/100ML	N18274 001	

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	B BRAUN	5GM/100ML;75MG/100ML	N18744 001	NOV 09, 1982
AP	MCGAW	5GM/100ML;75MG/100ML	N18744 001	NOV 09, 1982

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML;150MG/100ML;130MG/100ML; 280MG/100ML;91MG/100ML	N19870 001 JUN 10, 1993
	MCGAW	5GM/100ML;150MG/100ML;130MG/100ML; 280MG/100ML;91MG/100ML	N19870 001 JUN 10, 1993

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

@	B BRAUN	10GM/100ML;900MG/100ML	N18047 001
@	MCGAW	10GM/100ML;900MG/100ML	N18047 001

DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

@	B BRAUN	5GM/100ML;900MG/100ML	N18026 001
@	MCGAW	5GM/100ML;900MG/100ML	N18026 001

DIAZEPAM

CAPSULE, EXTENDED RELEASE; ORAL

VALRELEASE

+	ROCHE	15MG	N18179 001	
@		15MG	N18179 001	

INJECTABLE; INJECTION

DIAZEPAM

AP	MARSAM	5MG/ML	N72371 001	JAN 29, 1993
@		5MG/ML	N72371 001	JAN 29, 1993

DICLOFENAC POTASSIUM

TABLET; ORAL

CATAFLAM

AB	+ NOVARTIS	50MG	N20142 002	NOV 24, 1993

DICLOFENAC POTASSIUM

AB	INVAMED	50MG	N75229 001	NOV 20, 1998
AB	TEVA	50MG	N75219 001	AUG 06, 1998
AB	WATSON LABS	50MG	N75152 001	NOV 27, 1998

DICLOFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC

DICLOFENAC SODIUM

AB	ALCON	0.1% †	N20809 001	MAY 04, 1998

VOLTAREN

AB	+ CIBA	0.1%	N20037 001	MAR 28, 1991

TABLET, DELAYED RELEASE; ORAL

DICLOFENAC SODIUM

AB	CARLSBAD	25MG	N75185 002	NOV 13, 1998
AB		50MG	N75185 003	NOV 13, 1998
AB		75MG	N75185 001	NOV 13, 1998

† SEE SECTION 1.4 OF INTRODUCTION

DICYCLOMINE HYDROCHLORIDE

TABLET; ORAL
DICYCLOMINE HCL

AB	BARR	20MG	N84600 001 JUL 29, 1985
	@	20MG	N84600 001 JUL 29, 1985

DIETHYLSTILBESTROL; METHYLTESTOSTERONE

TABLET; ORAL
TYLOSTERONE

	@ LILLY	0.25MG;5MG	N07661 001

DIFLORASONE DIACETATE

CREAM; TOPICAL
DIFLORASONE DIACETATE

AB	ALTANA	0.05%	N75187 001 MAR 30, 1998

PSORCON

AB	+ DERMIK LABS	0.05%	N20205 001 NOV 20, 1992
RX	$	0.05%	N20205 001 NOV 20, 1992

DIGOXIN

INJECTABLE; INJECTION
DIGOXIN

AP	ABBOTT	0.25MG/ML	N40206 001 AUG 28, 1998

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
CARTIA XT

	@ ANDRX PHARMS	120MG	N74752 002 JUL 09, 1998
	@	180MG	N74752 001 JUL 09, 1998
	@	240MG	N74752 003 JUL 09, 1998

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
CARTIA XT

	@ ANDRX PHARMS	300MG	N74752 004 JUL 09, 1998

DILTIAZEM HCL

AB2	MYLAN	120MG	N75124 002 MAR 18, 1998
AB2		180MG	N75124 003 MAR 18, 1998
AB2		240MG	N75124 001 MAR 18, 1998

DILTIAZEM XR

AB2	TORPHARM	240MG	N74943 001 AUG 06, 1998

TIAZAC

BC	BIOVAIL	120MG	N20401 001 SEP 11, 1995
BC	+	120MG	N20401 001 SEP 11, 1995
BC		180MG	N20401 002 SEP 11, 1995
BC	+	180MG	N20401 002 SEP 11, 1995
BC		240MG	N20401 003 SEP 11, 1995
BC	+	240MG	N20401 003 SEP 11, 1995
BC		300MG	N20401 004 SEP 11, 1995
BC	+	300MG	N20401 004 SEP 11, 1995
		360MG	N20401 005 SEP 11, 1995
	+	360MG	N20401 005 SEP 11, 1995
	+	420MG	N20401 006 OCT 16, 1998

INJECTABLE; INJECTION
DILTIAZEM HCL

AP	ABBOTT	5MG/ML	N74941 001 APR 15, 1998
AP	TAYLOR PHARMA	5MG/ML	N75086 001 APR 09, 1998

TABLET; ORAL
DILTIAZEM HCL

AB	NOVOPHARM	30MG	N74084 001 FEB 25, 1994

DILTIAZEM HYDROCHLORIDE

TABLET; ORAL
DILTIAZEM HCL

AB	NOVOPHARM	60MG	N74084 002 FEB 25, 1994
	@	30MG	N74084 001 FEB 25, 1994
	@	60MG	N74084 002 FEB 25, 1994

DILTIAZEM MALATE

TABLET, EXTENDED RELEASE; ORAL
TIAMATE

+	HOECHST MARION RSSL	EQ 120MG HCL	N20506 001 OCT 04, 1996
+		EQ 180MG HCL	N20506 002 OCT 04, 1996
+		EQ 240MG HCL	N20506 003 OCT 04, 1996
+	MERCK	EQ 120MG HCL	N20506 001 OCT 04, 1996
+		EQ 180MG HCL	N20506 002 OCT 04, 1996
+		EQ 240MG HCL	N20506 003 OCT 04, 1996

DINOPROSTONE

INSERT, EXTENDED RELEASE; VAGINAL
CERVIDIL

+	CONTROLLED THERAP	10MG	N20411 001 MAR 30, 1995
+	FOREST LABS	10MG	N20411 001 MAR 30, 1995

DIPHENHYDRAMINE HYDROCHLORIDE

ELIXIR; ORAL
DIPHENHYDRAMINE HCL

AA	PUREPAC PHARM	12.5MG/5ML	N83237 001 JAN 25, 1982
	@	12.5MG/5ML	N83237 001 JAN 25, 1982

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DIPHENHYDRAMINE HCL

AP	ABBOTT	50MG/ML	N40140 001 NOV 20, 1998

DIPYRIDAMOLE

INJECTABLE; INJECTION
DIPYRIDAMOLE

AP	AM PHARM PARTNERS	5MG/ML	N74956 001 SEP 30, 1998
AP	BEDFORD	5MG/ML	N74939 001 APR 13, 1998

TABLET; ORAL
DIPYRIDAMOLE

AB	PUREPAC PHARM	25MG	N89425 001 JUL 12, 1990
	@	25MG	N89425 001 JUL 12, 1990

DISOPYRAMIDE PHOSPHATE

CAPSULE, EXTENDED RELEASE; ORAL
DISOPYRAMIDE PHOSPHATE

	@ KV PHARM	EQ 100MG BASE	N71929 001 AUG 19, 1988

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DOBUTAMINE HCL

AP	LUITPOLD	EQ 12.5MG BASE/ML	N74545 001 JUN 25, 1998
AP	MARSAM	EQ 12.5MG BASE/ML	N74279 001 FEB 18, 1998
AP		EQ 12.5MG BASE/ML	N74995 001 MAR 31, 1998

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC
COSOPT
+ MERCK — EQ 2% BASE;EQ 0.5% BASE — N20869 001 APR 07, 1998

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL
DOXEPIN HCL

AB	ROYCE LABS	EQ 10MG BASE	N72985 001	MAR 29, 1991
AB		EQ 25MG BASE	N72986 001	MAR 29, 1991
AB		EQ 50MG BASE	N72987 001	MAR 29, 1991
AB	WATSON LABS	EQ 10MG BASE	N72985 001	MAR 29, 1991
AB		EQ 25MG BASE	N72986 001	MAR 29, 1991
AB		EQ 50MG BASE	N72987 001	MAR 29, 1991

CONCENTRATE; ORAL
DOXEPIN HCL

> ADD > AA	SILARX	EQ 10MG BASE/ML	N74721 001	DEC 29, 1998

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
RUBEX

AP	BRISTOL MYERS	10MG/VIAL	N62926 001	APR 13, 1989
AP		50MG/VIAL	N62926 002	APR 13, 1989
		100MG/VIAL	N62926 003	APR 13, 1989
AP	BRISTOL MYERS SQUIBB	10MG/VIAL	N62926 001	APR 13, 1989
AP		50MG/VIAL	N62926 002	APR 13, 1989
		100MG/VIAL	N62926 003	APR 13, 1989

DOXYCYCLINE HYCLATE

CAPSULE; ORAL
PERIOSTAT
+ COLLAGENEX — EQ 20MG BASE — N50744 001 SEP 30, 1998

LIQUID, EXTENDED RELEASE; PERIODONTAL
ATRIDOX
+ ATRIX — EQ 10% W/W — N50751 001 SEP 03, 1998

DROPERIDOL

INJECTABLE; INJECTION
INAPSINE

AP	+ AKORN MFG	2.5MG/ML	N16796 001	
AP	+ JANSSEN	2.5MG/ML	N16796 001	

DYPHYLLINE

INJECTABLE; INJECTION
NEOTHYLLINE

	+ TEVA	250MG/ML	N09088 001	
	@	250MG/ML	N09088 001	

TABLET; ORAL
DILOR-400

> DLT > BP	SAVAGE LABS	400MG	N84751 001	
> ADD > BP	+	400MG	N84751 001	
> DLT >	NEOTHYLLINE			
> DLT > BP	TEVA	200MG	N07794 001	
> DLT > BP	+	400MG	N07794 002	
> ADD >	@	200MG	N07794 001	
> ADD >	@	400MG	N07794 002	

ECHOTHIOPHATE IODIDE

POWDER FOR RECONSTITUTION; OPHTHALMIC
PHOSPHOLINE IODIDE

+	AYERST	0.03%	N11963 002
+		0.06%	N11963 004
+		0.125%	N11963 001
+		0.25%	N11963 003
+	WYETH AYERST	0.03%	N11963 002
+		0.06%	N11963 004

ECHOTHIOPHATE IODIDE

POWDER FOR RECONSTITUTION; OPHTHALMIC
PHOSPHOLINE IODIDE

+	WYETH AYERST	0.125%	N11963 001
+		0.25%	N11963 003

EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION
EDROPHONIUM CHLORIDE

AP	ABBOTT	10MG/ML	N40131 001 FEB 24, 1998
AP	STERIS	10MG/ML	N40044 001 MAR 20, 1996
@		10MG/ML	N40044 001 MAR 20, 1996

EDROPHONIUM CHLORIDE PRESERVATIVE FREE

AP	STERIS	10MG/ML	N40043 001 MAR 20, 1996
@		10MG/ML	N40043 001 MAR 20, 1996

EFAVIRENZ

CAPSULE; ORAL
SUSTIVA

	DUPONT PHARMS	50MG	N20972 001 SEP 17, 1998	> DLT >
		100MG	N20972 002 SEP 17, 1998	> ADD >
+		200MG	N20972 003 SEP 17, 1998	

ENCAINIDE HYDROCHLORIDE

CAPSULE; ORAL
ENKAID

	BRISTOL MYERS SQUIBB	25MG	N18981 002 DEC 24, 1986
		35MG	N18981 003 DEC 24, 1986
@		25MG	N18981 002 DEC 24, 1986
@		35MG	N18981 003 DEC 24, 1986

ENOXAPARIN SODIUM

INJECTABLE; INJECTION
LOVENOX

+	RHONE POULENC RORER	40MG/0.4ML	N20164 002 JAN 30, 1998
+		60MG/0.6ML	N20164 003 MAR 27, 1998
+		80MG/0.8ML	N20164 004 MAR 27, 1998
+		100MG/ML	N20164 005 MAR 27, 1998

EPINEPHRINE

INJECTABLE; INTRAMUSCULAR
EPI E Z PEN JR

+	MERIDIAN MEDCL TECHN	0.15MG/DELIVERY	N19430 004 AUG 03, 1995

EPIPEN E Z PEN

+	MERIDIAN MEDCL TECHN	0.3MG/DELIVERY	N19430 003 AUG 03, 1995

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
OCTOCAINE

AP		NOVOCOL	0.01MG/ML;2%	N84048 001	
AP	+		0.02MG/ML;2%	N84048 002	
AP		SEPTODONT	0.01MG/ML;2%	N84048 001	
AP	+		0.02MG/ML;2%	N84048 002	

EPTIFIBATIDE

INJECTABLE; INJECTION
INTEGRILIN

+	COR	75MG/100ML	N20718 002 MAY 18, 1998
+		2MG/ML	N20718 001 MAY 18, 1998

ERYTHROMYCIN

OINTMENT; OPHTHALMIC
ERYTHROMYCIN

AT		ADV REMEDIES	0.5%	N64030 001 JUL 18, 1996
AT		AKORN	0.5%	N64030 001 JUL 18, 1996

OINTMENT; TOPICAL
AKNE-MYCIN

	+	EM INDS	2%	N50584 001 JAN 10, 1985
	+	HEALTHPOINT	2%	N50584 001 JAN 10, 1985

TABLET, DELAYED RELEASE; ORAL
E-MYCIN

AB	+	KNOLL PHARM	333MG	N60272 002
AB			333MG	N60272 002

ERY-TAB

AB		ABBOTT	250MG	N62298 001
AB	+		250MG	N62298 001
AB			333MG	N62298 003 MAR 29, 1982
AB	+		333MG	N62298 003 MAR 29, 1982
AB			500MG	N62298 002
AB	+		500MG	N62298 002

ERYTHROMYCIN ETHYLSUCCINATE

SUSPENSION; ORAL
ERYTHROMYCIN ETHYLSUCCINATE

	@	KV PHARM	EQ 200MG BASE/5ML	N62047 001
	@		EQ 400MG BASE/5ML	N62047 002

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION
BREVIBLOC

	+	BAXTER PHARM PROD	10MG/ML	N19386 001 AUG 15, 1988
	@		100MG/ML	N19386 003 DEC 31, 1986
	+		250MG/ML	N19386 002 DEC 31, 1986

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION
BREVIBLOC

	+	OHMEDA	10MG/ML	N19386 001 AUG 15, 1988
	@		100MG/ML	N19386 003 DEC 31, 1986
	+		250MG/ML	N19386 002 DEC 31, 1986

ESTAZOLAM

TABLET; ORAL
ESTAZOLAM

AB		ROYCE LABS	1MG	N74818 001 AUG 19, 1997
AB			2MG	N74818 002 AUG 19, 1997
AB		WATSON LABS	1MG	N74818 001 AUG 19, 1997
AB			2MG	N74818 002 AUG 19, 1997

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL
ALORA

BX		PROCTER AND GAMBLE	0.05MG/24HR	N20655 001 DEC 20, 1996
BX			0.075MG/24HR	N20655 002 DEC 20, 1996
BX			0.1MG/24HR	N20655 003 DEC 20, 1996
BX		THERATECH	0.05MG/24HR	N20655 001 DEC 20, 1996
BX			0.075MG/24HR	N20655 002 DEC 20, 1996
BX			0.1MG/24HR	N20655 003 DEC 20, 1996

CLIMARA

BX	+	BERLEX LABS	0.075MG/24HR	N20375 003 MAR 23, 1998

ESCLIM

BX		FOURNIER	0.025MG/24HR	N20847 001 AUG 04, 1998

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL

ESCLIM

BX		FOURNIER	0.0375MG/24HR	N20847 002 AUG 04, 1998
BX			0.05MG/24HR	N20847 003 AUG 04, 1998
BX			0.075MG/24HR	N20847 004 AUG 04, 1998
BX			0.1MG/24HR	N20847 005 AUG 04, 1998

FEMPATCH

BX	+	PARKE DAVIS	0.025MG/24HR	N20417 001 DEC 03, 1996

TABLET; ORAL

ESTRADIOL

> DLT >	AB	DURAMED	0.5MG	N40212 001 DEC 29, 1997
> DLT >	AB		1MG	N40212 002 DEC 29, 1997
> DLT >	AB		2MG	N40212 004 DEC 29, 1997
> DLT >			1.5MG	N40212 003 DEC 29, 1997
	AB	ENDEAVOR	0.5MG	N40138 001 JAN 30, 1998
	AB		1MG	N40138 002 JAN 30, 1998
	AB		2MG	N40138 003 JAN 30, 1998
> ADD >	AB	ESI LEDERLE	0.5MG	N40275 001 DEC 29, 1998
> ADD >	AB		1MG	N40275 002 DEC 29, 1998
> ADD >	AB		2MG	N40275 003 DEC 29, 1998

GYNODIOL

> ADD >	AB	DURAMED	0.5MG	N40212 001 DEC 29, 1997
> ADD >	AB		1MG	N40212 002 DEC 29, 1997
> ADD >	AB		2MG	N40212 004 DEC 29, 1997
> ADD >			1.5MG	N40212 003 DEC 29, 1997

ESTRADIOL; NORETHINDRONE ACETATE

FILM, EXTENDED RELEASE; TRANSDERMAL

COMBIPATCH

		RHONE POULENC RORER	0.05MG/24HR;0.14MG/24HR	N20870 001 AUG 07, 1998
	+		0.05MG/24HR;0.25MG/24HR	N20870 002 AUG 07, 1998

TABLET; ORAL

ACTIVELLE

	+	NOVO NORDISK	1MG;0.5MG	N20907 001 NOV 18, 1998

ESTRADIOL CYPIONATE

INJECTABLE; INJECTION

DEPO-ESTRADIOL

	+	PHARMACIA AND UPJOHN	1MG/ML	N85470 001
	+		3MG/ML	N85470 002
	@		1MG/ML	N85470 001
	@		3MG/ML	N85470 002

ESTRADIOL VALERATE

INJECTABLE; INJECTION

DELESTROGEN

AO	+	BRISTOL MYERS SQUIBB	20MG/ML	N09402 004
AO	+		40MG/ML	N09402 003
	+		10MG/ML	N09402 002
AO	+	SQUIBB	20MG/ML	N09402 004
AO	+		40MG/ML	N09402 003
	+		10MG/ML	N09402 002

ESTRADIOL VALERATE; TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION

DELADUMONE

	@	BRISTOL MYERS SQUIBB	4MG/ML;90MG/ML	N09545 001
	@	SQUIBB	4MG/ML;90MG/ML	N09545 001

DELADUMONE OB

	@	BRISTOL MYERS SQUIBB	8MG/ML;180MG/ML	N09545 002
	@	SQUIBB	8MG/ML;180MG/ML	N09545 002

ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

TABLET; ORAL-28
PREMPRO 14/14

		+	WYETH AYERST	0.625MG,0.625MG;5MG,5MG	N20527 003 JAN 09, 1998

ESTROGENS, ESTERIFIED

TABLET; ORAL
ESTRATAB

> ADD >	BP		SOLVAY	0.3MG	N86715 001
> ADD >	BP	+		0.625MG	N83209 001
> ADD >	BP	+		2.5MG	N83857 001
> DLT >	BS			0.3MG	N86715 001
> DLT >	BS	+		0.625MG	N83209 001
> DLT >	BS	+		2.5MG	N83857 001

MENEST

> ADD >	BP		MONARCH PHARMS	0.3MG	N84951 001
> ADD >	BP			0.625MG	N84948 001
> ADD >	BP			2.5MG	N84949 001
> DLT >	BS			0.3MG	N84951 001
> DLT >	BS			0.625MG	N84948 001
> DLT >	BS			2.5MG	N84949 001
				1.25MG	N84950 001
			SMITHKLINE BEECHAM	1.25MG	N84950 001

ESTRONE

INJECTABLE; INJECTION
THEELIN

	@	PARKE DAVIS	1MG/ML	N03977 001
	@		2MG/ML	N03977 002
	@		5MG/ML	N03977 003
	@	PARKEDALE	1MG/ML	N03977 001
	@		2MG/ML	N03977 002
	@		5MG/ML	N03977 003

ETHACRYNATE SODIUM

INJECTABLE; INJECTION
EDECRIN

	+	MERCK	EQ 50MG BASE/VIAL	N16093 001
	+	MERCK SHARP DOHME	EQ 50MG BASE/VIAL	N16093 001

ETHACRYNIC ACID

TABLET; ORAL
EDECRIN

		MERCK	25MG	N16092 001
	+		50MG	N16092 002
		MERCK SHARP DOHME	25MG	N16092 001
	+		50MG	N16092 002

ETHINYL ESTRADIOL; FLUOXYMESTERONE

TABLET; ORAL
HALODRIN

@	PHARMACIA AND UPJOHN	0.02MG;1MG	N11267 001

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL
PREVEN EMERGENCY CONTRACEPTIVE KIT

	+	GYNETICS	0.05MG;0.25MG	N20946 001 SEP 01, 1998

TABLET; ORAL-21
ALESSE

BX	+	WYETH AYERST	0.02MG;0.1MG	N20683 001 MAR 27, 1997
	+		0.02MG;0.1MG	N20683 001 MAR 27, 1997

LEVLITE

BX		BERLEX LABS	0.02MG;0.1MG	N20860 001 JUL 13, 1998
			0.02MG;0.1MG	N20860 001 JUL 13, 1998

LEVORA 0.15/30-21

AB		**SEARLE**	**0.03MG;0.15MG**	**N73592 001 DEC 13, 1993**
AB		**WATSON LABS**	**0.03MG;0.15MG**	**N73592 001 DEC 13, 1993**

TABLET; ORAL-28
ALESSE

BX		WYETH AYERST	0.02MG;0.1MG	N20683 002 MAR 27, 1997
			0.02MG;0.1MG	N20683 002 MAR 27, 1997

LEVLITE

BX		BERLEX LABS	0.02MG;0.1MG	N20860 002 JUL 13, 1998

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-28

	LEVLITE			
	BERLEX LABS	0.02MG;0.1MG	N20860 002	
			JUL 13, 1998	
	LEVORA 0.15/30-28			
AB	SEARLE	0.03MG;0.15MG	N73594 001	
			DEC 13, 1993	
AB	WATSON LABS	0.03MG;0.15MG	N73594 001	
			DEC 13, 1993	

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

	NORETHIN 1/35E-21			
AB	SEARLE	0.035MG;1MG	N71480 001	
			APR 12, 1988	
AB	WATSON LABS	0.035MG;1MG	N71480 001	
			APR 12, 1988	

TABLET; ORAL-28

	NORETHIN 1/35E-28			
AB	SEARLE	0.035MG;1MG	N71481 001	
			APR 12, 1988	
AB	WATSON LABS	0.035MG;1MG	N71481 001	
			APR 12, 1988	

ETODOLAC

CAPSULE; ORAL

	ETODOLAC			
AB	AESGEN	300MG	N74929 001	
			JAN 30, 1998	
AB	GENPHARM	200MG	N75071 001	
			SEP 30, 1998	
AB		300MG	N75071 002	
			SEP 30, 1998	
AB	TARO	200MG	N75078 001	
			APR 30, 1998	
AB		300MG	N75078 002	
			APR 30, 1998	

TABLET; ORAL

	ETODOLAC			
AB	CHELSEA LABS	400MG	N75069 001	
			APR 16, 1998	

ETODOLAC

TABLET; ORAL

	ETODOLAC			
AB	GENPHARM	400MG	N75012 001	
			SEP 30, 1998	
AB		500MG	N75012 002	
			SEP 30, 1998	
AB	MYLAN	400MG	N75104 001	
			FEB 06, 1998	
AB		500MG	N75104 002	
			NOV 20, 1998	
AB	RANBAXY	400MG	N75226 001	
			NOV 24, 1998	
AB		500MG	N75226 002	
			NOV 24, 1998	
AB	ROYCE LABS	400MG	N74892 001	
			APR 16, 1997	
AB	TARO	400MG	N75074 001	
			MAR 11, 1998	
AB	WATSON LABS	400MG	N74892 001	
			APR 16, 1997	
AB		500MG	N74892 002	
			OCT 29, 1998	
AB	ZENITH GOLDLINE	500MG	N74883 002	
			NOV 20, 1998	
	LODINE			
AB	+ WYETH AYERST	500MG	N18922 005	
			JUN 28, 1996	

TABLET, EXTENDED RELEASE; ORAL

	LODINE XL		
	+ WYETH AYERST	500MG	N20584 003
			JAN 20, 1998

ETOPOSIDE

INJECTABLE; INJECTION

	ETOPOSIDE			
AP	APPLIED ANAL	20MG/ML	N74983 001	
			SEP 30, 1998	
AP	MARSAM	20MG/ML	N74968 001	
			JAN 09, 1998	

ETOPOSIDE PHOSPHATE

INJECTABLE; INJECTION

	ETOPOPHOS				
+	BRISTOL MYERS SQUIBB	EQ 100MG BASE/VIAL	N20457 001 MAY 17, 1996	> DLT >	
	ETOPOPHOS PRESERVATIVE FREE				
+	BRISTOL MYERS SQUIBB	EQ 100MG BASE/VIAL	N20457 001 MAY 17, 1996		
+		EQ 500MG BASE/VIAL	N20906 001 FEB 27, 1998		

FAMOTIDINE

TABLET, ORALLY DISINTEGRATING; ORAL

	PEPCID RPD		
	MERCK	20MG	N20752 001 MAY 28, 1998
+		40MG	N20752 002 MAY 28, 1998

FENFLURAMINE HYDROCHLORIDE

TABLET; ORAL

	PONDIMIN		
+	ROBINS AH	20MG	N16618 001
@		20MG	N16618 001

FENOFIBRATE

CAPSULE; ORAL

	LIPIDIL		
@	ABBOTT	100MG	N19304 001 DEC 31, 1993
@	LABS FOURNIER	100MG	N19304 001 DEC 31, 1993
	TRICOR (MICRONIZED)		
+	ABBOTT	67MG	N19304 002 FEB 09, 1998

FENOLDOPAM MESYLATE

INJECTABLE; INJECTION

	CORLOPAM				
> ADD > +	ELAN PHARMS	EQ 10MG BASE/ML	N19922 001 SEP 23, 1997		
> ADD >					

FENOLDOPAM MESYLATE

INJECTABLE; INJECTION

	CORLOPAM				
+	NEUREX	EQ 10MG BASE/ML	N19922 001 SEP 23, 1997	> DLT >	

FENOPROFEN CALCIUM

CAPSULE; ORAL

	FENOPROFEN CALCIUM			
AB	DANBURY PHARMA	EQ 200MG BASE	N72981 001 AUG 19, 1991	
AB		EQ 300MG BASE	N72982 001 AUG 19, 1991	
@		EQ 200MG BASE	N72981 001 AUG 19, 1991	
@		EQ 300MG BASE	N72982 001 AUG 19, 1991	

FENTANYL CITRATE

INJECTABLE; INJECTION

	FENTANYL CITRATE			
AP	ABBOTT	EQ 0.05MG BASE/ML	N72786 001 SEP 24, 1991	
AP +	ELKINS SINN	EQ 0.05MG BASE/ML	N19101 001 JUL 11, 1984	
	FENTANYL CITRATE PRESERVATIVE FREE			
AP	ABBOTT	EQ 0.05MG BASE/ML	N72786 001 SEP 24, 1991	
AP +	ELKINS SINN	EQ 0.05MG BASE/ML	N19101 001 JUL 11, 1984	
AP	MARSAM	EQ 0.05MG BASE/ML	N74917 001 FEB 03, 1998	
	SUBLIMAZE			
AP +	JANSSEN	EQ 0.05MG BASE/ML	N16619 001	
	SUBLIMAZE PRESERVATIVE FREE			
AP +	JANSSEN	EQ 0.05MG BASE/ML	N16619 001	

TROCHE/LOZENGE; ORAL

	ACTIQ		
	ANESTA	EQ 0.2MG BASE	N20747 001 NOV 04, 1998
		EQ 0.4MG BASE	N20747 002 NOV 04, 1998

FENTANYL CITRATE

TROCHE/LOZENGE; ORAL

	ACTIQ			
	ANESTA	EQ 0.6MG BASE	N20747 003	NOV 04, 1998
		EQ 0.8MG BASE	N20747 004	NOV 04, 1998
		EQ 1.2MG BASE	N20747 005	NOV 04, 1998
+		EQ 1.6MG BASE	N20747 006	NOV 04, 1998

FERRIC AMMONIUM CITRATE

POWDER FOR RECONSTITUTION; ORAL

	FERRISELTZ			
+	NYCOMED AMERSHAM	600MG/PACKET	N20292 001	OCT 14, 1997
+	ONCOMEMBRANE	600MG/PACKET	N20292 001	OCT 14, 1997

FLOSEQUINAN

TABLET; ORAL

	MANOPLAX			
	KNOLL PHARM	50MG	N19960 001	DEC 30, 1992
		75MG	N19960 002	DEC 30, 1992
+		100MG	N19960 003	DEC 30, 1992
@		50MG	N19960 001	DEC 30, 1992
@		75MG	N19960 002	DEC 30, 1992
@		100MG	N19960 003	DEC 30, 1992

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL

	FLUOCINOLONE ACETONIDE			
AT	TARO	**0.01%**	**N40035 001**	OCT 31, 1994

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL

	FLUOCINOLONE ACETONIDE			
AT	TARO	**0.1%**	**N40035 001**	OCT 31, 1994

FLUOCINONIDE

CREAM; TOPICAL

	FLUOCINONIDE			
AB	DRAXIS HLTH	**0.05%**	**N72494 001**	JAN 19, 1989
AB	TARO	**0.05%**	**N72494 001**	JAN 19, 1989

FLUOROURACIL

INJECTABLE; INJECTION

	ADRUCIL			
AP	PHARMACIA AND UPJOHN	**50MG/ML**	**N81225 001**	AUG 28, 1991
AP	+	**50MG/ML**	**N81225 001**	AUG 28, 1991
	FLUOROURACIL			
AP	AM PHARM PARTNERS	**50MG/ML**	**N40278 001**	SEP 30, 1998
AP		**50MG/ML**	**N40279 001**	SEP 30, 1998
AP	+ ICN PUERTO RICO	**50MG/ML**	**N12209 001**	
AP	+ ROCHE	**50MG/ML**	**N12209 001**	

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION

	FLUPHENAZINE DECANOATE			
AO	KING PHARMS	**25MG/ML**	**N74966 001**	APR 16, 1998

FLURANDRENOLIDE; NEOMYCIN SULFATE

CREAM; TOPICAL

	CORDRAN-N		
+	LILLY	0.05%;EQ 3.5MG BASE/GM	N50346 001
@		0.05%;EQ 3.5MG BASE/GM	N50346 001

FLURANDRENOLIDE; NEOMYCIN SULFATE

OINTMENT; TOPICAL
CORDRAN-N
* LILLY 0.05%;EQ 3.5MG BASE/GM N50345 001
@ 0.05%;EQ 3.5MG BASE/GM N50345 001

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL
DALMANE
AB ICN PUERTO RICO **15MG** **N16721 001**
AB + **30MG** **N16721 002**
AB ROCHE **15MG** **N16721 001**
AB + **30MG** **N16721 002**

FLUVOXAMINE MALEATE

TABLET; ORAL
LUVOX
@ SOLVAY 25MG N20243 001 DEC 05, 1994
25MG N20243 001 DEC 05, 1994

FOMIVIRSEN SODIUM

INJECTABLE; INJECTION
VITRAVENE PRESERVATIVE FREE
+ CIBA VISION OPHTHLMC 6.6MG/ML N20961 001 AUG 26, 1998

GABAPENTIN

CAPSULE; ORAL
NEURONTIN
> DLT > * PARKE DAVIS PHARMS 100MG N20235 001 DEC 30, 1993
> DLT > 400MG N20235 003 DEC 30, 1993
> ADD > 100MG N20235 001 DEC 30, 1993
> ADD > + 400MG N20235 003 DEC 30, 1993

GABAPENTIN

TABLET; ORAL
NEURONTIN
PARKE DAVIS 600MG N20882 001 OCT 09, 1998
\+ 800MG N20882 002 OCT 09, 1998

GANCICLOVIR

IMPLANT; IMPLANTATION
VITRASERT
\+ BAUSCH AND LOMB 4.5MG N20569 001 MAR 04, 1996
* CHIRON VISION 4.5MG N20569 001 MAR 04, 1996

GEMFIBROZIL

CAPSULE; ORAL
LOPID
@ PARKE DAVIS 200MG N18422 001
@ 300MG N18422 002
@ PARKE DAVIS PHARMS 200MG N18422 001
@ 300MG N18422 002

TABLET; ORAL
GEMFIBROZIL
AB TORPHARM **600MG** **N75034 001** JUL 20, 1998

LOPID
AB * PARKE DAVIS **600MG** **N18422 003** NOV 20, 1986
AB + PARKE DAVIS PHARMS **600MG** **N18422 003** NOV 20, 1986

GENTAMICIN SULFATE

INJECTABLE; INJECTION
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
AP B BRAUN **EQ 40MG BASE/100ML** **N62814 008** AUG 28, 1987
AP **EQ 60MG BASE/100ML** **N62814 009** AUG 28, 1987

GENTAMICIN SULFATE

INJECTABLE; INJECTION
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	B BRAUN	EQ 70MG BASE/100ML	N62814 010 AUG 28, 1987
AP		EQ 0.8MG BASE/ML	N62814 001 AUG 28, 1987
AP		EQ 80MG BASE/100ML	N62814 011 AUG 28, 1987
AP		EQ 90MG BASE/100ML	N62814 012 AUG 28, 1987
AP		EQ 100MG BASE/100ML	N62814 013 AUG 28, 1987
AP		EQ 1.2MG BASE/ML	N62814 002 AUG 28, 1987
AP		EQ 120MG BASE/100ML	N62814 014 AUG 28, 1987
AP		EQ 1.4MG BASE/ML	N62814 003 AUG 28, 1987
AP		EQ 1.6MG BASE/ML	N62814 004 AUG 28, 1987
AP		EQ 1.8MG BASE/ML	N62814 005 AUG 28, 1987
AP		EQ 2MG BASE/ML	N62814 006 AUG 28, 1987
AP		EQ 2.4MG BASE/ML	N62814 007 AUG 28, 1987
AP	MCGAW	EQ 40MG BASE/100ML	N62814 008 AUG 28, 1987
AP		EQ 60MG BASE/100ML	N62814 009 AUG 28, 1987
AP		EQ 70MG BASE/100ML	N62814 010 AUG 28, 1987
AP		EQ 0.8MG BASE/ML	N62814 001 AUG 28, 1987
AP		EQ 80MG BASE/100ML	N62814 011 AUG 28, 1987
AP		EQ 90MG BASE/100ML	N62814 012 AUG 28, 1987
AP		EQ 100MG BASE/100ML	N62814 013 AUG 28, 1987
AP		EQ 1.2MG BASE/ML	N62814 002 AUG 28, 1987
AP		EQ 120MG BASE/100ML	N62814 014 AUG 28, 1987
AP		EQ 1.4MG BASE/ML	N62814 003 AUG 28, 1987

GENTAMICIN SULFATE

INJECTABLE; INJECTION
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	MCGAW	EQ 1.6MG BASE/ML	N62814 004 AUG 28, 1987
AP		EQ 1.8MG BASE/ML	N62814 005 AUG 28, 1987
AP		EQ 2MG BASE/ML	N62814 006 AUG 28, 1987
AP		EQ 2.4MG BASE/ML	N62814 007 AUG 28, 1987

OINTMENT; OPHTHALMIC
GENTAMICIN SULFATE

AT	ADV REMEDIES	EQ 0.3% BASE	N64093 001 AUG 31, 1995
AT	AKORN	EQ 0.3% BASE	N64093 001 AUG 31, 1995

GLUCAGON HYDROCHLORIDE RECOMBINANT

INJECTABLE; INJECTION
GLUCAGEN

+	NOVO NORDISK	EQ 1MG BASE/VIAL	N20918 001 JUN 22, 1998

GLUCAGON, BIOSYNTHETIC

INJECTABLE; INJECTION
GLUCAGON

+	LILLY	1MG/VIAL	N20928 001 SEP 11, 1998

GLYBURIDE

TABLET; ORAL
GLYBURIDE (MICRONIZED)

AB	INVAMED	1.5MG	N75174 001 JUN 22, 1998
AB		3MG	N75174 002 JUN 22, 1998
AB	MYLAN	1.5MG	N74792 001 JUN 26, 1998

GLYBURIDE

TABLET; ORAL
GLYBURIDE (MICRONIZED)

AB	MYLAN	3MG	N74792 002	JUN 26, 1998

GLYCOPYRROLATE

TABLET; ORAL
GLYCOPYRROLATE

AA	DANBURY PHARMA	1MG	N86902 001	
AA		2MG	N86900 001	
@		1MG	N86902 001	
@		2MG	N86900 001	

ROBINUL

AA	+ ROBINS AH	1MG	N12827 001	
+		1MG	N12827 001	

ROBINUL FORTE

AA	+ ROBINS AH	2MG	N12827 002	
+		2MG	N12827 002	

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC
NEOSPORIN

AT	+ GLAXO WELLCOME	0.025MG/ML;EQ 1.75MG BASE/ML; 10,000 UNITS/ML	N60582 001	
AT	+ MONARCH PHARMS	0.025MG/ML;EQ 1.75MG BASE/ML; 10,000 UNITS/ML	N60582 001	

GRANISETRON HYDROCHLORIDE

TABLET; ORAL
KYTRIL

@	SMITHKLINE BEECHAM	EQ 2MG BASE	N20305 002	JUN 15, 1998

GREPAFLOXACIN HYDROCHLORIDE

TABLET; ORAL
RAXAR

+	GLAXO WELLCOME	EQ 200MG BASE	N20695 001	NOV 06, 1997

GREPAFLOXACIN HYDROCHLORIDE

TABLET; ORAL
RAXAR

	GLAXO WELLCOME	EQ 200MG BASE	N20695 001	NOV 06, 1997
		EQ 400MG BASE	N20695 002	MAY 14, 1998
+		EQ 600MG BASE	N20695 003	MAY 14, 1998

GUANABENZ ACETATE

TABLET; ORAL
GUANABENZ ACETATE

AB	EON	EQ 4MG BASE	N74517 001	SEP 30, 1998
AB		EQ 8MG BASE	N74517 002	SEP 30, 1998

GUANETHIDINE MONOSULFATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL
ESIMIL

+	NOVARTIS	10MG;25MG	N13553 001	
@		10MG;25MG	N13553 001	

GUANFACINE HYDROCHLORIDE

TABLET; ORAL
GUANFACINE HCL

AB	GENPHARM	EQ 1MG BASE	N75109 001	NOV 25, 1998
AB		EQ 2MG BASE	N75109 002	NOV 25, 1998
AB	ROYCE LABS	EQ 1MG BASE	N74762 001	JUN 25, 1997
AB		EQ 2MG BASE	N74762 002	JUN 25, 1997
AB	WATSON LABS	EQ 1MG BASE	N74762 001	JUN 25, 1997
AB		EQ 2MG BASE	N74762 002	JUN 25, 1997

HALOPERIDOL

TABLET; ORAL

HALOPERIDOL

AB	DANBURY PHARMA	**10MG**	**N72113 001 AUG 27, 1991**
AB		**20MG**	**N72353 001 AUG 27, 1991**
@		10MG	N72113 001 AUG 27, 1991
@		20MG	N72353 001 AUG 27, 1991
AB	PUREPAC PHARM	**0.5MG**	**N71071 001 NOV 03, 1986**
AB		**1MG**	**N71072 001 NOV 03, 1986**
AB		**2MG**	**N71073 001 NOV 03, 1986**
AB		**5MG**	**N71074 001 NOV 03, 1986**
AB		**10MG**	**N71075 001 AUG 04, 1987**
AB		**20MG**	**N71076 001 AUG 04, 1987**
@		0.5MG	N71071 001 NOV 03, 1986
@		1MG	N71072 001 NOV 03, 1986
@		2MG	N71073 001 NOV 03, 1986
@		5MG	N71074 001 NOV 03, 1986
@		10MG	N71075 001 AUG 04, 1987
@		20MG	N71076 001 AUG 04, 1987

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

HALOPERIDOL DECANOATE

AO	BEDFORD	**EQ 50MG BASE/ML**	**N74811 001 JAN 30, 1998**
AO		**EQ 100MG BASE/ML**	**N75305 001 SEP 28, 1998**

HALOPERIDOL LACTATE

INJECTABLE; INJECTION

HALOPERIDOL

AP	MARSAM	**EQ 5MG BASE/ML**	**N72516 001 FEB 25, 1993**
AP		**EQ 5MG BASE/ML**	**N72517 001 FEB 25, 1993**
@		EQ 5MG BASE/ML	N72516 001 FEB 25, 1993
@		EQ 5MG BASE/ML	N72517 001 FEB 25, 1993

HEPARIN SODIUM

INJECTABLE; INJECTION

HEP FLUSH KIT IN PLASTIC CONTAINER

@	AM PHARM PARTNERS	10 UNITS/ML	N17029 017 DEC 05, 1985
@		100 UNITS/ML	N17029 018 DEC 05, 1985
@	FUJISAWA	10 UNITS/ML	N17029 017 DEC 05, 1985
@		100 UNITS/ML	N17029 018 DEC 05, 1985

HEPARIN LOCK FLUSH

AP	AM PHARM PARTNERS	**10 UNITS/ML**	**N17029 007 MAY 06, 1982**
AP		**100 UNITS/ML**	**N17029 006**
@		100 UNITS/ML	N17651 010
AP	FUJISAWA	**10 UNITS/ML**	**N17029 007 MAY 06, 1982**
AP		**100 UNITS/ML**	**N17029 006**
@		100 UNITS/ML	N17651 010
AP	SOLOPAK	**10 UNITS/ML**	**N88457 001 OCT 25, 1984**
@		10 UNITS/ML	N88457 001 OCT 25, 1984

HEPARIN LOCK FLUSH PRESERVATIVE FREE

@	AM PHARM PARTNERS	10 UNITS/ML	N17029 011 SEP 22, 1987
@		100 UNITS/ML	N17029 012 SEP 22, 1987
@	FUJISAWA	10 UNITS/ML	N17029 011 SEP 22, 1987
@		100 UNITS/ML	N17029 012 SEP 22, 1987

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN LOCK FLUSH PRESERVATIVE FREE IN PLASTIC CONTAINER

	@	AM PHARM PARTNERS	10 UNITS/ML	N17029 008 SEP 22, 1987
	@		100 UNITS/ML	N17029 009 SEP 22, 1987
	@	FUJISAWA	10 UNITS/ML	N17029 008 SEP 22, 1987
	@		100 UNITS/ML	N17029 009 SEP 22, 1987

HEPARIN SODIUM

AP		AM PHARM PARTNERS	1,000 UNITS/ML	N17029 001
AP			1,000 UNITS/ML	N17979 001
AP			5,000 UNITS/ML	N17651 006
AP			10,000 UNITS/ML	N17029 003
AP			10,000 UNITS/ML	N17979 002
AP			20,000 UNITS/ML	N17029 004
	@		1,000 UNITS/ML	N17651 005
	@		5,000 UNITS/ML	N17029 002
	@		5,000 UNITS/ML	N17979 003
	@		10,000 UNITS/ML	N17651 003
	@		20,000 UNITS/ML	N17651 008
AP		FUJISAWA	1,000 UNITS/ML	N17029 001
AP			1,000 UNITS/ML	N17979 001
AP			5,000 UNITS/ML	N17651 006
AP			10,000 UNITS/ML	N17029 003
AP			10,000 UNITS/ML	N17979 002
AP			20,000 UNITS/ML	N17029 004
	@		1,000 UNITS/ML	N17651 005
	@		5,000 UNITS/ML	N17029 002
	@		5,000 UNITS/ML	N17979 003
	@		10,000 UNITS/ML	N17651 003
	@		20,000 UNITS/ML	N17651 008

HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		B BRAUN	200 UNITS/100ML	N19953 001 JUL 20, 1992
	@		200 UNITS/100ML	N19042 001 MAR 29, 1985
AP		MCGAW	200 UNITS/100ML	N19953 001 JUL 20, 1992
	@		200 UNITS/100ML	N19042 001 MAR 29, 1985

HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5%

AP		ABBOTT	10,000 UNITS/100ML	N18911 006 JAN 30, 1985

HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5%

AP		ABBOTT	5,000 UNITS/100ML	N18911 007 JAN 30, 1985
	@		5,000 UNITS/100ML	N18911 007 JAN 30, 1985

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

AP		ABBOTT	5,000 UNITS/100ML	N19339 001 MAR 27, 1985
			5,000 UNITS/100ML	N19339 001 MAR 27, 1985

HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

	@	B BRAUN	5,000 UNITS/100ML	N19802 001 JUL 20, 1992
	@	MCGAW	5,000 UNITS/100ML	N19802 001 JUL 20, 1992

HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	@	B BRAUN	200 UNITS/100ML	N19042 002 MAR 29, 1985
	@	MCGAW	200 UNITS/100ML	N19042 002 MAR 29, 1985

HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

AP		B BRAUN	4,000 UNITS/100ML	N19952 001 JUL 20, 1992
AP		MCGAW	4,000 UNITS/100ML	N19952 001 JUL 20, 1992

HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%

AP		ABBOTT	5,000 UNITS/100ML	N18911 009 JAN 30, 1985
AP			10,000 UNITS/100ML	N18911 008 JAN 30, 1985
	@		5,000 UNITS/100ML	N18911 009 JAN 30, 1985
	@		10,000 UNITS/100ML	N18911 008 JAN 30, 1985

HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

AP		B BRAUN	5,000 UNITS/100ML	N19952 004 JUL 20, 1992

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

AP		B BRAUN	10,000 UNITS/100ML	N19952 005 JUL 20, 1992
	@		5,000 UNITS/100ML	N19134 001 MAR 29, 1985
AP		MCGAW	5,000 UNITS/100ML	N19952 004 JUL 20, 1992
AP			10,000 UNITS/100ML	N19952 005 JUL 20, 1992
	@		5,000 UNITS/100ML	N19134 001 MAR 29, 1985

HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

	@	B BRAUN	5,000 UNITS/100ML	N19802 005 JUL 20, 1992
	@		10,000 UNITS/100ML	N19802 002 JUL 20, 1992
	@	MCGAW	5,000 UNITS/100ML	N19802 005 JUL 20, 1992
	@		10,000 UNITS/100ML	N19802 002 JUL 20, 1992

HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	@	B BRAUN	5,000 UNITS/100ML	N19135 001 MAR 29, 1985
	@		5,000 UNITS/100ML	N19802 003 JUL 20, 1992
	@	MCGAW	5,000 UNITS/100ML	N19135 001 MAR 29, 1985
	@		5,000 UNITS/100ML	N19802 003 JUL 20, 1992

HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	@	B BRAUN	1,000 UNITS/100ML	N19042 004 MAR 29, 1985
	@	MCGAW	1,000 UNITS/100ML	N19042 004 MAR 29, 1985

HEPARIN SODIUM IN PLASTIC CONTAINER

AP		AM PHARM PARTNERS	1,000 UNITS/ML	N17029 013 DEC 05, 1985
AP			5,000 UNITS/ML	N17029 014 DEC 05, 1985
AP			10,000 UNITS/ML	N17029 015 DEC 05, 1985

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM IN PLASTIC CONTAINER

AP		AM PHARM PARTNERS	20,000 UNITS/ML	N17029 016 DEC 05, 1985
AP		FUJISAWA	1,000 UNITS/ML	N17029 013 DEC 05, 1985
AP			5,000 UNITS/ML	N17029 014 DEC 05, 1985
AP			10,000 UNITS/ML	N17029 015 DEC 05, 1985
AP			20,000 UNITS/ML	N17029 016 DEC 05, 1985

HEPARIN SODIUM PRESERVATIVE FREE

AP	+	AM PHARM PARTNERS	1,000 UNITS/ML	N17029 010 APR 28, 1986
AP	+	FUJISAWA	1,000 UNITS/ML	N17029 010 APR 28, 1986

HEPFLUSH-10

AP		AM PHARM PARTNERS	10 UNITS/ML	N17651 009 JUN 26, 1984
AP		FUJISAWA	10 UNITS/ML	N17651 009 JUN 26, 1984

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

APRESOLINE

AP	+	NOVARTIS	20MG/ML	N08303 003
	@		20MG/ML	N08303 003

HYDRALAZINE HCL

AP		LUITPOLD	20MG/ML	N40136 001 JUN 10, 1997
AP	+		20MG/ML	N40136 001 JUN 30, 1997
AP	+	SOLOPAK	20MG/ML	N88517 001 AUG 22, 1985
AP			20MG/ML	N88517 001 AUG 22, 1985

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

AVAPRO HCT

@	SANOFI	12.5MG;75MG	N20758 001 SEP 30, 1997

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL
AVAPRO HCT
+ SANOFI 12.5MG;150MG N20758 002 SEP 30, 1997

IRBESARTAN-HYDROCHLOROTHIAZIDE
@ SANOFI 12.5MG;75MG N20758 001 SEP 30, 1997
+ 12.5MG;150MG N20758 002 SEP 30, 1997

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL
METHYLDOPA AND HYDROCHLOROTHIAZIDE
AB INVAMED 15MG;250MG N70829 001 MAR 09, 1987
AB 25MG;250MG N70830 001 MAR 09, 1987
@ 15MG;250MG N70829 001 MAR 09, 1987
@ 25MG;250MG N70830 001 MAR 09, 1987

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL
PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE
AB DANBURY PHARMA 25MG;40MG N71498 001 DEC 18, 1991
AB 25MG;80MG N71501 001 DEC 18, 1991
@ 25MG;40MG N71498 001 DEC 18, 1991
@ 25MG;80MG N71501 001 DEC 18, 1991

HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL
HYDROPRES 25
BP MERCK 25MG;0.125MG N11958 002
BP MERCK SHARP DOHME 25MG;0.125MG N11958 002
HYDROPRES 50
BP + MERCK 50MG;0.125MG N11958 003

HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL
HYDROPRES 50
BP + MERCK SHARP DOHME 50MG;0.125MG N11958 003

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE
AB GENEVA PHARMS 25MG;25MG N86881 001
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE
AB GENEVA PHARMS 25MG;25MG N86881 001

HYDROCHLOROTHIAZIDE; TIMOLOL MALEATE

TABLET; ORAL
TIMOLIDE 10-25
+ MERCK 25MG;10MG N18061 001
+ MERCK SHARP DOHME 25MG;10MG N18061 001

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL
TRIAMTERENE AND HYDROCHLOROTHIAZIDE
AB BARR 25MG;37.5MG **N74970 001** JAN 06, 1998

TABLET; ORAL
TRIAMTERENE AND HYDROCHLOROTHIAZIDE
AB BARR 25MG;37.5MG **N71251 002** MAY 05, 1998

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL
DIOVAN HCT
NOVARTIS 12.5MG;80MG N20818 001 MAR 06, 1998
+ 12.5MG;160MG N20818 002 MAR 06, 1998

HYDROCORTISONE

AEROSOL, TOPICAL

AEROSEB-HC

	+	ALLERGAN HERBERT	0.5%	N85805 001
	@		0.5%	N85805 001

CREAM; TOPICAL

ANUSOL HC

AT		PARKE DAVIS	2.5%	N88250 001 JUN 06, 1984
AT		PARKEDALE	2.5%	N88250 001 JUN 06, 1984

ELDECORT

	@	ELDER	1%	N80459 001
	@		2.5%	N84055 001
	@	ICN	1%	N80459 001
	@		2.5%	N84055 001

HYDROCORTISONE

> ADD >	AT	ALPHARMA US PHARM	1%	N87795 001 MAY 03, 1983
> DLT >	AT	NMC	1%	N87795 001 MAY 03, 1983

LOTION; TOPICAL

CETACORT

AT		GALDERMA	0.5%	N80426 002
AT			1%	N80426 001
AT		HEALTHPOINT	0.5%	N80426 002
AT			1%	N80426 001

SOLUTION; TOPICAL

TEXACORT

AT	+	GENDERM	1%	N80425 001
AT	+	MEDICIS	1%	N80425 001

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OPHTHALMIC

CORTISPORIN

AT	+	GLAXO WELLCOME	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N50169 001
AT	+	MONARCH PHARMS	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N50169 001

SUSPENSION/DROPS; OTIC

CORTISPORIN

	@	GLAXO WELLCOME	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N60613 001

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OTIC

CORTISPORIN

AT	+	MONARCH PHARMS	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N60613 001

HYDROCORTISONE VALERATE

CREAM; TOPICAL

HYDROCORTISONE VALERATE

AB		COPLEY PHARM	0.2%	N74489 001 AUG 12, 1998
AB		TARO	0.2%	N75042 001 AUG 25, 1998

WESTCORT

AB	+	WESTWOOD SQUIBB	0.2%	N17950 001

OINTMENT; TOPICAL

HYDROCORTISONE VALERATE

AB		TARO	0.2%	N75043 001 AUG 25, 1998

WESTCORT

AB	+	WESTWOOD SQUIBB	0.2%	N18726 001 AUG 08, 1983

HYDROMORPHONE HYDROCHLORIDE

SOLUTION; ORAL

DILAUDID

AA	+	KNOLL PHARM	5MG/5ML	N19891 001 DEC 07, 1992

HYDROMORPHONE HCL

AA		ROXANE	5MG/5ML	N74653 001 JUL 29, 1998

TABLET; ORAL

DILAUDID

AB	+	KNOLL PHARM	8MG	N19892 001 DEC 07, 1992

HYDROMORPHONE HCL

AB		ROXANE	8MG	N74597 001 JUL 29, 1998

HYDROXYAMPHETAMINE HYDROBROMIDE; TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC

	PAREMYD			
+	AKORN	1%;0.25%	N19261 001	JAN 30, 1992
+	ALLERGAN	1%;0.25%	N19261 001	JAN 30, 1992

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

	HYDROXYCHLOROQUINE SULFATE			
AB	MYLAN	**200MG**	**N40274 001**	MAY 29, 1998
	HYDROXYCHLOROQUINE SULFATE			
AB	ROYCE LABS	**200MG**	**N40133 001**	NOV 30, 1995
AB	WATSON LABS	**200MG**	**N40133 001**	NOV 30, 1995

HYDROXYUREA

CAPSULE; ORAL

	DROXIA			
	BRISTOL MYERS SQUIBB	300MG	N16295 003	FEB 28, 1998
		200MG	N16295 002	FEB 25, 1998
		300MG	N16295 003	FEB 25, 1998
+		400MG	N16295 004	FEB 25, 1998
	HYDREA			
AB +	BRISTOL MYERS SQUIBB	**500MG**	**N16295 001**	
AB +	SQUIBB	**500MG**	**N16295 001**	
	HYDROXYUREA			
AB	BARR	**500MG**	**N75143 001**	OCT 16, 1998
AB	DURAMED	**500MG**	**N75020 001**	JUL 30, 1998

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL

	HYDROXYZINE HCL			
AB	ROYCE LABS	**10MG**	**N81149 001**	MAR 18, 1994
AB		**25MG**	**N81150 001**	MAR 18, 1994
AB		**50MG**	**N81151 001**	MAR 18, 1994
AB	WATSON LABS	**10MG**	**N81149 001**	MAR 18, 1994
AB		**25MG**	**N81150 001**	MAR 18, 1994
AB		**50MG**	**N81151 001**	MAR 18, 1994

HYDROXYZINE PAMOATE

CAPSULE; ORAL

	HYDROXYZINE PAMOATE			
AB	DANBURY PHARMA	**EQ 50MG HCL**	**N87767 001**	AUG 16, 1982
AB		**EQ 100MG HCL**	**N87790 001**	AUG 16, 1982
	@	EQ 50MG HCL	N87767 001	AUG 16, 1982
	@	EQ 100MG HCL	N87790 001	AUG 16, 1982

IBUPROFEN

SUSPENSION; ORAL

	CHILDREN'S ADVIL			
BX	AM HOME PRODS	100MG/5ML	N19833 002	SEP 19, 1989
BX	WHITEHALL ROBINS	100MG/5ML	N19833 002	SEP 19, 1989
	IBUPROFEN			
AB	ALPHARMA	**100MG/5ML**	**N74978 001**	MAR 25, 1998
	MOTRIN			
AB +	MCNEIL	**100MG/5ML**	**N19842 001**	SEP 19, 1989
BX +		100MG/5ML	N19842 001	SEP 19, 1989

IBUPROFEN

TABLET; ORAL

	IBUPROFEN			
AB	INVAMED	**400MG**	**N72064 001**	**JAN 14, 1988**
AB		**600MG**	**N72065 001**	**JAN 14, 1988**
AB		**800MG**	**N71938 001**	**JAN 14, 1988**
	@	400MG	N72064 001	JAN 14, 1988
	@	600MG	N72065 001	JAN 14, 1988
	@	800MG	N71938 001	JAN 14, 1988

INDAPAMIDE

TABLET; ORAL

	INDAPAMIDE			
AB	ALPHAPHARM	**1.25MG**	**N75105 001**	JUL 23, 1998
AB		**2.5MG**	**N75105 002**	JUL 23, 1998
> DLT > **AB**	NOVOPHARM	**1.25MG**	**N74665 001**	**APR 04, 1997**
> DLT > **AB**		**2.5MG**	**N74665 002**	**APR 04, 1997**
> ADD >	@	1.25MG	N74665 001	APR 04, 1997
> ADD >	@	2.5MG	N74665 002	APR 04, 1997
AB	TEVA	**1.25MG**	**N74498 002**	FEB 12, 1998
> ADD > **AB**	TRIGEN	**1.25MG**	**N75201 001**	DEC 04, 1998
> ADD > **AB**		**2.5MG**	**N75201 002**	DEC 04, 1998

INDINAVIR SULFATE

CAPSULE; ORAL

	CRIXIVAN		
> ADD >	MERCK	EQ 333MG BASE	N20685 005 DEC 17, 1998

INDOMETHACIN

CAPSULE; ORAL

	INDOMETHACIN			
AB	DANBURY PHARMA	**25MG**	**N72996 001**	**JUL 31, 1991**
AB		**50MG**	**N72997 001**	**JUL 31, 1991**
	@	25MG	N72996 001	JUL 31, 1991
	@	50MG	N72997 001	JUL 31, 1991
AB	EON	**75MG**	**N74464 001**	MAY 28, 1998

INSULIN LISPRO

INJECTABLE; INJECTION

	HUMALOG PEN		
+	LILLY	100 UNITS/ML	N20563 002 AUG 06, 1998

IODAMIDE MEGLUMINE

INJECTABLE; INJECTION

	RENOVUE-DIP		
+	BRACCO	24%	N17903 001
	@	24%	N17903 001

IOPAMIDOL

INJECTABLE; INJECTION

	IOPAMIDOL			
AP	ELKINS SINN	**51%**	**N74629 004**	MAR 31, 1998
	IOPAMIDOL-250			
AP	ABBOTT	**51%**	**N75005 001**	FEB 24, 1998
	IOPAMIDOL-300			
AP	ABBOTT	**61%**	**N75005 002**	FEB 24, 1998
	IOPAMIDOL-370			
AP	ABBOTT	**76%**	**N75005 003**	FEB 24, 1998

IOTROLAN

INJECTABLE; INTRATHECAL						
OSMOVIST 190						
BERLEX LABS	40.6%	N19580 001	> DLT >			
		DEC 07, 1989	> DLT >			
@	40.6%	N19580 001	> ADD >			
		DEC 07, 1989				
OSMOVIST 240						
BERLEX LABS	51.3%	N19580 002				
		DEC 07, 1989				
@	51.3%	N19580 002				
		DEC 07, 1989				

IOVERSOL

INJECTABLE; INJECTION						
OPTIRAY 240						
+ MALLINCKRODT	51%	N20923 001				
		MAY 28, 1998				
OPTIRAY 320						
+ MALLINCKRODT	68%	N20923 002				
		MAY 29, 1998	> ADD >			
			> ADD >			
OPTIRAY 350						
+ MALLINCKRODT	74%	N20923 003				
		MAY 28, 1998	> ADD >	AB		
			> ADD >			

IPRATROPIUM BROMIDE

AEROSOL, METERED; INHALATION						
ATROVENT						
BOEHRINGER INGELHEIM	0.018MG/INH	N19085 001				
		DEC 29, 1986				
+	0.018MG/INH	N19085 001				
		DEC 29, 1986				

ISOPROTERENOL HYDROCHLORIDE

AEROSOL, METERED; INHALATION						
ISUPREL						
+ SANOFI	0.111MG/INH	N11178 001				
+	0.103MG/INH	N11178 001				

ISOPROTERENOL HYDROCHLORIDE; PHENYLEPHRINE BITARTRATE

AEROSOL, METERED, INHALATION						
DUO-MEDIHALER						
+ 3M	0.16MG/INH;0.24MG/INH	N13296 001				
@	0.16MG/INH;0.24MG/INH	N13296 001				

ISOSORBIDE DINITRATE

TABLET; SUBLINGUAL						
SORBITRATE						
ZENECA	2.5MG	N16191 002				
		APR 01, 1996				
	5MG	N16191 001				
		APR 01, 1996				
@	2.5MG	N16191 002				
		APR 01, 1996				
@	5MG	N16191 001				
		APR 01, 1996				
TABLET, EXTENDED RELEASE; ORAL						
ISORDIL						
+ WYETH AYERST	**40MG**	**N12882 001**	> ADD >	**AB**		
		JUL 29, 1988	> ADD >			
ISOSORBIDE DINITRATE						
INWOOD LABS	**40MG**	**N40009 001**	> ADD >	**AB**		
		DEC 30, 1998	> ADD >			

ISOSORBIDE MONONITRATE

TABLET; ORAL						
ISOSORBIDE MONONITRATE						
PUREPAC PHARM	**10MG**	**N75037 002**		**AB**		
		OCT 30, 1998				
	20MG	**N75037 001**		**AB**		
		OCT 30, 1998				
TEVA	**20MG**	**N75147 001**		**AB**		
		NOV 27, 1998				
MONOKET						
SCHWARZ	**10MG**	**N20215 002**		**AB**		
		JUN 30, 1993				
TABLET, EXTENDED RELEASE; ORAL						
IMDUR						
+ SCHERING	**30MG**	**N20225 001**	> ADD >	**AB**		
		AUG 12, 1993	> ADD >			

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE; ORAL

		IMDUR			
AB	+	SCHERING	**60MG**	**N20225 002**	
				AUG 12, 1993	
		ISOSORBIDE MONONITRATE			
AB		ELAN PHARM	**60MG**	**N75041 001**	
				SEP 22, 1998	
AB		KREMERS URBAN	**60MG**	**N75155 001**	
				OCT 30, 1998	
> ADD > **AB**		PUREPAC PHARM	**30MG**	**N75306 001**	
> ADD >				DEC 31, 1998	
> ADD > **AB**			**60MG**	**N75306 002**	
> ADD >				DEC 31, 1998	

ISOSULFAN BLUE

INJECTABLE; INJECTION

	LYMPHAZURIN			
	+ HIRSCH INDS	1%		N18310 001
	+ US SURGCL	1%		N18310 001

KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

	KETALAR			
AP	+ PARKE DAVIS	**EQ 50MG BASE/ML**	**N16812 002**	
AP	+	**EQ 100MG BASE/ML**	**N16812 003**	
	+	EQ 10MG BASE/ML	N16812 001	
AP	+ PARKEDALE	**EQ 50MG BASE/ML**	**N16812 002**	
AP	+	**EQ 100MG BASE/ML**	**N16812 003**	
	+	EQ 10MG BASE/ML	N16812 001	

KETOPROFEN

CAPSULE, EXTENDED RELEASE; ORAL

ORUVAIL			
+ WYETH AYERST	100MG		N19816 003
			FEB 08, 1995
+	150MG		N19816 002
			FEB 08, 1995
	100MG		N19816 003
			FEB 08, 1995
	150MG		N19816 002
			FEB 08, 1995

LABETALOL HYDROCHLORIDE

TABLET; ORAL

	LABETALOL HCL			
AB	APOTHECON	**100MG**	**N75223 001**	
			NOV 20, 1998	
AB		**200MG**	**N75223 002**	
			NOV 20, 1998	
AB		**300MG**	**N75223 003**	
			NOV 20, 1998	
AB	EON	**100MG**	**N75113 001**	
			AUG 04, 1998	
AB		**200MG**	**N75113 002**	
			AUG 04, 1998	
AB		**300MG**	**N75113 003**	
			AUG 04, 1998	
AB	TEVA	**100MG**	**N74989 001**	
			SEP 30, 1998	
AB		**200MG**	**N74989 002**	
			SEP 30, 1998	
AB		**300MG**	**N74989 003**	
			SEP 30, 1998	
AB	WATSON LABS	**100MG**	**N75133 001**	
			AUG 03, 1998	
AB		**200MG**	**N75133 002**	
			AUG 03, 1998	
AB		**300MG**	**N75133 003**	
			AUG 03, 1998	
AB	ZENITH GOLDLINE	**100MG**	**N74787 001**	
			AUG 03, 1998	
AB		**200MG**	**N74787 002**	
			AUG 03, 1998	
AB		**300MG**	**N74787 003**	
			AUG 03, 1998	

LACTULOSE

POWDER FOR RECONSTITUTION; ORAL

LACTULOSE			
INALCO	10GM/PACKET		N74712 001
			DEC 10, 1997
+	10GM/PACKET		N74712 001
			DEC 10, 1997

LAMIVUDINE

SOLUTION; ORAL

> ADD >	EPIVIR-HBV			
> ADD >	+ GLAXO WELLCOME	5MG/ML	N21004 001	
> ADD >			DEC 08, 1998	

TABLET; ORAL

> ADD >	EPIVIR-HBV			
> ADD >	+ GLAXO WELLCOME	100MG	N21003 001	
> ADD >			DEC 08, 1998	

LAMOTRIGINE

TABLET, CHEWABLE; ORAL

	LAMICTAL CD			
	GLAXO WELLCOME	5MG	N20764 001	
			AUG 24, 1998	
		25MG	N20764 002	
			AUG 24, 1998	
	+	100MG	N20764 003	
			AUG 24, 1998	

LEFLUNOMIDE

TABLET; ORAL

	ARAVA			
	HOECHST MARION RSSL	10MG	N20905 001	
			SEP 10, 1998	
		20MG	N20905 002	
			SEP 10, 1998	
	+	100MG	N20905 003	
			SEP 10, 1998	
	QUINTILES	10MG	N20905 001	
			SEP 10, 1998	
		20MG	N20905 002	
			SEP 10, 1998	
	‡	100MG	N20905 003	
			SEP 10, 1998	

LEPIRUDIN

INJECTABLE; INJECTION

	REFLUDAN			
	+ HOECHST MARION RSSL	50MG/VIAL	N20807 001	
			MAR 06, 1998	

LEUPROLIDE ACETATE

INJECTABLE; INJECTION

	LEUPROLIDE ACETATE			
AP	BEDFORD LABS	**1MG/0.2ML**	**N74728 001**	
			AUG 04, 1998	
	LUPRON			
AP	+ TAP HOLDINGS	**1MG/0.2ML**	**N19010 001**	
			APR 09, 1985	

LEVODOPA

CAPSULE; ORAL

	DOPAR			
	ROBERTS LABS	100MG	N16913 003	
		250MG	N16913 001	
	‡	500MG	N16913 002	
	@	100MG	N16913 003	
	+	250MG	N16913 001	
	@	500MG	N16913 002	

LEVORPHANOL TARTRATE

INJECTABLE; INJECTION

	LEVO-DROMORAN			
	+ ICN	2MG/ML	N08719 001	
			DEC 19, 1991	
	‡ ROCHE	2MG/ML	N08719 001	
			DEC 19, 1991	

TABLET; ORAL

	LEVO-DROMORAN			
	+ ICN	2MG	N08720 001	
			DEC 19, 1991	
	‡ ROCHE	2MG	N08720 001	
			DEC 19, 1991	

LIDOCAINE

AEROSOL; ORAL

	XYLOCAINE			
	ASTRA	10%	N14394 001	
	+ ASTRA PHARMS	10%	N14394 001	

LIDOCAINE; PRILOCAINE

AEROSOL; TOPICAL

	EMLA			
+	ASTRA PHARMS	2.5%;2.5%	N20962 001	
			FEB 04, 1998	

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

	LIDOCAINE HCL			
AP	ABBOTT	1%	N80408 001	
AP		1.5%	N80408 002	
AP		4%	N88295 001	
			MAY 17, 1984	
AP	ELKINS SINN	1%	N84625 001	
AP		2%	N84625 002	
AP	FUJISAWA	1%	N80404 002	
AP		2%	N17584 001	
AP		2%	N80404 003	
AP		4%	N17584 002	
AP	INTL MEDICATION	20%	N17702 001	
	LIDOCAINE HCL PRESERVATIVE FREE			
AP	ABBOTT	1%	N80408 001	
AP		1.5%	N80408 002	
AP		4%	N88295 001	
			MAY 17, 1984	
AP	AM PHARM PARTNERS	1%	N80404 002	
AP		2%	N17584 001	
AP		2%	N80404 003	
AP		4%	N17584 002	
AP	ELKINS SINN	1%	N84625 001	
AP		2%	N84625 002	
AP	INTL MEDICATION	20%	N17702 001	
	LIDOCAINE HCL PRESERVATIVE FREE IN PLASTIC CONTAINER			
AP	ABBOTT	1%	N40302 001	
			SEP 28, 1998	
AP		2%	N40302 002	
			SEP 28, 1998	
	XYLOCAINE			
AP	ASTRA	2%	N16801 001	
AP		4%	N16801 002	
AP	+	10%	N16801 003	
AP	+	20%	N16801 004	
	XYLOCAINE 4%			
AP	+ ASTRA	4%	N10417 001	
	XYLOCAINE 4% PRESERVATIVE FREE			
AP	+ ASTRA PHARMS	4%	N10417 001	

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

	XYLOCAINE PRESERVATIVE FREE			
AP	ASTRA PHARMS	2%	N16801 001	
AP		4%	N16801 002	
AP	+	10%	N16801 003	
AP	+	20%	N16801 004	

LISINOPRIL

TABLET; ORAL

	ZESTRIL			
AB	+ ZENECA	2.5MG	N19777 005	
			APR 29, 1993	
AB		2.5MG	N19777 005	
			APR 29, 1993	
AB		10MG	N19777 002	
			MAY 19, 1988	
AB	+	10MG	N19777 002	
			MAY 19, 1988	

LORATADINE

TABLET; ORAL

	CLARITIN REDITABS			
	SCHERING	10MG	N20704 001	
			DEC 23, 1996	

TABLET, ORALLY DISINTEGRATING; ORAL

	CLARITIN REDITABS			
+	SCHERING	10MG	N20704 001	
			DEC 23, 1996	

LORAZEPAM

INJECTABLE; INJECTION

	LORAZEPAM			
AP	AKORN	2MG/ML	N74974 001	
			JUL 23, 1998	
AP	ELKINS SINN	2MG/ML	N74496 001	
			SEP 28, 1998	
AP		4MG/ML	N74496 002	
			SEP 28, 1998	
AP	TAYLOR	2MG/ML	N75025 001	
			JUL 23, 1998	

LORAZEPAM

TABLET; ORAL
LORAZEPAM

AB	ROYCE LABS	0.5MG	N72926 001	OCT 31, 1991
AB		1MG	N72927 001	OCT 31, 1991
AB		2MG	N72928 001	OCT 31, 1991
AB	WATSON LABS	0.5MG	N72926 001	OCT 31, 1991
AB		1MG	N72927 001	OCT 31, 1991
AB		2MG	N72928 001	OCT 31, 1991

LOTEPREDNOL ETABONATE

SUSPENSION/DROPS; OPHTHALMIC
ALREX

+	PHARMOS	0.2%	N20803 001 MAR 09, 1998

LOTEMAX

+	PHARMOS	0.5%	N20583 001 MAR 09, 1998
+		0.5%	N20841 001 MAR 09, 1998

LOXAPINE HYDROCHLORIDE

CONCENTRATE; ORAL
LOXITANE C

*	COCENSYS	EQ 25MG BASE/ML	N17658 001
+	WATSON LABS	EQ 25MG BASE/ML	N17658 001

INJECTABLE; INJECTION
LOXITANE IM

*	COCENSYS	EQ 50MG BASE/ML	N18039 001
+	WATSON LABS	EQ 50MG BASE/ML	N18039 001

LOXAPINE SUCCINATE

CAPSULE; ORAL
LOXITANE

AB	COCENSYS	EQ 5MG BASE	N17525 001

LOXAPINE SUCCINATE

CAPSULE; ORAL
LOXITANE

AB	COCENSYS	EQ 10MG BASE	N17525 002
AB	*	EQ 25MG BASE	N17525 003
AB		EQ 50MG BASE	N17525 004
AB	WATSON LABS	EQ 5MG BASE	N17525 001
AB		EQ 10MG BASE	N17525 002
AB	+	EQ 25MG BASE	N17525 003
AB		EQ 50MG BASE	N17525 004

TABLET; ORAL
LOXITANE

@	COCENSYS	EQ 10MG BASE	N17525 006
@		EQ 25MG BASE	N17525 007
@		EQ 50MG BASE	N17525 008
@	WATSON LABS	EQ 10MG BASE	N17525 006
@		EQ 25MG BASE	N17525 007
@		EQ 50MG BASE	N17525 008

MAFENIDE ACETATE

CREAM; TOPICAL
SULFAMYLON

+	BERTEK	EQ 85MG BASE/GM	N16763 001
*	DOW HICKAM	EQ 85MG BASE/GM	N16763 001

POWDER FOR RECONSTITUTION; TOPICAL
SULFAMYLON

+	MYLAN	5%	N19832 003 JUN 05, 1998

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC

INJECTABLE; INJECTION
ISOLYTE S PH 7.4 IN PLASTIC CONTAINER

	B BRAUN	30MG/100ML;37MG/100ML;0.82MG/100ML; 370MG/100ML;530MG/100ML;500MG/100ML; 12MG/100ML	N19696 001 SEP 29, 1989

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC

INJECTABLE; INJECTION
ISOLYTE S PH 7.4 IN PLASTIC CONTAINER

	MCGAW	30MG/100ML;37MG/100ML;0.82MG/100ML; 370MG/100ML;530MG/100ML;500MG/100ML; 12MG/100ML	N19696 001 SEP 29, 1989

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION
ISOLYTE S IN PLASTIC CONTAINER

AP	B BRAUN	30MG/100ML;37MG/100ML;370MG/100ML; 530MG/100ML;500MG/100ML	N18252 001
AP		30MG/100ML;37MG/100ML;370MG/100ML; 530MG/100ML;500MG/100ML	N19711 001 SEP 29, 1989
AP	MCGAW	30MG/100ML;37MG/100ML;370MG/100ML; 530MG/100ML;500MG/100ML	N18252 001
AP		30MG/100ML;37MG/100ML;370MG/100ML; 530MG/100ML;500MG/100ML	N19711 001 SEP 29, 1989

MALATHION

LOTION; TOPICAL
OVIDE

@	GENDERM	0.5%	N18613 001 AUG 02, 1982
@	MEDICIS	0.5%	N18613 001 AUG 02, 1982

MANNITOL

INJECTABLE; INJECTION
MANNITOL 10% IN PLASTIC CONTAINER

AP	B BRAUN	10GM/100ML	N20006 002 JUL 26, 1993
AP	MCGAW	10GM/100ML	N20006 002 JUL 26, 1993

MANNITOL 15% IN PLASTIC CONTAINER

AP	B BRAUN	15GM/100ML	N20006 003 JUL 26, 1993
AP	MCGAW	15GM/100ML	N20006 003 JUL 26, 1993

MANNITOL 20%

AP	B BRAUN	20GM/100ML	N14738 001
AP	MCGAW	20GM/100ML	N14738 001

MANNITOL 20% IN PLASTIC CONTAINER

AP	B BRAUN	20GM/100ML	N20006 004 JUL 26, 1993
AP	MCGAW	20GM/100ML	N20006 004 JUL 26, 1993

MANNITOL 5% IN PLASTIC CONTAINER

AP	B BRAUN	5GM/100ML	N20006 001 JUL 26, 1993
AP	MCGAW	5GM/100ML	N20006 001 JUL 26, 1993

SOLUTION; IRRIGATION
RESECTISOL IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML	N16772 002
	MCGAW	5GM/100ML	N16772 002

MECAMYLAMINE HYDROCHLORIDE

TABLET; ORAL
INVERSINE

+	LAYTON	2.5MG	N10251 001
+	MERCK SHARP DOHME	2.5MG	N10251 001

MEGESTROL ACETATE

TABLET; ORAL
MEGESTROL ACETATE

AB	PHARMACHEMIE	40MG	N74745 001 FEB 27, 1998

MEPERIDINE HYDROCHLORIDE

TABLET; ORAL
MEPERIDINE HCL

AA	ROYCE LABS	50MG	N40186 001 JUN 30, 1997

MEPERIDINE HYDROCHLORIDE

TABLET; ORAL
MEPERIDINE HCL

> ADD >	**AA**	VINTAGE PHARMS	**50MG**	**N40191 001** DEC 17, 1998
> ADD >	**AA**		**100MG**	**N40191 002** DEC 17, 1998
> ADD >	**AA**	WATSON LABS	**50MG**	**N40186 001** JUN 30, 1997

MEPROBAMATE

TABLET; ORAL
MEPROBAMATE

AA	DANBURY PHARMA	**600MG**	**N84274 001**
	@	600MG	N84274 001

MESALAMINE

CAPSULE, EXTENDED RELEASE; ORAL
PENTASA

‡	HOECHST MARION RSSL	250MG	N20049 001 MAY 10, 1993
+	ROBERTS LABS	250MG	N20049 001 MAY 10, 1993

MESTRANOL; NORETHINDRONE

TABLET; ORAL-21
NORETHIN 1/50M-21

AB	SEARLE	**0.05MG;1MG**	**N71539 001** APR 12, 1988
AB	WATSON LABS	**0.05MG;1MG**	**N71539 001** APR 12, 1988

TABLET; ORAL-28
NORETHIN 1/50M-28

AB	SEARLE	**0.05MG;1MG**	**N71540 001** APR 12, 1988
AB	WATSON LABS	**0.05MG;1MG**	**N71540 001** APR 12, 1988

METFORMIN HYDROCHLORIDE

TABLET; ORAL
GLUCOPHAGE

	BRISTOL MYERS SQUIBB	500MG	N20357 001 MAR 03, 1995
‡		850MG	N20357 002 MAR 03, 1995
+		500MG	N20357 001 MAR 03, 1995
		625MG	N20357 003 NOV 05, 1998
		750MG	N20357 004 NOV 05, 1998
		850MG	N20357 002 MAR 03, 1995
+		1GM	N20357 005 NOV 05, 1998

METHADONE HYDROCHLORIDE

CONCENTRATE; ORAL
METHADONE HCL

AA	ROXANE	**10MG/ML**	**N40180 001** APR 30, 1998

TABLET; ORAL
METHADONE HCL

AA	EON	**5MG**	**N40241 001** MAY 29, 1998
AA		**10MG**	**N40241 002** MAY 29, 1998

TABLET, DISPERSIBLE; ORAL
METHADONE HCL

AA	EON	**40MG**	**N75082 001** MAR 25, 1998

METHOCARBAMOL

INJECTABLE; INJECTION
METHOCARBAMOL

AP	MARSAM	**100MG/ML**	**N89849 001** DEC 27, 1991
	@	100MG/ML	N89849 001 DEC 27, 1991

METHOCARBAMOL

TABLET; ORAL

	FORBAXIN				
AA	FOREST LABS	**750MG**	**N85136 001**		
	@	750MG	N85136 001		
	METHOCARBAMOL				
AA	INWOOD LABS	**500MG**	**N85137 001**		
	@	500MG	N85137 001		

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION

	METHYLDOPATE HCL				
> DLT > **AP**	FAULDING	**50MG/ML**	**N70691 001**		
> DLT >			JUN 19, 1987		
> DLT > **AP**		**50MG/ML**	**N70849 001**		
> DLT >			JUN 19, 1987		
> ADD >	@	50MG/ML	N70691 001		
> ADD >			JUN 19, 1987		
> ADD >	@	50MG/ML	N70849 001		
> ADD >			JUN 19, 1987		

METHYLPHENIDATE HYDROCHLORIDE

TABLET; ORAL

	METHYLPHENIDATE HCL				
AB	MALLINCKRODT	**5MG**	**N40300 001**		
			NOV 27, 1998		
AB		**10MG**	**N40300 002**		
			NOV 27, 1998		
AB		**20MG**	**N40300 003**		
			NOV 27, 1998		

TABLET, EXTENDED RELEASE; ORAL

	METHYLPHENIDATE HCL				
> DLT > **AB**	MD PHARM	**20MG**	**N89601 001**		
> DLT >			JUN 01, 1988		
> ADD > **AB**	MEDEVA PHARMS CA	**20MG**	**N89601 001**		
> ADD >			JUN 01, 1988		

METHYLPREDNISOLONE

TABLET; ORAL

	METHYLPREDNISOLONE				
> ADD > **AB**	VINTAGE PHARMS	**4MG**	**N40183 001**		
> ADD >			DEC 22, 1998		

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

	METOCLOPRAMIDE HCL				
> DLT > **AP**	BEDFORD	**EQ 5MG BASE/ML**	**N72155 001**		
> DLT >			MAR 30, 1992		
> DLT > **AP**		**EQ 5MG BASE/ML**	**N72244 001**		
> DLT >			MAR 30, 1992		
> DLT > **AP**		**EQ 5MG BASE/ML**	**N72247 001**		
> DLT >			MAY 18, 1992		
> ADD >	@	EQ 5MG BASE/ML	N72155 001		
> ADD >			MAR 30, 1992		
> ADD >	@	EQ 5MG BASE/ML	N72244 001		
> ADD >			MAR 30, 1992		
> ADD >	@	EQ 5MG BASE/ML	N72247 001		
> ADD >			MAY 18, 1992		

TABLET; ORAL

	METOCLOPRAMIDE HCL				
AB	INVAMED	**EQ 5MG BASE**	**N72436 001**		
			JUN 22, 1989		
AB		**EQ 10MG BASE**	**N70850 001**		
			FEB 03, 1987		
	@	EQ 5MG BASE	N72436 001		
			JUN 22, 1989		
	@	EQ 10MG BASE	N70850 001		
			FEB 03, 1987		

METOPROLOL TARTRATE

INJECTABLE; INJECTION

	METOPROLOL TARTRATE				
AP	ABBOTT	**1MG/ML**	**N75160 001**		
			JUL 06, 1998		

METRONIDAZOLE

LOTION; TOPICAL

	METROLOTION				
+	GALDERMA	0.75%	N20901 001		
			NOV 24, 1998		

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL
MEXILETINE HCL

AB	DANBURY PHARMA	**150MG**	**N74865 001**	APR 13, 1998
AB		**200MG**	**N74865 002**	APR 13, 1998
AB		**250MG**	**N74865 003**	APR 13, 1998

MICONAZOLE NITRATE

TAMPON; VAGINAL
MONISTAT 5

>ADD>	+ ADVANCED CARE PRODS	100MG	N18592 001	OCT 27, 1989
>DLT>	+ JOHNSON RW	100MG	N18592 001	OCT 27, 1989

MIDAZOLAM HYDROCHLORIDE

SYRUP; ORAL
VERSED

	+ ROCHE	EQ 2MG BASE/ML	N20942 001	OCT 15, 1998

MITOMYCIN

INJECTABLE; INJECTION
MITOMYCIN

AP	SUPERGEN	**5MG/VIAL**	**N64144 001**	APR 30, 1998
AP		**20MG/VIAL**	**N64144 002**	APR 30, 1998

>ADD> MODAFINIL

>ADD> TABLET; ORAL
>ADD> PROVIGIL

>ADD>	CEPHALON	100MG	N20717 001	DEC 24, 1998
>ADD>	+	200MG	N20717 002	DEC 24, 1998

MONTELUKAST SODIUM

TABLET; ORAL
SINGULAIR

	+ MERCK	EQ 10MG BASE	N20829 002	FEB 20, 1998

TABLET, CHEWABLE; ORAL
SINGULAIR

	+ MERCK	EQ 5MG BASE	N20830 001	FEB 20, 1998

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL
KADIAN

	+ FAULDING	20MG	N20616 001	JUL 03, 1996
	+	50MG	N20616 002	JUL 03, 1996
	+	100MG	N20616 003	JUL 03, 1996
	+ FAULDING SVCS	20MG	N20616 001	JUL 03, 1996
	+	50MG	N20616 002	JUL 03, 1996
	+	100MG	N20616 003	JUL 03, 1996

TABLET, EXTENDED RELEASE; ORAL
MORPHINE SULFATE

AB	AB GENERICS	**15MG**	**N74862 001**	JUL 07, 1998
AB		**30MG**	**N74862 002**	JUL 07, 1998
AB		**60MG**	**N74862 003**	JUL 07, 1998
AB		**100MG**	**N74769 001**	JUL 02, 1998
AB		**200MG**	**N74769 002**	JUL 02, 1998
AB	ENDO PHARMS	**15MG**	**N75295 001**	OCT 28, 1998
AB		**30MG**	**N75295 002**	OCT 28, 1998
AB		**60MG**	**N75295 003**	OCT 28, 1998

MORPHINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

		MS CONTIN		
AB	+	PURDUE FREDERICK	15MG	N19516 003 SEP 12, 1989
AB	+		30MG	N19516 001 MAY 29, 1987
AB	+		60MG	N19516 002 APR 08, 1988
AB	+		100MG	N19516 004 JAN 16, 1990
AB	+		200MG	N19516 005 NOV 08, 1993
BC	+		15MG	N19516 003 SEP 12, 1989
BC	+		30MG	N19516 001 MAY 29, 1987
BC	+		60MG	N19516 002 APR 08, 1988
BC	+		100MG	N19516 004 JAN 16, 1990

MYCOPHENOLATE MOFETIL

SUSPENSION; ORAL

		CELLCEPT		
	+	ROCHE GLOBAL	200MG/ML	N50759 001 OCT 01, 1998

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

INJECTABLE; INJECTION

		CELLCEPT		
	+	ROCHE GLOBAL	500MG/VIAL	N50758 001 AUG 12, 1998

NADOLOL

TABLET; ORAL

		CORGARD		
AB		BRISTOL MYERS SQUIBB	20MG	N18063 005 OCT 28, 1986
AB			40MG	N18063 001
AB			80MG	N18063 002
AB			120MG	N18063 003
AB	+	BRISTOL MYERS SQUIBB	160MG	N18063 004
AB		SQUIBB	20MG	N18063 005 OCT 28, 1986
AB			40MG	N18063 001
AB			80MG	N18063 002
AB			120MG	N18063 003
AB	+		160MG	N18063 004

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

		NALBUPHINE HCL		
AP		KING PHARMS	10MG/ML	N74471 001 MAR 19, 1998
AP			20MG/ML	N74471 002 MAR 19, 1998

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

		NALOXONE HCL		
AP		ABBOTT	0.4MG/ML	N70172 001 SEP 24, 1986
	@		0.4MG/ML	N70172 001 SEP 24, 1986

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

		PENTAZOCINE AND NALOXONE HYDROCHLORIDES		
AB		ROYCE LABS	EQ 0.5MG BASE; EQ 50MG BASE	N74736 001 JAN 21, 1997
AB		WATSON LABS	EQ 0.5MG BASE; EQ 50MG BASE	N74736 001 JAN 21, 1997

NALTREXONE HYDROCHLORIDE

TABLET; ORAL

	NALTREXONE HCL			
AB	BARR	50MG	N74918 001	MAY 08, 1998
	REVIA			
AB	+ DUPONT MERCK	50MG	N18932 001	NOV 20, 1984

NAPROXEN

TABLET, DELAYED RELEASE; ORAL

	EC-NAPROSYN			
AB	+ SYNTEX	375MG	N20067 002	OCT 14, 1994
AB	+	500MG	N20067 003	OCT 14, 1994
	NAPROXEN			
AB	INVAMED	375MG	N75061 001	FEB 18, 1998
AB		500MG	N75061 002	FEB 18, 1998
AB	PUREPAC PHARM	375MG	N74936 001	FEB 24, 1998
AB		500MG	N74936 002	FEB 24, 1998
AB	TEVA	375MG	N75227 001	JUN 30, 1998
AB		500MG	N75227 002	JUN 30, 1998

NAPROXEN SODIUM

TABLET; ORAL

	NAPROXEN SODIUM			
AB	AL HIKMA	EQ 250MG BASE	N74480 002	FEB 18, 1998
AB	INVAMED	EQ 250MG BASE	N74495 001	DEC 05, 1994
AB		EQ 275MG BASE	N74495 001	DEC 05, 1994
AB		EQ 500MG BASE	N74495 002	DEC 05, 1994
AB		EQ 550MG BASE	N74495 002	DEC 05, 1994

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL

	AMERGE		
	GLAXO WELLCOME	EQ 1MG BASE	N20763 002 FEB 10, 1998
	+	EQ 2.5MG BASE	N20763 001 FEB 10, 1998

NEOMYCIN SULFATE

TABLET; ORAL

	NEOMYCIN SULFATE		
	TEVA	EQ 350MG BASE	N60304 001
	+	EQ 350MG BASE	N60304 001

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION; IRRIGATION

	NEOSPORIN G.U. IRRIGANT		
AT	GLAXO WELLCOME	EQ 40MG BASE/ML; 200,000 UNITS/ML	N60707 001
AT	MONARCH PHARMS	EQ 40MG BASE/ML; 200,000 UNITS/ML	N60707 001

NEVIRAPINE

SUSPENSION; ORAL

	VIRAMUNE		
	+ BOEHRINGER INGELHEIM	50MG/5ML	N20933 001 SEP 11, 1998

NIACIN

TABLET; ORAL

	NIACIN		
AA	DANBURY PHARMA	500MG	N83305 001
	@	500MG	N83305 001

NICARDIPINE HYDROCHLORIDE

CAPSULE; ORAL

	NICARDIPINE HCL			
AB	GENPHARM	20MG	N74928 001	MAR 19, 1998

NICARDIPINE HYDROCHLORIDE

CAPSULE; ORAL

		NICARDIPINE HCL		
AB		GENPHARM	**30MG**	**N74928 002** MAR 19, 1998

NITROGLYCERIN

AEROSOL; ORAL

		NITROLINGUAL		
> DLT >	+	POHL BOSKAMP	0.4MG/SPRAY	N18705 001 OCT 31, 1985
> DLT >				

AEROSOL; SUBLINGUAL

		NITROLINGUAL		
> ADD >	+	POHL BOSKAMP	0.4MG/SPRAY	N18705 001 OCT 31, 1985
> ADD >				

FILM, EXTENDED RELEASE; TRANSDERMAL

		MINITRAN		
AB		3M	**0.1MG/HR**	**N89771 001** AUG 30, 1996
AB1			**0.1MG/HR**	**N89771 001** AUG 30, 1996
AB			**0.2MG/HR**	**N89772 001** AUG 30, 1996
AB1			**0.2MG/HR**	**N89772 001** AUG 30, 1996
AB			**0.4MG/HR**	**N89773 001** AUG 30, 1996
AB1			**0.4MG/HR**	**N89773 001** AUG 30, 1996
AB			**0.6MG/HR**	**N89774 001** AUG 30, 1996
AB1			**0.6MG/HR**	**N89774 001** AUG 30, 1996
		NITRO-DUR		
AB	+	KEY PHARMS	**0.1MG/HR**	**N20145 001** APR 04, 1995
AB1	+		**0.1MG/HR**	**N20145 001** APR 04, 1995
AB	+		**0.2MG/HR**	**N20145 002** APR 04, 1995
AB1	+		**0.2MG/HR**	**N20145 002** APR 04, 1995
AB	+		**0.4MG/HR**	**N20145 004** APR 04, 1995

NITROGLYCERIN

FILM, EXTENDED RELEASE; TRANSDERMAL

		NITRO-DUR		
AB1	+	KEY PHARMS	**0.4MG/HR**	**N20145 004** APR 04, 1995
AB	+		**0.6MG/HR**	**N20145 005** APR 04, 1995
AB1	+		**0.6MG/HR**	**N20145 005** APR 04, 1995
		NITROGLYCERIN		
AB2		HERCON LABS	**0.2MG/HR**	**N89884 001** OCT 30, 1998
AB2			**0.4MG/HR**	**N89885 001** OCT 30, 1998
AB2			**0.6MG/HR**	**N89886 001** OCT 30, 1998
AB2		MYLAN	**0.1MG/HR**	**N75033 001** FEB 06, 1998
AB			**0.2MG/HR**	**N74609 001** AUG 30, 1996
AB2			**0.2MG/HR**	**N74609 001** AUG 30, 1996
AB			**0.4MG/HR**	**N74607 001** AUG 30, 1996
AB2			**0.4MG/HR**	**N74607 001** AUG 30, 1996
AB			**0.6MG/HR**	**N74559 001** AUG 30, 1996
AB2			**0.6MG/HR**	**N74559 001** AUG 30, 1996
		TRANSDERM-NITRO		
AB2	+	NOVARTIS	**0.1MG/HR**	**N20144 001** FEB 27, 1996
AB	+		**0.2MG/HR**	**N20144 002** FEB 27, 1996
AB2	+		**0.2MG/HR**	**N20144 002** FEB 27, 1996
AB	+		**0.4MG/HR**	**N20144 003** FEB 27, 1996
AB2	+		**0.4MG/HR**	**N20144 003** FEB 27, 1996
AB	+		**0.6MG/HR**	**N20144 004** FEB 27, 1996
AB2	+		**0.6MG/HR**	**N20144 004** FEB 27, 1996
BX	+		**0.1MG/HR**	**N20144 001** FEB 27, 1996

NORETHINDRONE

TABLET; ORAL
NOR-QD

+	SEARLE	0.35MG	N17060 001	
+	WATSON LABS	0.35MG	N17060 001	

NORETHINDRONE ACETATE

TABLET; ORAL
AYGESTIN

AB	WYETH AYERST	5MG	N18405 001	APR 21, 1982
AB	+	5MG	N18405 001	APR 21, 1982

NORLUTATE

AB	+ PARKE DAVIS	5MG	N12184 002	
	@	5MG	N12184 002	

NYSTATIN

SUSPENSION; ORAL
NYSTATIN

AA	UDL	100,000 UNITS/ML	N64142 001	JUN 25, 1998

OCTREOTIDE ACETATE

INJECTABLE; INJECTION
SANDOSTATIN LAR

		EQ 10MG BASE/VIAL	N21008 001	NOV 25, 1998
		EQ 20MG BASE/VIAL	N21008 002	NOV 25, 1998
	+	EQ 30MG BASE/VIAL	N21008 003	NOV 25, 1998

OLANZAPINE

TABLET; ORAL
ZYPREXA

	@ LILLY	2.5MG	N20592 001	SEP 30, 1996
	+	2.5MG	N20592 001	SEP 30, 1996

> ADD >
> ADD >

OLANZAPINE

TABLET; ORAL
ZYPREXA

	@ LILLY	15MG	N20592 005	SEP 09, 1997
	@	20MG	N20592 006	SEP 09, 1997

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL
PRILOSEC

	+ ASTRA MERCK	40MG	N19810 002	JAN 15, 1998

ORPHENADRINE CITRATE

TABLET, EXTENDED RELEASE; ORAL
NORFLEX

AB	+ 3M	100MG	N12157 001	

ORPHENADRINE CITRATE

AB	INVAMED	100MG	N40284 001	JUN 19, 1998

OXAZEPAM

TABLET; ORAL
OXAZEPAM

AB	DANBURY PHARMA	15MG	N71494 001	APR 21, 1987
	@	15MG	N71494 001	APR 21, 1987

SERAX

AB	+ WYETH AYERST	15MG	N15539 008	
	+	15MG	N15539 008	

OXYBUTYNIN CHLORIDE

SYRUP; ORAL
DITROPAN

AA	+ ALZA	5MG/5ML	N18211 001	
AA	+ HOECHST MARION RSSL	5MG/5ML	N18211 001	

OXYBUTYNIN CHLORIDE

AA	NOVEX	5MG/5ML	N74997 001	OCT 15, 1997

OXYBUTYNIN CHLORIDE

SYRUP; ORAL
OXYBUTYNIN CHLORIDE

> DLT >	AA		NU PHARM	5MG/5ML	N74597 001
> DLT					OCT 15, 1997
> ADD >	AA		PHARM ASSOC	5MG/5ML	N75137 001
> ADD >					DEC 18, 1998

TABLET; ORAL
DITROPAN

	AB	+	ALZA	5MG	N17577 001
	AB	+	HOECHST MARION RSSL	5MG	N17577 001

TABLET, EXTENDED RELEASE; ORAL
DITROPAN XL

> ADD >		+	ALZA	5MG	N20897 001
> ADD >					DEC 16, 1998
> ADD >		+		10MG	N20897 002
> ADD >					DEC 16, 1998

OXYCODONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
OXYCONTIN

BX	+	PURDUE PHARMA	10MG	N20553 001
				DEC 12, 1995

ROXICODONE

BX		ROXANE	10MG	N20932 001
				OCT 26, 1998
	+		30MG	N20932 002
				OCT 26, 1998

OXYTETRACYCLINE

TABLET; ORAL
TERRAMYCIN

	+	PFIZER	250MG	N50287 001
	@		250MG	N50287 001

OXYTOCIN

INJECTABLE; INJECTION
PITOCIN

AP	+	KING PHARMS	10 USP UNITS/ML	N18261 001
AP	+	PARKEDALE	10 USP UNITS/ML	N18261 001

PARICALCITOL

INJECTABLE; INJECTION
ZEMPLAR

	+	ABBOTT	0.005MG/ML	N20819 001
				APR 17, 1998

PAROMOMYCIN SULFATE

CAPSULE; ORAL
HUMATIN

> DLT >	AA		KING PHARMS	EQ 250MG BASE	N62310 001
	AB	+	PARKE DAVIS	EQ 250MG BASE	N60521 001
	AA	+	PARKEDALE	EQ 250MG BASE	N60521 001
> ADD >	AA			EQ 250MG BASE	N62310 001

PAROMOMYCIN SULFATE

AA		CARACO	EQ 250MG BASE	N64171 001
				JUN 30, 1997
AB			EQ 250MG BASE	N64171 001
				JUN 30, 1997

PAROXETINE HYDROCHLORIDE

CAPSULE; ORAL
PAXIL

	SMITHKLINE BEECHAM	EQ 10MG BASE	N20885 001
			OCT 09, 1998
		EQ 20MG BASE	N20885 002
			OCT 09, 1998
		EQ 30MG BASE	N20885 003
			OCT 09, 1998
+		EQ 40MG BASE	N20885 004
			OCT 09, 1998

PENTOSAN POLYSULFATE SODIUM

CAPSULE; ORAL
ELMIRON

+	ALZA	100MG	N20193 001
			SEP 26, 1996
+	BAKER NORTON	100MG	N20193 001
			SEP 26, 1996

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL

	PENTOXIFYLLINE			
AB	BIOVAIL	**400MG**	**N75028 001**	
			JUL 20, 1998	
AB	WATSON LABS	**400MG**	**N75107 001**	
			SEP 04, 1998	

PERINDOPRIL ERBUMINE

TABLET; ORAL

	ACEON			
	@ HUESCHEN	2MG	N20184 001	
			DEC 30, 1993	
	@	4MG	N20184 002	
			DEC 30, 1993	
	@	8MG	N20184 003	
			DEC 30, 1993	
	@ RHONE POULENC RORER	2MG	N20184 001	
			DEC 30, 1993	
	@	4MG	N20184 002	
			DEC 30, 1993	
	@	8MG	N20184 003	
			DEC 30, 1993	

PERMETHRIN

CREAM; TOPICAL

	ELIMITE			
AB	+ ALLERGAN	**5%**	**N19855 001**	
			AUG 25, 1989	
	PERMETHRIN			
AB	ALPHARMA	**5%**	**N74806 001**	
			JAN 23, 1998	

PERPHENAZINE

TABLET; ORAL

	PERPHENAZINE			
> ADD > **AB**	VINTAGE PHARMS	**2MG**	**N40226 001**	
> ADD >			DEC 31, 1998	
> ADD > **AB**		**4MG**	**N40226 002**	
> ADD >			DEC 31, 1998	
> ADD > **AB**		**8MG**	**N40226 003**	
> ADD >			DEC 31, 1998	

PERPHENAZINE

TABLET; ORAL

	PERPHENAZINE			
> ADD > **AB**	VINTAGE PHARMS	**16MG**	**N40226 004**	
> ADD >			DEC 31, 1998	

PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE

TABLET; ORAL

	AZO GANTANOL			
	+ ROCHE	100MG;500MG	N13294 001	
			SEP 10, 1987	
	@	100MG;500MG	N13294 001	
			SEP 10, 1987	

PHENAZOPYRIDINE HYDROCHLORIDE; SULFISOXAZOLE

TABLET; ORAL

	AZO GANTRISIN			
	+ ROCHE	50MG;500MG	N19358 001	
			AUG 31, 1990	
	@	50MG;500MG	N19358 001	
			AUG 31, 1990	

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

	PHENTERMINE HCL			
AA	EON	**37.5MG**	**N88414 001**	
			OCT 19, 1983	
	@	37.5MG	N88414 001	
			OCT 19, 1983	

TABLET; ORAL

	PHENTERMINE HCL			
	+ EON	30MG	N88605 001	
			SEP 28, 1987	
	@	30MG	N88605 001	
			SEP 28, 1987	
AA	PUREPAC PHARM	**37.5MG**	**N40276 001**	
			NOV 25, 1998	

PHENTOLAMINE MESYLATE

INJECTABLE; INJECTION
PHENTOLAMINE MESYLATE

AP		BEDFORD	**5MG/VIAL**	**N40235 001** MAR 11, 1998
		REGITINE		
AP	+	NOVARTIS	**5MG/VIAL**	**N08278 003**

PHENYTOIN SODIUM

INJECTABLE; INJECTION
PHENYTOIN SODIUM

AP		SMITH AND NEPHEW	**50MG/ML**	**N88519 001** DEC 19, 1984
	@		50MG/ML	N88519 001 DEC 19, 1984

PHENYTOIN SODIUM, EXTENDED

CAPSULE; ORAL
DILANTIN

> ADD >	**AB**	+	PARKE DAVIS	**100MG**	**N84349 002**
> ADD >			**EXTENDED PHENYTOIN SODIUM**		
> ADD >	**AB**		MYLAN	**100MG**	**N40298 001** DEC 28, 1998

PHENYTOIN SODIUM, PROMPT

CAPSULE; ORAL
PROMPT PHENYTOIN SODIUM

BX	+	DANBURY PHARMA	100MG	N80905 001
	@		100MG	N80905 001
	+	ZENITH GOLDLINE	100MG	N80259 001
BX		ZENITH LABS	100MG	N80259 001

PILOCARPINE

DRUG DELIVERY SYSTEM; OPHTHALMIC
OCUSERT PILO-40

+	AKORN	11MG	N17548 001
+	ALZA	11MG	N17548 001

PINDOLOL

TABLET; ORAL
PINDOLOL

AB	PUREPAC PHARM	**5MG**	**N74125 001** APR 28, 1993
AB		**10MG**	**N74125 002** APR 28, 1993
@		5MG	N74125 001 APR 28, 1993
@		10MG	N74125 002 APR 28, 1993
AB	ROYCE LABS	**5MG**	**N74437 001** FEB 27, 1995
AB		**10MG**	**N74437 002** FEB 27, 1995
AB	WATSON LABS	**5MG**	**N74437 001** FEB 27, 1995
AB		**10MG**	**N74437 002** FEB 27, 1995

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION
ZOSYN IN PLASTIC CONTAINER

+	LEDERLE	EQ 40MG BASE/ML; EQ 5MG BASE/ML	N50750 001 FEB 24, 1998
+		EQ 4GM BASE/100ML; EQ 500MG BASE/100ML	N50750 003 FEB 24, 1998
+		EQ 60MG BASE/ML; EQ 7.5MG BASE/ML	N50750 002 FEB 24, 1998

PIROXICAM

CAPSULE; ORAL
PIROXICAM

AB	ROYCE LABS	**10MG**	**N74460 001** SEP 29, 1995
AB		**20MG**	**N74460 002** SEP 29, 1995
AB	WATSON LABS	**10MG**	**N74460 001** SEP 29, 1995
AB		**20MG**	**N74460 002** SEP 29, 1995

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS

POWDER FOR RECONSTITUTION; ORAL

	PEG-LYTE			
AA	INVAMED	**236GM/BOT;2.97GM/BOT;6.74GM/BOT; 5.86GM/BOT;22.74GM/BOT**	**N73098 001 AUG 31, 1993**	
	@	236GM/BOT;2.97GM/BOT;6.74GM/BOT; 5.86GM/BOT;22.74GM/BOT	N73098 001 AUG 31, 1993	

POLYMYXIN B SULFATE

INJECTABLE; INJECTION

	AEROSPORIN			
AP	+ GLAXO WELLCOME	**EQ 500,000 U BASE/VIAL**	**N62036 001**	
	@	EQ 500,000 U BASE/VIAL	N62036 001	
	POLYMYXIN B SULFATE			
AP	+ BEDFORD	**EQ 500,000 U BASE/VIAL**	**N60716 001**	
AP	PFIZER	**EQ 500,000 U BASE/VIAL**	**N60716 001**	

POWDER; FOR RX COMPOUNDING

	POLY-RX			
AA	PHARMA TEK	**100,000,000 UNITS/BOT**	**N61578 001**	
	+	100,000,000 UNITS/BOT	N61578 001	
	POLYMYXIN B SULFATE			
AA	PADDOCK	**100,000,000 UNITS/BOT**	**N62455 001 JUL 27, 1983**	
	@	100,000,000 UNITS/BOT	N62455 001 JUL 27, 1983	

POLYMYXIN B SULFATE; TRIMETHOPRIM

SOLUTION/DROPS; OPHTHALMIC

	TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE			
> ADD > **AT**	TAYLOR PHARMA	**10,000 UNITS/ML; EQ 1MG BASE/ML**	**N65006 001 DEC 17, 1998**	

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS; OPHTHALMIC

	TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE			
AT	ALCON	**10,000 UNITS/ML; EQ 1MG BASE/ML**	**N64211 001 APR 13, 1998**	

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

	K-LEASE			
AB	SAVAGE LABS	**8MEQ**	**N73398 001 JAN 28, 1992**	
AB		**10MEQ**	**N72427 001 MAR 28, 1990**	
	@	8MEQ	N73398 001 JAN 28, 1992	
	@	10MEQ	N72427 001 MAR 28, 1990	

> DLT > GRANULE, FOR RECONSTITUTION ER; ORAL

> DLT >	MICRO-K LS			
> DLT >	+ ROBINS AH	20MEQ/PACKET	N19561 003 AUG 26, 1988	
> ADD >	@	20MEQ/PACKET	N19561 003 AUG 26, 1988	

INJECTABLE; INJECTION

	POTASSIUM CHLORIDE			
AP	B BRAUN	**2MEQ/ML**	**N85870 001**	
AP	MCGAW	**2MEQ/ML**	**N85870 001**	
	POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER			
AP	+ ABBOTT	**29.8MG/ML**	**N20161 006 AUG 11, 1998**	
AP	+ BAXTER HLTHCARE	**29.8MG/ML**	**N19904 002 DEC 26, 1989**	
	POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER			
AP	+ ABBOTT	**2.24GM/100ML**	**N20161 003 AUG 11, 1998**	
AP	+ BAXTER HLTHCARE	**2.24GM/100ML**	**N19904 003 DEC 26, 1989**	
	POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER			
AP	+ ABBOTT	**2.98GM/100ML**	**N20161 004 AUG 11, 1998**	
AP	+ BAXTER HLTHCARE	**2.98GM/100ML**	**N19904 004 DEC 26, 1989**	

TABLET, EXTENDED RELEASE; ORAL

	K-DUR 20			
AB	+ KEY PHARMS	**20MEQ**	**N19439 001 JUN 13, 1986**	
	KLOR-CON M20			
AB	UPSHER SMITH	**20MEQ**	**N74726 001 NOV 20, 1998**	
	TEN-K			
BC	NOVARTIS	**10MEQ**	**N19381 001 APR 16, 1986**	

POTASSIUM CHLORIDE

TABLET, EXTENDED RELEASE; ORAL
TEN-K
@ NOVARTIS 10MEQ N19381 001
APR 16, 1986

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION
POTASSIUM CHLORIDE 0.037% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 37MG/100ML;900MG/100ML N19708 001
SEP 29, 1989
@ 37MG/100ML;900MG/100ML N19708 001
SEP 29, 1989
POTASSIUM CHLORIDE 0.075% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 75MG/100ML;900MG/100ML N19708 002
SEP 29, 1989
@ 75MG/100ML;900MG/100ML N19708 002
SEP 29, 1989
POTASSIUM CHLORIDE 0.11% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 110MG/100ML;900MG/100ML N19708 003
SEP 29, 1989
@ 110MG/100ML;900MG/100ML N19708 003
SEP 29, 1989
POTASSIUM CHLORIDE 0.22% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 220MG/100ML;900MG/100ML N19708 005
SEP 29, 1989
@ 220MG/100ML;900MG/100ML N19708 005
SEP 29, 1989
POTASSIUM CHLORIDE 0.3% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
AP B BRAUN 300MG/100ML;900MG/100ML N19708 006
SEP 29, 1989
@ 300MG/100ML;900MG/100ML N19708 006
SEP 29, 1989
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER
@ B BRAUN 75MG/100ML;900MG/100ML N18722 001
NOV 09, 1982
@ MCGAW 75MG/100ML;900MG/100ML N18722 001
NOV 09, 1982

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER
@ B BRAUN 150MG/100ML;900MG/100ML N18722 002
NOV 09, 1982
@ MCGAW 150MG/100ML;900MG/100ML N18722 002
NOV 09, 1982
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER
@ B BRAUN 220MG/100ML;900MG/100ML N18722 003
NOV 09, 1982
@ MCGAW 220MG/100ML;900MG/100ML N18722 003
NOV 09, 1982
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
@ B BRAUN 300MG/100ML;900MG/100ML N18722 004
NOV 09, 1982
@ MCGAW 300MG/100ML;900MG/100ML N18722 004
NOV 09, 1982

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL
MIRAPEX
PHARMACIA AND UPJOHN 0.5MG N20667 006
FEB 12, 1998

PREDNISOLONE

SYRUP; ORAL
PRE-PRED
AA WE PHARMS 15MG/5ML **N40192 001**
MAY 28, 1998
PREDNISOLONE
AA WE PHARMS 15MG/5ML **N40192 001**
MAY 28, 1998
PRELONE
AA + MURO 15MG/5ML **N89081 001**
FEB 04, 1986

TABLET; ORAL
PREDNISOLONE
BX DANBURY PHARMA 5MG N80354 001
BX + 5MG N80354 001
BX + GENEVA PHARMS 5MG N80339 001

PREDNISOLONE

TABLET; ORAL
PREDNISOLONE
@ GENEVA PHARMS 5MG N80339 001

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC
SULSTER
AT + AKORN EQ 0.23% PHOSPHATE;10% N74511 001 JUL 30, 1996
@ EQ 0.23% PHOSPHATE;10% N74511 001 JUL 30, 1996

PREDNISONE

TABLET; ORAL
PREDNISONE
AB PUREPAC PHARM 5MG N80353 001
AB 10MG N86062 001
AB 20MG N86061 001
@ 5MG N80353 001
@ 10MG N86062 001
@ 20MG N86061 001

PRIMIDONE

SUSPENSION; ORAL
MYSOLINE
+ ELAN PHARMA 250MG/5ML N10401 001
+ WYETH AYERST 250MG/5ML N10401 001

TABLET; ORAL
MYSOLINE
AB + ELAN PHARMA 250MG N09170 002
+ 50MG N09170 003
AB + WYETH AYERST 250MG N09170 002
+ 50MG N09170 003

PROCAINAMIDE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
PROCAINAMIDE HCL
AB INVAMED 500MG N89284 001 JUN 23, 1986

PROCAINAMIDE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
PROCAINAMIDE HCL
@ INVAMED 500MG N89284 001 JUN 23, 1986
AB SIDMAK LABS NJ 250MG N88958 001 DEC 02, 1985
@ 250MG N88958 001 DEC 02, 1985

PROCAN SR
AB PARKE DAVIS 500MG N86065 001
AB 750MG N87510 001 APR 01, 1982
AB + 1GM N88489 001 JAN 16, 1985
AB + PARKEDALE 500MG N86065 001
AB + 750MG N87510 001 APR 01, 1982
AB + 1GM N88489 001 JAN 16, 1985

PROCARBAZINE HYDROCHLORIDE

CAPSULE; ORAL
MATULANE
+ ROCHE EQ 50MG BASE N16785 001
+ SIGMA TAU EQ 50MG BASE N16785 001

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION
PROCHLORPERAZINE EDISYLATE
AP MARSAM EQ 5MG BASE/ML N89675 001 DEC 05, 1988
@ EQ 5MG BASE/ML N89675 001 DEC 05, 1988

PROCHLORPERAZINE MALEATE

TABLET; ORAL
PROCHLORPERAZINE MALEATE
AB TRIGEN EQ 5MG BASE N40268 001 FEB 27, 1998
AB EQ 10MG BASE N40268 002 FEB 27, 1998

PROCHLORPERAZINE MALEATE

TABLET; ORAL
PROCHLORPERAZINE MALEATE

AB	ZENITH GOLDLINE	EQ 5MG BASE	N40162 001 JAN 20, 1998
AB		EQ 10MG BASE	N40162 002 JAN 20, 1998

PROGESTERONE

CAPSULE; ORAL
PROMETRIUM

+	SCHERING PLOUGH	100MG	N19781 001 MAY 14, 1998

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
PROMETHAZINE HCL

AP	MARSAM	25MG/ML	N89463 001 MAY 02, 1988
AP		50MG/ML	N89477 001 MAY 02, 1988
@		25MG/ML	N89463 001 MAY 02, 1988
@		50MG/ML	N89477 001 MAY 02, 1988

SYRUP; ORAL
PROMETHAZINE HCL

AA	HI TECH PHARMA	6.25MG	N40026 001 SEP 25, 1998

TABLET; ORAL
PROMETHAZINE HCL

RP	DANBURY PHARMA	12.5MG	N83712 001
@		12.5MG	N83712 001

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL
PROPOXYPHENE HCL

AA	DANBURY PHARMA	65MG	N80908 002
@		65MG	N80908 002
AA	PUREPAC PHARM	65MG	N83278 001

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL
PROPOXYPHENE HCL

@	PUREPAC PHARM	65MG	N83278 001

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL
PROPRANOLOL HCL

AB	DANBURY PHARMA	60MG	N71098 001 OCT 06, 1986
@		60MG	N71098 001 OCT 06, 1986
AB	INVAMED	10MG	N71658 001 JUL 05, 1988
AB		20MG	N71687 001 JUL 05, 1988
AB		40MG	N71688 001 JUL 05, 1988
AB		60MG	N72197 001 JUL 05, 1988
AB		80MG	N71689 001 JUL 05, 1988
AB		90MG	N72198 001 JUL 05, 1988
@		10MG	N71658 001 JUL 05, 1988
@		20MG	N71687 001 JUL 05, 1988
@		40MG	N71688 001 JUL 05, 1988
@		60MG	N72197 001 JUL 05, 1988
@		80MG	N71689 001 JUL 05, 1988
@		90MG	N72198 001 JUL 05, 1988

PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
NOVAFED

+	HOECHST MARION RSSL	120MG	N17603 001
@		120MG	N17603 001

QUETIAPINE FUMARATE

TABLET; ORAL
SEROQUEL

>ADD>		ZENECA	EQ 150MG BASE	N20639 004
>ADD>				DEC 20, 1998

QUINIDINE SULFATE

TABLET; ORAL
QUINIDINE SULFATE

AB		DANBURY PHARMA	100MG	N85584 001
	@		100MG	N85584 001
AB		PUREPAC PHARM	200MG	N84003 001
	@		200MG	N84003 001

TABLET, EXTENDED RELEASE; ORAL
QUINIDEX

AB	+	ROBINS AH	300MG	N12796 002
AB	+	WYETH AYERST	300MG	N12796 002

RAMIPRIL

CAPSULE; ORAL
ALTACE

>DLT>		HOECHST MARION RSSL	1.25MG	N19901 001
>DLT>				JAN 28, 1991
>DLT>			2.5MG	N19901 002
>DLT>				JAN 28, 1991
>DLT>			5MG	N19901 003
>DLT>				JAN 28, 1991
>DLT>	+		10MG	N19901 004
>DLT>				JAN 28, 1991
>ADD>		KING PHARMS	1.25MG	N19901 001
>ADD>				JAN 28, 1991
>ADD>			2.5MG	N19901 002
>ADD>				JAN 28, 1991
>ADD>			5MG	N19901 003
>ADD>				JAN 28, 1991
>ADD>	+		10MG	N19901 004
>ADD>				JAN 28, 1991

RANITIDINE HYDROCHLORIDE

SYRUP; ORAL
ZANTAC

		GLAXO WELLCOME	EQ 15MG BASE/ML	N19675 001
				DEC 30, 1988
	+		EQ 15MG BASE/ML	N19675 001
				DEC 30, 1988

TABLET; ORAL
RANITIDINE HCL

AB		MYLAN	EQ 150MG BASE	N74552 001
				JUL 30, 1998
AB			EQ 300MG BASE	N74552 002
				JUL 30, 1998
AB		RANBAXY	EQ 150MG BASE	N75000 001
				JAN 30, 1998
AB			EQ 300MG BASE	N75000 002
				JAN 30, 1998
>ADD>	AB	WOCKHARDT	EQ 150MG BASE	N75208 001
>ADD>				DEC 17, 1998
>ADD>	AB		EQ 300MG BASE	N75208 002
>ADD>				DEC 17, 1998
	AB	ZENITH GOLDLINE	EQ 150MG BASE	N75165 001
				SEP 30, 1998
	AB		EQ 300MG BASE	N75165 002
				SEP 30, 1998

RAUWOLFIA SERPENTINA

TABLET; ORAL
RAUWOLFIA SERPENTINA

	DANBURY PHARMA	50MG	N80907 001
@		50MG	N80907 001

RIBAVIRIN

CAPSULE; ORAL
REBETOL

	+	SCHERING PLOUGH RES	300MG	N20903 001
			†	JUN 03, 1998
	+		200MG	N20903 001
				JUN 03, 1998

† SEE SECTION 1.5 OF INTRODUCTION

RIFAMPIN

CAPSULE; ORAL

	RIFADIN			
AB	HOECHST MARION RSSL	150MG		N62303 001
	RIFAMPIN			
AB	EON	150MG		N64150 002 JAN 02, 1998
	RIMACTANE			
AB	GENEVA PHARMS	300MG		N50429 001
AB	NOVARTIS	300MG		N50429 001

RIFAPENTINE

TABLET; ORAL

	PRIFTIN			
+	HOECHST MARION RSSL	150MG		N21024 001 JUN 22, 1998

RISEDRONATE SODIUM

TABLET; ORAL

	ACTONEL			
+	PROCTER AND GAMBLE	30MG		N20835 001 MAR 27, 1998

RITODRINE HYDROCHLORIDE

INJECTABLE; INJECTION

	RITODRINE HCL			
AP	ABBOTT	10MG/ML		N71618 001 FEB 28, 1991
AP		15MG/ML		N71619 001 FEB 28, 1991
	+	10MG/ML		N71618 001 FEB 28, 1991
	+	15MG/ML		N71619 001 FEB 28, 1991
	YUTOPAR			
AP	+ ASTRA	10MG/ML		N18580 001
AP	+	15MG/ML		N18580 002
	@	10MG/ML		N18580 001
	@	15MG/ML		N18580 002

RIZATRIPTAN BENZOATE

TABLET; ORAL

	MAXALT			
	MERCK	EQ 5MG BASE		N20864 001 JUN 29, 1998
+		EQ 10MG BASE		N20864 002 JUN 29, 1998

TABLET, ORALLY DISINTEGRATING; ORAL

	MAXALT			
	MERCK	EQ 5MG BASE		N20864 001 JUN 29, 1998
+		EQ 10MG BASE		N20864 002 JUN 29, 1998
	MAXALT-MLT			
	MERCK	EQ 5MG BASE		N20865 001 JUN 29, 1998
+		EQ 10MG BASE		N20865 002 JUN 29, 1998

SACROSIDASE

SOLUTION; ORAL

	SUCRAID			
+	ORPHAN MEDCL	8,500 IU/ML		N20772 001 APR 09, 1998

SAQUINAVIR

CAPSULE; ORAL

	FORTOVASE			
+	ROCHE	EQ 200MG BASE		N20828 001 NOV 07, 1997
+		200MG		N20828 001 NOV 07, 1997

SELEGILINE HYDROCHLORIDE

CAPSULE; ORAL

	ELDEPRYL			
AB	+ SOMERSET	5MG		N20647 001 MAY 15, 1996
	SELEGILINE HCL			
AB	ESI LEDERLE	5MG		N75352 001 NOV 30, 1998

SELEGILINE HYDROCHLORIDE

CAPSULE; ORAL
SELEGILINE HCL

> ADD >	AB	TORPHARM	5MG	N75321 001	
> ADD				DEC 04, 1998	

TABLET; ORAL
SELEGILINE HCL

AB	ESI LEDERLE	5MG	N74641 001	
			AUG 02, 1996	
AB	LEDERLE	5MG	N74641 001	
			AUG 02, 1996	
AB	NORTON WATERFORD	5MG	N74756 001	
			NOV 25, 1998	
AB	STASON	5MG	N74912 001	
			APR 30, 1998	

SEVELAMER HYDROCHLORIDE

CAPSULE; ORAL
RENAGEL

+	GELTEX	403MG	N20926 001
			OCT 30, 1998

SILDENAFIL CITRATE

TABLET; ORAL
VIAGRA

	PFIZER	25MG	N20895 001
			MAR 27, 1998
		50MG	N20895 002
			MAR 27, 1998
+		100MG	N20895 003
			MAR 27, 1998

SILVER SULFADIAZINE

CREAM; TOPICAL
SILVADENE

> DLT >	AB	+	HOECHST MARION RSSL	1%	N17381 001
> ADD >	AB	+	KING PHARMS	1%	N17381 001

SIMETHICONE-CELLULOSE

SUSPENSION; ORAL
SONORX

+	BRACCO	7.5MG/ML	N20773 001
			OCT 29, 1998

SIMVASTATIN

TABLET; ORAL
ZOCOR

	MERCK	5MG	N19766 001
			DEC 23, 1991
+		40MG	N19766 004
			DEC 23, 1991
+		5MG	N19766 001
			DEC 23, 1991
		40MG	N19766 004
			DEC 23, 1991
+		80MG	N19766 005
			JUL 10, 1998

SODIUM CHLORIDE

INJECTABLE; INJECTION
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	B BRAUN	450MG/100ML	N19635 001
			MAR 09, 1988
@		450MG/100ML	N18184 001
AP	MCGAW	450MG/100ML	N19635 001
			MAR 09, 1988
@		450MG/100ML	N18184 001

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	B BRAUN	900MG/100ML	N17464 001
AP		900MG/100ML	N19635 002
			MAR 09, 1988
AP	MCGAW	900MG/100ML	N17464 001
AP		900MG/100ML	N19635 002
			MAR 09, 1988

SODIUM CHLORIDE 3% IN PLASTIC CONTAINER

@	B BRAUN	3GM/100ML	N19635 003
			MAR 09, 1988
@	MCGAW	3GM/100ML	N19635 003
			MAR 09, 1988

SODIUM CHLORIDE 5% IN PLASTIC CONTAINER

@	B BRAUN	5GM/100ML	N19635 004
			MAR 09, 1988

SODIUM CHLORIDE

INJECTABLE; INJECTION
SODIUM CHLORIDE 5% IN PLASTIC CONTAINER

@	MCGAW	5GM/100ML	N19615 004 MAR 09, 1988

SODIUM LACTATE

INJECTABLE; INJECTION
SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER

@	B BRAUN	1.87GM/100ML	N18186 001
@	MCGAW	1.87GM/100ML	N18186 001

SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER

AP	B BRAUN	**1.87GM/100ML**	**N20004 001** APR 21, 1992
AP	MCGAW	**1.87GM/100ML**	**N20004 001** APR 21, 1992

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL

KAYEXALATE

AA	SANOFI	**453.6GM/BOT**	**N11287 001**
AA	+	**453.6GM/BOT**	**N11287 001**

KIONEX

AA	PADDOCK	**454GM/BOT**	**N40029 001** FEB 06, 1998

SOMATROPIN, BIOSYNTHETIC

INJECTABLE; INJECTION
GENOTROPIN

+	PHARMACIA AND UPJOHN	13.8MG/VIAL	N20280 007 OCT 23, 1996

SOTALOL HYDROCHLORIDE

TABLET; ORAL
BETAPACE

@	BERLEX LABS	120MG	N19865 005 APR 20, 1994
		160MG	N19865 002 OCT 30, 1992

SOTALOL HYDROCHLORIDE

TABLET; ORAL
BETAPACE

+	BERLEX LABS	240MG	N19865 003 OCT 30, 1992
		120MG	N19865 005 APR 20, 1994
+		160MG	N19865 002 OCT 30, 1992
		240MG	N19865 003 OCT 30, 1992

SOYBEAN OIL

INJECTABLE; INJECTION

INTRALIPID 30%

AP	+	PHARMACIA AND UPJOHN	**30%**	**N19942 001** DEC 30, 1993

LIPOSYN III 30%

AP	+	ABBOTT	**30%**	**N20181 001** JAN 13, 1998

NUTRILIPID 10%

AP	+	B BRAUN	**10%**	**N19531 001** MAY 28, 1993
AP	+	MCGAW	**10%**	**N19531 001** MAY 28, 1993

NUTRILIPID 20%

AP	+	B BRAUN	**20%**	**N19531 002** MAY 28, 1993
AP	+	MCGAW	**20%**	**N19531 002** MAY 28, 1993

SPARFLOXACIN

TABLET; ORAL
ZAGAM

+	MYLAN	200MG	N20677 001 DEC 19, 1996
+	RHONE POULENC RORER	200MG	N20677 001 DEC 19, 1996

STREPTOMYCIN SULFATE

INJECTABLE; INJECTION
STREPTOMYCIN SULFATE

AP	+	PFIZER	**EQ 1GM BASE/VIAL**	**N60076 001**

STREPTOMYCIN SULFATE

INJECTABLE; INJECTION

	STREPTOMYCIN SULFATE				
	PFIZER	EQ 1GM BASE/2.5ML	N60111 001		
	+	EQ 1GM BASE/2.5ML	N60111 001		
AP	PHARMA TEK	**EQ 1GM BASE/VIAL**	**N64210 001** JUN 30, 1998	> DLT >	

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION

	SUCOSTRIN				
AP	+ APOTHECON	20MG/ML	N08847 001		
	@	20MG/ML	N08847 001		

SUCRALFATE

TABLET; ORAL

	SUCRALFATE				
AB	RATIOPHARM	**1GM**	**N74415 001** JUN 08, 1998		

SUFENTANIL CITRATE

INJECTABLE; INJECTION

	SUFENTA				
AP	+ AKORN	**EQ 0.05MG BASE/ML**	**N19050 001** MAY 04, 1984		
AP	+ JANSSEN	**EQ 0.05MG BASE/ML**	**N19050 001** MAY 04, 1984		
	SUFENTANIL CITRATE				
AP	STERIS	**EQ 0.05MG BASE/ML**	**N74406 001** DEC 15, 1995		
	@	EQ 0.05MG BASE/ML	N74406 001 DEC 15, 1995		

SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC

	SULF-10				
AT	CIBA	**10%**	**N80025 001**		
	@	10%	N80025 001		

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION

	SEPTRA				
AP	+ GLAXO WELLCOME	**80MG/ML;16MG/ML**	**N18452 001**		
AP	+ MONARCH PHARMS	**80MG/ML;16MG/ML**	**N18452 001**		
	SULFAMETHOXAZOLE AND TRIMETHOPRIM				
AP	BEDFORD	**80MG/ML;16MG/ML**	**N72383 001** APR 29, 1992	> DLT > > DLT > > ADD > > ADD >	
	@	80MG/ML;16MG/ML	N72383 001 APR 29, 1992		

SUSPENSION; ORAL

	COTRIM PEDIATRIC				
AB	TEVA	**200MG/5ML;40MG/5ML**	**N70028 001** JUN 02, 1987		
	SEPTRA				
AB	GLAXO WELLCOME	**200MG/5ML;40MG/5ML**	**N17598 001**		
AB	MONARCH PHARMS	**200MG/5ML;40MG/5ML**	**N17598 001**		
	SMZ-TMP				
AB	TEVA	**200MG/5ML;40MG/5ML**	**N18812 001** JAN 28, 1983		
	SMZ-TMP PEDIATRIC				
AB	TEVA	**200MG/5ML;40MG/5ML**	**N18812 002** JUN 10, 1983		
	SULFAMETHOXAZOLE AND TRIMETHOPRIM				
AB	TEVA	**200MG/5ML;40MG/5ML**	**N18812 001** JAN 28, 1983		
AB		**200MG/5ML;40MG/5ML**	**N18812 002** JUN 10, 1983		
AB		**200MG/5ML;40MG/5ML**	**N70028 001** JUN 02, 1987		

TABLET; ORAL

	SEPTRA				
AB	GLAXO WELLCOME	**400MG;80MG**	**N17376 001**		
AB	MONARCH PHARMS	**400MG;80MG**	**N17376 001**		
	SEPTRA DS				
AB	GLAXO WELLCOME	**800MG;160MG**	**N17376 002**		
AB	MONARCH PHARMS	**800MG;160MG**	**N17376 002**		
	SMZ-TMP				
AB	TEVA	**400MG;80MG**	**N18242 001**		
AB		**800MG;160MG**	**N18242 002**		
	SULFAMETHOXAZOLE AND TRIMETHOPRIM				
AB	TEVA	**400MG;80MG**	**N18242 001**		
AB		**800MG;160MG**	**N18242 002**		

SULFANILAMIDE

CREAM; VAGINAL

		AVC			
> DLT >	AT	+ HOECHST MARION RSSL	15%		N06530 003
> DLT >					JAN 27, 1987
> ADD >	AT	+ KING PHARMS	15%		N06530 003
> ADD >					JAN 27, 1987

SUPPOSITORY; VAGINAL

		AVC			
> DLT >		+ HOECHST MARION RSSL	1.05GM		N06530 004
> DLT >					JAN 27, 1987
> ADD >		+ KING PHARMS	1.05GM		N06530 004
> ADD >					JAN 27, 1987

SULFASALAZINE

TABLET; ORAL

	SULFASALAZINE			
AB	SUPERPHARM	500MG		N89339 001
				OCT 26, 1987
	@	500MG		N89339 001
				OCT 26, 1987

SULFINPYRAZONE

TABLET; ORAL

	SULFINPYRAZONE			
AB	DANBURY PHARMA	100MG		N87667 001
				MAY 26, 1982
	@	100MG		N87667 001
				MAY 26, 1982

SUTILAINS

OINTMENT; TOPICAL

	TRAVASE			
	+ KNOLL PHARM	82,000 UNITS/GM		N12828 001
	@	82,000 UNITS/GM		N12828 001

TACRINE HYDROCHLORIDE

CAPSULE; ORAL

	COGNEX			
	PARKE DAVIS	EQ 10MG BASE		N20070 001
				SEP 09, 1993
		EQ 20MG BASE		N20070 002
				SEP 09, 1993
		EQ 30MG BASE		N20070 003
				SEP 09, 1993
	+	EQ 40MG BASE		N20070 004
				SEP 09, 1993
	PARKE DAVIS PHARMS	EQ 10MG BASE		N20070 001
				SEP 09, 1993
		EQ 20MG BASE		N20070 002
				SEP 09, 1993
		EQ 30MG BASE		N20070 003
				SEP 09, 1993
	+	EQ 40MG BASE		N20070 004
				SEP 09, 1993

TACROLIMUS

CAPSULE; ORAL

	PROGRAF			
	+ FUJISAWA	EQ 1MG BASE		N50708 001
				APR 08, 1994
	+	EQ 5MG BASE		N50708 002
				APR 08, 1994
	+ FUJISAWA HLTHCARE	EQ 1MG BASE		N50708 001
				APR 08, 1994
	+	EQ 5MG BASE		N50708 002
				APR 08, 1994

INJECTABLE; INJECTION

	PROGRAF			
	+ FUJISAWA	EQ 5MG BASE/ML		N50709 001
				APR 08, 1994
	+ FUJISAWA HLTHCARE	EQ 5MG BASE/ML		N50709 001
				APR 08, 1994

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

INJECTABLE; INJECTION

	TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT			
BS	DRAXIMAGE	N/A		N17881 001
				DEC 30, 1987

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

INJECTABLE; INJECTION
TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT

BS	MERCK SHARP DOHME	N/A	N17881 001 DEC 30, 1987

TECHNETIUM TC-99M APCITIDE

INJECTABLE; INJECTION
ACUTECT

	DIATIDE	N/A	N20887 001 SEP 14, 1998

TECHNETIUM TC-99M DISOFENIN KIT

INJECTABLE; INJECTION
HEPATOLITE

	DUPONT	N/A	N18467 001 MAR 16, 1982
	DUPONT PHARMS	N/A	N18467 001 MAR 16, 1982

TECHNETIUM TC-99M GLUCEPTATE KIT

INJECTABLE; INJECTION
GLUCOSCAN

AP	**DUPONT**	**N/A**	**N17907 001**
	@	N/A	N17907 001

TECHNESCAN GLUCEPTATE

AP	**DRAXIMAGE**	**N/A**	**N18272 001** **JAN 27, 1982**
		N/A	N18272 001 JAN 27, 1982

TECHNETIUM TC-99M LIDOFENIN KIT

INJECTABLE; INJECTION
TECHNESCAN HIDA

	DRAXIMAGE	N/A	N18489 001 OCT 31, 1986
	MERCK	N/A	N18489 001 OCT 31, 1986

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION
TECHNESCAN MDP KIT

AP	DRAXIMAGE	**N/A**	**N18035 001**
AP	MERCK SHARP DOHME	**N/A**	**N18035 001**

TECHNETIUM TC-99M PENTETATE KIT

INJECTABLE; INJECTION
DTPA

AP	DRAXIMAGE	**N/A**	**N18511 001** DEC 29, 1989
AP	MERCK	**N/A**	**N18511 001** **DEC 29, 1989**

TECHNETIUM TC-99M SULFUR COLLOID KIT

SOLUTION; INJECTION, ORAL
AN-SULFUR COLLOID

AP	CIS	**N/A**	**N17858 001**
	@	**N/A**	**N17858 001**

TESULOID

AP	BRACCO	**N/A**	**N16923 001**
	@	N/A	N16923 001

TELMISARTAN

TABLET; ORAL
MICARDIS

	BOEHRINGER INGELHEIM	40MG	N20850 001 NOV 10, 1998
	+	80MG	N20850 002 NOV 10, 1998

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL
HYTRIN

AB	ABBOTT	**EQ 1MG BASE**	**N20347 001** DEC 14, 1994
AB	+	**EQ 2MG BASE**	**N20347 002** DEC 14, 1994
AB		**EQ 5MG BASE**	**N20347 003** DEC 14, 1994

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

		HYTRIN			
	AB	ABBOTT	EQ 10MG BASE	N20347 004	DEC 14, 1994
		TERAZOSIN HCL			
	AB	GENEVA PHARMS	EQ 1MG BASE	N74823 001	MAR 30, 1998
	AB		EQ 2MG BASE	N74823 002	MAR 30, 1998
	AB		EQ 5MG BASE	N74823 003	MAR 30, 1998
	AB		EQ 10MG BASE	N74823 004	MAR 30, 1998

TABLET; ORAL

		HYTRIN			
> ADD >	AB	ABBOTT	EQ 1MG BASE	N19057 001	AUG 07, 1987
> ADD >	AB	+	EQ 2MG BASE	N19057 002	AUG 07, 1987
> ADD >	AB		EQ 5MG BASE	N19057 003	AUG 07, 1987
> ADD >	AB		EQ 10MG BASE	N19057 004	AUG 07, 1987
		TERAZOSIN HCL			
> ADD >	AB	GENEVA PHARMS	EQ 1MG BASE	N74315 001	DEC 31, 1998
> ADD >	AB		EQ 2MG BASE	N74315 002	DEC 31, 1998
> ADD >	AB		EQ 5MG BASE	N74315 003	DEC 31, 1998
> ADD >	AB		EQ 10MG BASE	N74315 004	DEC 31, 1998

TERBINAFINE

GEL; TOPICAL

	LAMISIL			
+	NOVARTIS	1%	N20846 001	APR 29, 1998

TERFENADINE

TABLET; ORAL

		SELDANE			
AB	+	HOECHST MARION RSSL	60MG	N18949 001	MAY 08, 1985
		TERFENADINE			
AB		BAKER NORTON	60MG	N74475 001	JAN 03, 1997

TESTOSTERONE

FILM, EXTENDED RELEASE; TRANSDERMAL

		ANDRODERM			
RX	+	THERATECH	2.5MG/24HR	N20489 001	SEP 29, 1995
	+		2.5MG/24HR	N20489 001	SEP 29, 1995

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

		ACHROMYCIN V			
> DLT >	AB	ESI LEDERLE	250MG	N50278 003	
> DLT >	AB	+	500MG	N50278 001	
> ADD >	AB	LEDERLE	250MG	N50278 003	
> ADD >	AB	+	500MG	N50278 001	

TABLET; ORAL

	SUMYCIN			
	APOTHECON	50MG	N61147 003	
		100MG	N61147 002	
	@	50MG	N61147 003	
	@	100MG	N61147 002	

THALIDOMIDE

CAPSULE; ORAL

	THALOMID			
+	CELGENE	50MG	N20785 001	JUL 16, 1998

THEOPHYLLINE

CAPSULE; ORAL
ELIXOPHYLLIN

BX		FOREST LABS	100MG	N85545 001 JUL 31, 1984
BX	+		200MG	N83921 001 JUL 31, 1984
	@		100MG	N85545 001 JUL 31, 1984
	@		200MG	N83921 001 JUL 31, 1984

CAPSULE, EXTENDED RELEASE; ORAL
ELIXOPHYLLIN SR

BC		FOREST LABS	125MG	N86826 001 JAN 29, 1985
BC			250MG	N86826 002 JAN 29, 1985
	@		125MG	N86826 001 JAN 29, 1985
	@		250MG	N86826 002 JAN 29, 1985

THEOPHYLLINE

>_DLT_>	BC	FAULDING	100MG	N89976 001 JAN 04, 1995
>_DLT_>	BC		200MG	N89977 001 JAN 04, 1995
>_DLT_>	BC		300MG	N89932 001 JAN 04, 1995
>_ADD_>		@	100MG	N89976 001 JAN 04, 1995
>_ADD_>		@	200MG	N89977 001 JAN 04, 1995
>_ADD_>		@	300MG	N89932 001 JAN 04, 1995

TABLET; ORAL
QUIBRON-T

	+	MONARCH PHARMS	300MG	N88656 001 AUG 22, 1985
	+	ROBERTS LABS	300MG	N88656 001 AUG 22, 1985

TABLET, EXTENDED RELEASE; ORAL
QUIBRON-T/SR

BC		KING PHARMS	300MG	N87563 001 JUN 21, 1983
BC		MONARCH PHARMS	300MG	N87563 001 JUN 21, 1983

THIAMYLAL SODIUM

INJECTABLE; INJECTION
SURITAL

+	PARKE DAVIS	1GM/VIAL	N07600 003
+		5GM/VIAL	N07600 005
+		10GM/VIAL	N07600 009
@	PARKEDALE	1GM/VIAL	N07600 003
@		5GM/VIAL	N07600 005
@		10GM/VIAL	N07600 009

THIORIDAZINE HYDROCHLORIDE

CONCENTRATE; ORAL
THIORIDAZINE HCL

AA	PHARM ASSOC	**100MG/ML**	**N40213 001 MAY 29, 1998**

TABLET; ORAL
THIORIDAZINE HCL

AB	DANBURY PHARMA	**25MG**	**N88755 001 JUL 24, 1984**
@		25MG	N88755 001 JUL 24, 1984

THYROTROPIN ALFA

INJECTABLE; INJECTION
THYROGEN

+	GENZYME	1.1MG/VIAL	N20898 001 NOV 30, 1998

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL
TICLID

@	ROCHE	125MG	N19979 001 MAR 24, 1993

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL
TICLID

	+	ROCHE	250MG	N19979 002 OCT 31, 1991
	@	SYNTEX	125MG	N19979 001 MAR 24, 1993
	*		250MG	N19979 002 OCT 31, 1991

TIMOLOL MALEATE

SOLUTION, GEL FORMING/DROPS; OPHTHALMIC
TIMOLOL MALEATE

AB		ALCON	EQ 0.25% BASE	N20963 001 OCT 21, 1998
AB			EQ 0.5% BASE	N20963 002 OCT 21, 1998

TIMOPTIC-XE

AB	+	MERCK	EQ 0.25% BASE	N20330 001 NOV 04, 1993
AB	+		EQ 0.5% BASE	N20330 002 NOV 04, 1993

SOLUTION/DROPS; OPHTHALMIC
TIMOLOL MALEATE

AT		ADV REMEDIES	EQ 0.25% BASE	N74465 001 MAR 25, 1997
AT			EQ 0.5% BASE	N74466 001 MAR 25, 1997
AT			EQ 0.5% BASE	N74466 001 MAR 25, 1997
AT		AKORN	EQ 0.25% BASE	N74465 001 MAR 25, 1997

TABLET; ORAL
BLOCADREN

AB		MERCK	5MG	N18017 001
AB			10MG	N18017 002
AB	+		20MG	N18017 004
AB		MERCK SHARP DOHME	5MG	N18017 001
AB			10MG	N18017 002
AB	*		20MG	N18017 004

TIROFIBAN HYDROCHLORIDE

INJECTABLE; INJECTION
AGGRASTAT

	+	MERCK	EQ 0.05MG BASE/ML	N20913 001 MAY 14, 1998
	+		EQ 0.25MG BASE/ML	N20912 001 MAY 14, 1998

TOLBUTAMIDE

TABLET; ORAL
TOLBUTAMIDE

AB	ZENITH GOLDLINE	500MG	N87093 001
AB	ZENITH LABS	500MG	N87093 001

TOLCAPONE

TABLET; ORAL
TASMAR

	ROCHE	100MG	N20697 001 JAN 29, 1998
+		200MG	N20697 002 JAN 29, 1998

TOLTERODINE TARTRATE

TABLET; ORAL
DETROL

	PHARMACIA AND UPJOHN	1MG	N20771 001 MAR 25, 1998
+		2MG	N20771 002 MAR 25, 1998

TOPIRAMATE

CAPSULE; ORAL
TOPAMAX SPRINKLE

	JOHNSON RW	15MG	N20844 001 OCT 26, 1998
		25MG	N20844 002 OCT 26, 1998
+		50MG	N20844 003 OCT 26, 1998

TORSEMIDE

INJECTABLE; INJECTION

		DEMADEX		
	*	BOEHRINGER MANNHEIM	10MG/ML	N20137 002 AUG 23, 1993
	+	ROCHE	10MG/ML	N20137 002 AUG 23, 1993

TABLET; ORAL

		DEMADEX		
		BOEHRINGER MANNHEIM	5MG	N20136 001 AUG 23, 1993
			10MG	N20136 002 AUG 23, 1993
			20MG	N20136 003 AUG 23, 1993
	*		100MG	N20136 004 AUG 23, 1993
		ROCHE	5MG	N20136 001 AUG 23, 1993
			10MG	N20136 002 AUG 23, 1993
			20MG	N20136 003 AUG 23, 1993
	+		100MG	N20136 004 AUG 23, 1993

TRETINOIN

CREAM; TOPICAL

		AVITA		
AB	*	PENEDERM	0.025%	N20404 003 JAN 14, 1997
AB			0.025%	N20404 003 JAN 14, 1997
		RETIN-A		
> ADD > AB	+	JOHNSON AND JOHNSON	0.05%	N17522 001
> ADD > AB	+		0.1%	N17340 001
> ADD >		TRETINOIN		
> ADD > AB		SPEAR PHARMS	0.025%	N75264 001 DEC 24, 1998
> ADD > AB			0.05%	N75265 001 DEC 24, 1998
> ADD > AB			0.1%	N75213 001 DEC 24, 1998

TRETINOIN

GEL; TOPICAL

		AVITA		
BT		PENEDERM	0.025%	N20400 001 JAN 29, 1998
BX			0.025%	N20400 001 JAN 29, 1998
		RETIN-A		
BT	+	JOHNSON AND JOHNSON	0.025%	N17579 002
BX	*		0.025%	N17579 002

SOLUTION; TOPICAL

		RETIN-A		
	*	J AND J	0.05%	N16921 001
AT	+	JOHNSON AND JOHNSON	0.05%	N16921 001
		TRETINOIN		
AT		COPLEY PHARM	0.05%	N74873 001 JUN 19, 1998

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

		TRIAMCINOLONE ACETONIDE		
	@	ALPHARMA	0.025%	N87797 001 JUN 07, 1982
AT		NMC	0.025%	N87797 001 JUN 07, 1982

TRIAMCINOLONE DIACETATE

SYRUP; ORAL

KENACORT			
SQUIBB		EQ 4MG BASE/5ML	N12515 001
@		EQ 4MG BASE/5ML	N12515 001

TRICHLORMETHIAZIDE

TABLET; ORAL

	TRICHLORMETHIAZIDE		
BP	DANBURY PHARMA	2MG	N83847 001
BP		4MG	N83855 001
	@	2MG	N83847 001
	@	4MG	N83855 001

TRIFLUOPERAZINE HYDROCHLORIDE

TABLET; ORAL
TRIFLUOPERAZINE HCL

AB		ZENITH GOLDLINE	EQ 1MG BASE	N87612 001 NOV 19, 1982
AB			EQ 2MG BASE	N87613 001 NOV 19, 1982
AB		ZENITH LABS	EQ 1MG BASE	N87612 001 NOV 19, 1982
AB			EQ 2MG BASE	N87613 001 NOV 19, 1982

TRIFLURIDINE

SOLUTION/DROPS; OPHTHALMIC
VIROPTIC

AT	*	GLAXO WELLCOME	1%	N18299 001
AT	+	MONARCH PHARMS	1%	N18299 001

TRIHEXYPHENIDYL HYDROCHLORIDE

TABLET; ORAL
TRIHEXYPHENIDYL HCL

AA		CIRCA	2MG	N40184 001 FEB 06, 1998
AA			5MG	N40184 002 FEB 06, 1998
> ADD > AA		VINTAGE PHARMS	2MG	N40254 001 DEC 24, 1998
> ADD > AA			5MG	N40254 002 DEC 24, 1998

TRIMEPRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL
TEMARIL

	*	ALLERGAN HERBERT	EQ 5MG BASE	N11316 004
	@		EQ 5MG BASE	N11316 004

SYRUP; ORAL
TEMARIL

		ALLERGAN HERBERT	EQ 2.5MG BASE/5ML	N11316 003
	@		EQ 2.5MG BASE/5ML	N11316 003

TABLET; ORAL
TEMARIL

	*	ALLERGAN HERBERT	EQ 2.5MG BASE	N11316 001

TRIMEPRAZINE TARTRATE

TABLET; ORAL
TEMARIL

	@	ALLERGAN HERBERT	EQ 2.5MG BASE	N11316 001

TRIMETHAPHAN CAMSYLATE

INJECTABLE; INJECTION
ARFONAD

	*	ROCHE	50MG/ML	N08983 001
	@		50MG/ML	N08983 001

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
TIGAN

AP	+	ROBERTS LABS	100MG/ML	N17530 001
AP	*	SMITHKLINE BEECHAM	100MG/ML	N17530 001

TRIMETHOPRIM

TABLET; ORAL
PROLOPRIM

AB		GLAXO WELLCOME	100MG	N17943 001
AB	*		200MG	N17943 003 JUL 14, 1982
AB		MONARCH PHARMS	100MG	N17943 001
AB	+		200MG	N17943 003 JUL 14, 1982

TRIMETREXATE GLUCURONATE

INJECTABLE; INJECTION
NEUTREXIN

	+	US BIOSCIENCE	EQ 200MG BASE/VIAL	N20326 002 JUL 31, 1998

TROGLITAZONE

TABLET; ORAL
REZULIN

AB		PARKE DAVIS	200MG	N20720 001 JAN 29, 1997

TROGLITAZONE

TABLET; ORAL
REZULIN

AB	PARKE DAVIS	300MG	N20720 003 AUG 04, 1997
AB		400MG	N20720 002 JAN 29, 1997
AB	PARKE DAVIS PHARMS	200MG	N20720 001 JAN 29, 1997
AB		300MG	N20720 003 AUG 04, 1997
AB		400MG	N20720 002 JAN 29, 1997

TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC
TROPICAMIDE

AT	AKORN	1%	N88447 001 AUG 28, 1985
	@	1%	N88447 001 AUG 28, 1985

UREA, C-14

CAPSULE; ORAL
PYTEST

+	BALLARD MEDCL	1 uCi	N20617 001 MAY 09, 1997
+	TRI MED SPECLTS	1 uCi	N20617 001 MAY 09, 1997

PYTEST KIT

+	BALLARD MEDCL	1 uCi	N20617 002 MAY 09, 1997
+	TRI MED SPECLTS	1 uCi	N20617 002 MAY 09, 1997

UROFOLLITROPIN

INJECTABLE; INTRAMUSCULAR
FERTINEX

+	SERONO	75 IU/AMP	N19415 002 SEP 18, 1986
+		150 IU/AMP	N19415 003 SEP 18, 1986

UROFOLLITROPIN

INJECTABLE; INTRAMUSCULAR
METRODIN

+	SERONO	75 IU/AMP	N19415 002 SEP 18, 1986
+		150 IU/AMP	N19415 003 SEP 18, 1986

VALRUBICIN

SOLUTION; INTRAVESICAL
VALSTAR PRESERVATIVE FREE

+	ANTHRA	40MG/ML	N20892 001 SEP 25, 1998

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
VERELAN

+	ELAN	120MG	N19614 001 MAY 29, 1990
+		180MG	N19614 003 JAN 09, 1992
+		240MG	N19614 002 MAY 29, 1990
+		360MG	N19614 004 MAY 10, 1996
+	LEDERLE	120MG	N19614 001 MAY 29, 1990
+		180MG	N19614 003 JAN 09, 1992
+		240MG	N19614 002 MAY 29, 1990
+		360MG	N19614 004 MAY 10, 1996

VERELAN PM

+	ELAN PHARM	100MG	N20943 001 NOV 25, 1998
+		200MG	N20943 002 NOV 25, 1998
+		300MG	N20943 003 NOV 25, 1998

INJECTABLE; INJECTION
VERAPAMIL HCL

AP	ABBOTT	2.5MG/ML	N75136 001 OCT 20, 1998

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION

	VERAPAMIL HCL			
AP	MARSAM	**2.5MG/ML**	**N72233 001**	
			FEB 26, 1993	
AP		**2.5MG/ML**	**N73485 001**	
			SEP 27, 1993	
	@	2.5MG/ML	N72233 001	
			FEB 26, 1993	
	@	2.5MG/ML	N73485 001	
			SEP 27, 1993	

VIDARABINE

INJECTABLE; INJECTION

	VIRA-A		
	@ PARKE DAVIS	EQ 187.4MG BASE/ML	N50523 001
	@ PARKEDALE	EQ 187.4MG BASE/ML	N50523 001

OINTMENT; OPHTHALMIC

	VIRA-A		
+	PARKE DAVIS	3%	N50486 001
+	PARKEDALE	3%	N50486 001

VINCRISTINE SULFATE

INJECTABLE; INJECTION

	VINCRISTINE SULFATE		
+	FAULDING	1MG/VIAL	N71559 001
			APR 11, 1988
+		2MG/VIAL	N71560 001
			APR 11, 1988
+		5MG/VIAL	N71561 001
			APR 11, 1988
	@	1MG/VIAL	N71559 001
			APR 11, 1988
	@	2MG/VIAL	N71560 001
			APR 11, 1988
	@	5MG/VIAL	N71561 001
			APR 11, 1988

WARFARIN SODIUM

TABLET; ORAL

	COUMADIN		
AB	DUPONT MERCK	**3MG**	**N09218 025**
			NOV 18, 1996
AB		**6MG**	**N09218 026**
			NOV 18, 1996
	WARFARIN SODIUM		
AB	BARR	**3MG**	**N40145 008**
			NOV 05, 1998
AB		**6MG**	**N40145 009**
			NOV 05, 1998

WATER FOR INJECTION, STERILE

LIQUID; N/A

	STERILE WATER FOR INJECTION IN PLASTIC CONTAINER		
AP	B BRAUN	**100%**	**N19633 001**
			FEB 29, 1988
AP	MCGAW	**100%**	**N19633 001**
			FEB 29, 1988

ACETAMINOPHEN; ASPIRIN; CAFFEINE

TABLET; ORAL
EXCEDRIN (MIGRAINE)
+ BRISTOL MYERS 250MG;250MG;65MG N20802 001 JAN 14, 1998

ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE

TABLET, CHEWABLE; ORAL
GAVISCON
+ HOECHST MARION RSSL 80MG;20MG N18685 001 DEC 09, 1983
80MG;20MG N18685 001 DEC 09, 1983
+ 160MG;40MG N18685 002 DEC 09, 1983
GAVISCON-2
+ HOECHST MARION RSSL 160MG;40MG N18685 002 DEC 09, 1983

CHLORHEXIDINE GLUCONATE

SOLUTION; TOPICAL
CHG SCRUB
ECOLAB 4% N19258 002 JUL 22, 1986
HUNTINGTON LABS 4% N19258 002 JUL 22, 1986
CIDA-STAT
ECOLAB 2% N19258 001 JUL 22, 1986
HUNTINGTON LABS 2% N19258 001 JUL 22, 1986
MICROCOL
> DLT > J AND J 0.5% N72292 001 JAN 28, 1992
> DLT >
PREVACARE R
> ADD > J AND J 0.5% N72292 001 JAN 28, 1992
> ADD >

CIMETIDINE

TABLET; ORAL
CIMETIDINE
LEK PHARM 100MG N75122 001 JUN 19, 1998

CIMETIDINE

TABLET; ORAL
CIMETIDINE
LEK PHARM 200MG N75122 002 JUN 19, 1998
NOVOPHARM 200MG N74961 001 JUN 19, 1998
PERRIGO 100MG N74972 001 JUN 19, 1998
200MG N75285 001 OCT 29, 1998
PHARM FORM 200MG N74963 001 JUN 19, 1998
TORPHARM 100MG N74948 001 JUN 19, 1998

CLEMASTINE FUMARATE

TABLET; ORAL
TAVIST-1
+ NOVARTIS 1.34MG N17661 003 AUG 21, 1992
@ 1.34MG N17661 003 AUG 21, 1992
+ 1.34MG N20925 001 AUG 21, 1992

CLOTRIMAZOLE

CREAM; VAGINAL
GYNE-LOTRIMIN 3
+ SCHERING PLOUGH 2% N20574 001 NOV 24, 1998

TABLET; VAGINAL
GYNIX
COPLEY PHARM 100MG N73249 001 FEB 13, 1998

FAMOTIDINE

TABLET, CHEWABLE; ORAL
PEPCID AC
+ MERCK 10MG N20801 001 SEP 24, 1998

IBUPROFEN

CAPSULE; ORAL
IBUPROFEN
PHARM FORM 200MG N74782 001 JUL 06, 1998

SUSPENSION; ORAL
CHILDREN'S ADVIL-FLAVORED
+ WHITEHALL ROBINS 100MG/5ML N20589 002 NOV 07, 1997
100MG/5ML N20589 002 NOV 07, 1997

> ADD > CHILDREN'S IBUPROFEN
> ADD > PERRIGO 100MG/5ML N74937 001 DEC 22, 1998

SUSPENSION/DROPS; ORAL
> ADD > IBUPROFEN
> ADD > PERRIGO 40MG/ML N75217 001 DEC 16, 1998
> ADD >
PEDIATRIC ADVIL
+ WHITEHALL ROBINS 100MG/2.5ML N20812 001 JAN 30, 1998

TABLET; ORAL
IBUPRIN
SIDMAK LABS NJ 200MG N71773 001 JUL 16, 1987
@ 200MG N71773 001 JUL 16, 1987

IBUPROFEN
DANBURY PHARMA 200MG N71905 001 MAR 08, 1988
200MG N71905 001 MAR 08, 1988
+ MCNEIL 200MG N73019 001 MAR 30, 1994
200MG N73019 001 MAR 30, 1994
NOVOPHARM 200MG N74931 001 JUL 20, 1998
PHARM FORM 200MG N74782 001 JUL 06, 1998

NUPRIN
BRISTOL MYERS 200MG N72035 001 FEB 16, 1988
200MG N72036 001 FEB 16, 1988

IBUPROFEN

TABLET; ORAL
NUPRIN
@ BRISTOL MYERS 200MG N72035 001 FEB 16, 1988
@ 200MG N72036 001 FEB 16, 1988
MCNEIL 200MG N19012 001 MAY 18, 1984
@ 200MG N19012 003 JUL 29, 1987
+ 200MG N19012 001 MAY 18, 1984
200MG N19012 003 JUL 29, 1987

TABLET, CHEWABLE; ORAL
> ADD > CHILDREN'S ADVIL
> ADD > WHITEHALL ROBINS 50MG N20944 001 DEC 18, 1998
> ADD >
> ADD > JUNIOR STRENGTH ADVIL
> ADD > WHITEHALL ROBINS 100MG N20944 002 DEC 18, 1998
> ADD >
JUNIOR STRENGTH MOTRIN
MCNEIL 100MG N20601 003 NOV 15, 1996
+ 100MG N20601 003 NOV 15, 1996

INSULIN BIOSYNTHETIC HUMAN

INJECTABLE; INJECTION
HUMULIN R PEN
+ LILLY 100 UNITS/ML N18780 005 AUG 06, 1998

INSULIN BIOSYNTHETIC HUMAN; INSULIN SUSP ISOPHANE BIOSYNTHETIC HUMAN

INJECTABLE; INJECTION
HUMULIN 70/30 PEN
+ LILLY 30 UNITS/ML;70 UNITS/ML N19717 002 AUG 06, 1998

MICONAZOLE NITRATE

CREAM; VAGINAL

	MONISTAT 3			
	+ ADVANCED CARE PRODS	4%	N20827 001	
			MAR 30, 1998	

SUPPOSITORY; VAGINAL

	MONISTAT 7			
> ADD >	+ ADVANCED CARE PRODS	100MG	N18520 002	
> ADD >			FEB 15, 1991	
> DLT >	+ JOHNSON RW	100MG	N18520 002	
> DLT >			FEB 15, 1991	

MINOXIDIL

SOLUTION; TOPICAL

	MINOXIDIL (FOR MEN)			
	NOVEX	2%	N74924 001	
			APR 29, 1998	
	NU PHARM	2%	N74924 001	> ADD >
			APR 29, 1998	> ADD >
				> ADD >
	MINOXIDIL (FOR WOMEN)			
	NOVEX	2%	N74924 002	> ADD >
			APR 29, 1998	> ADD >
	NU PHARM	2%	N74924 002	
			APR 29, 1998	

NAPHAZOLINE HYDROCHLORIDE; PHENIRAMINE MALEATE

SOLUTION/DROPS; OPHTHALMIC

	OCUHIST			> ADD >
	AKORN	0.025%;0.3%	N20485 001	> ADD >
			JAN 31, 1996	> DLT >
				> DLT >
	VISINE-A			
	AKORN	0.025%;0.3%	N20485 001	
			JAN 31, 1996	

NAPROXEN SODIUM

TABLET; ORAL

	ALEVE			
> ADD >	+ BAYER	EQ 200MG BASE	N20204 002	
> ADD >			JAN 11, 1994	
> DLT >	+ HAMILTON PHARMS	EQ 200MG BASE	N20204 002	
> DLT >			JAN 11, 1994	

NAPROXEN SODIUM

TABLET; ORAL

NAPROXEN SODIUM			
PAR PHARM	EQ 200MG BASE	N75168 001	
		JUL 28, 1998	

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL

NICOTROL			
+ MCNEIL	15MG/16HR	N20536 001	
		JUL 03, 1996	
+ PHARMACIA AND UPJOHN	15MG/16HR	N20536 001	
		JUL 03, 1996	

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL

	NICORETTE (MINT)			
	+ SMITHKLINE BEECHAM	EQ 2MG BASE	N18612 003	
			DEC 23, 1998	
	+	EQ 4MG BASE	N20066 003	
			DEC 23, 1998	

POVIDONE-IODINE

SOLUTION; TOPICAL

	POVIDONE IODINE			
> ADD >	+ ALLEGIANCE HLTHCARE	1%	N19522 001	
> ADD >			MAR 31, 1989	
> DLT >	+ PHARMASEAL	1%	N19522 001	
> DLT >			MAR 31, 1989	

RANITIDINE HYDROCHLORIDE

TABLET, EFFERVESCENT; ORAL

ZANTAC 75			
+ GLAXO WELLCOME	EQ 75MG BASE	N20745 001	
		FEB 26, 1998	

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 12 DEC '98

NO DECEMBER 1998 APPROVALS

This data is provided to the Division of Data Management and Services from the Office of Orphan Products Development and it is not edited prior to publication.

Orphan Product Designations and Approvals List
January 1998 through December 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
1,5-(Butylimino) -1,5 dideoxy,D-glucitol TN=	Treatment of Fabry's disease.	Oxford GlycoSciences 10, The Quadrant Abington Science Park, Abington Oxfordshire OX14 3YS UK DD=05/12/1998
1,5-(Butylimino) -1,5 dideoxy,D-glucitol TN=	Treatment of Gaucher disease.	Oxford GlycoSciences 10, The Quadrant Abington Science Park, Abington Oxfordshire OX14 3YS UK DD=05/29/1998
3-(3,5-dimethyl-1H-2ylmethylene) -1,3-dihydro-indol-2-one TN=	Treatment of Kaposi's sarcoma.	Sugen, Inc. 230 East Grand Ave. South San Francisco, CA 94080 DD=09/11/1998
40SD02 TN=	Treatment of chronic iron overload resulting from conventional transfusional treatment of beta-thalassemia major and sickle cell anemia.	Biomedical Frontiers, Inc. 1095 10th Ave., S.E. Minneapolis, MN 55414 DD=12/21/1998
Aldesleukin TN= Proleukin	Treatment of metastatic melanoma.	Chiron Corporation 4560 Horton Street Emeryville, CA 94608 DD=09/10/1996 MA=01/09/1998
Aldesleukin TN= Proleukin	Treatment of acute myelogenous leukemia.	Chiron Corporation 4560 Horton St. Emeryville, CA 94608 DD=07/31/1998

Orphan Product Designations and Approvals List
January 1998 through December 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Aldesleukin TN= Proleukin	For the treatment non-Hodgkin's lymphoma.	Chiron Corporation 4560 Horton St. Emeryville, CA 94608 DD=11/24/1998
Aliperetinate TN= Panretin	For the topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma.	Ligand Pharmaceuticals Inc. 10275 Science Center Drive San Diego, CA 92121 DD=03/24/1998
Alpha-galactosidase A TN=	Long-term enzyme replacement therapy for the treatment of Fabry disease.	Transkaryotic Therapies Inc. 195 Albany St. Cambridge, MA 02139 DD=06/22/1998
Amifostine TN= Ethyol	Reduction of the incidence and severity of radiation-induced xerostomia.	U.S. Bioscience, Inc. One Tower Bridge 100 Front Street, Suite 400 Conshohocken, PA 19428 DD=05/12/1998
Amifostine TN= Ethyol	For the reduction of the incidence and severity of toxicities associated with cisplatin administration.	U.S. Bioscience, Inc. One Tower Bridge 100 Front St., Suite #400 West Conshohocken, PA 19428 DD=11/24/1998
Arsenic trioxide TN=	Treatment of acute promyelocytic leukemia.	PolaRx, Inc. 787 7th Ave., 48th Floor New York, NY 10019 DD=03/03/1998

Orphan Product Designations and Approvals List
January 1998 through December 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Basiliximab TN= Simulect	Prophylaxis of solid organ rejection.	Novartis Pharmaceuticals Corporation 59 Route 10 East Hanover, NJ 07936 DD=12/12/1997 MA=05/12/1998
Beclomethasone dipropionate TN=	For oral administration in the treatment of intestinal graft-versus-host disease.	George B. McDonald, M.D. Fred Hutchinson Cancer Research Center 1100 Fairview Avenue North (SC-113); PO Box 19024 Seattle, WA 98109 DD=03/27/1998
Benzydamine hydrochloride TN= Tantum	Prophylactic treatment of oral mucositis resulting from radiation therapy for head and neck cancer.	Angelini Pharmaceuticals, Inc. 70 Grand Avenue River Edge, NJ 07661 DD=05/18/1998
Bindarit TN=	Treatment of lupus nephritis.	Angelini Pharmaceuticals, Inc. 70 Grand Avenue River Edge, NJ 07661 DD=02/03/1998
Botulinum toxin type A TN= Dysport	Treatment of spasmodic torticollis (cervical dystonia).	Ipsen Limited 1 Bath Road Maidenhead, Berkshire U.K. SL6 4UH DD=08/12/1998

Orphan Product Designations and Approvals List
January 1998 through December 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Carbamylglutamic acid TN=	Treatment of N-acetylglutamate synthetase deficiency.	Orphan Europe Immeuble "Le Guillaumet" 60 avenue du President Wilson 92046 Paris France, DD=01/20/1998
Corticotropin-releasing factor, human TN= Xerecept	Treatment of peritumoral brain edema.	Neurobiological Technologies, Inc. 1387 Marina Way South Richmond, CA 94804 DD=04/06/1998
Dexamethasone TN=	For use in posterior segment drug delivery system in the treatment of idiopathic intermediate uveitis.	Oculex Pharmaceuticals 639 N. Pastoria Avenue Sunnyvale, CA 94086 DD=09/11/1998
Dimethylsulfoxide TN=	Treatment of palmar-plantar erythrodysesthesia syndrome.	Cancer Technologies, Inc. 7301 East 22nd Street Suite 10E Tucson, AZ 85710 DD=04/06/1998
Doxorubicin liposome TN= Doxil	Treatment of ovarian cancer.	Sequus Pharmaceuticals, Inc. 960 Hamilton Ct. Menlo Park, CA 94025 DD=11/04/1998
Filgrastim TN= Neupogen	Reduction in the duration of neutropenia, fever, antibiotic use, and hospitalization, following induction and consolidation treatment for acute myeloid leukemia.	Amgen, Inc. 1840 DeHavilland Drive Thousand Oaks, CA 91320 DD=11/07/1996 MA=04/02/1998

Orphan Product Designations and Approvals List
January 1998 through December 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Follitropin alfa, recombinant TN= Gonal-F	For the initiation and re-initiation of spermatogenesis in adult males with reproductive failure due to hypothalamic or pituitary dysfunction, hypogonadotropic hypogonadism.	Serono Laboratories, Inc. 100 Longwater Circle Norwell, MA 02061 DD=12/21/1998
Fructose-1,6-diphosphate TN=	Treatment of painful vaso-occlusive episodes associated with sickle cell disease.	Cypros Pharmaceutical Corporation 2714 Loker Avenue West Carlsbad, CA 92008 DD=05/29/1998
Humanized anti-CD2 monoclonal antibody TN=	Treatment of graft-versus-host disease.	MedImmune, Inc. 35 West Watkins Mill Rd. Gaithersburg, MD 20878 DD=11/13/1998
Humanized anti-human CD2 MAb TN= MEDI-507	For the induction of donor-specific immunologic unresponsiveness resulting in prophylaxis of organ rejection without the need for chronic immunosuppressive therapy, in patients receiving allogeneic renal transplants.	Biotransplant, Inc. Building 75, 3rd. Ave. Charlestown Navy Yard Charlestown, MA 02129 DD=09/17/1998
Hydroxyurea TN= Droxia	Treatment of patients with sickle cell anemia as shown by the presence of hemoglobin S.	Bristol-Myers Squibb Pharmaceutical Research Institute P.O. Box 4000 Princeton, NJ 08543 DD=10/01/1990 MA=02/25/1998

Orphan Product Designations and Approvals List
January 1998 through December 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Infliximab TN= Remicade	Treatment of moderately to severely active Crohn's disease for the reduction of the signs and symptoms, in patients who have an inadequate response to conventional therapy; and treatment of patients with fistulizing Crohn's disease for the reduction in the number of draining enterocutaneous fistula(s).	Centocor, Inc. 200 Great Valley Parkway Malvern, PA 19355 DD=11/14/1995 MA=08/24/1998
Interferon Beta-1a TN= Avonex	Treatment of juvenile rheumatoid arthritis.	Biogen, Inc. 14 Cambridge Center Cambridge, MA 02142 DD=10/14/1998
L-baclofen TN=	Treatment of trigeminal neuralgia.	Pharmascience Labs 8400 Darnley Road Montreal, Quebec Canada H4T 1M4 DD=01/06/1998
Lamotrigine TN= Lamictal	Treatment of Lennox-Gastaut syndrome.	Glaxo Wellcome Research and Development 5 Moore Drive P.O. Box 13398 Research Triangle Park, NC 27709 DD=08/23/1995 MA=08/24/1998
Lepirudin TN= Refluden	Treatment of heparin-associated thrombocytopenia type II.	Hoechst Marion Roussel Frankfurt am Main Germany DD=02/13/1997 MA=03/06/1998

Orphan Product Designations and Approvals List
January 1998 through December 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Liposomal Cyclosporin A TN= Cyclospire	For aerosolized administration in the prevention and treatment of lung allograft rejection and pulmonary rejection events associated with bone marrow transplantation.	Vernon Knight, M.D. Baylor College of Medicine, Dept. of Molecular Physiology One Baylor Plaza Houston, TX 77030 DD=04/30/1998
Liposomal N-Acetylglucosminyl-N-Acetylmuramly-L-Ala-D-isoGln-L-Ala -gylcerolidpalmitoyl TN= ImmTher	Treatment of osteosarcoma.	Endorex Corp. 900 North Shore Drive Lake Bluff, IL 60044 DD=06/10/1998
Liposomal N-Acetylglucosminyl-N-Acetylmuramly-L-Ala-D-isoGln-L-Ala -gylcerolidpalmitoyl TN= ImmTher	Treatment of Ewing's sarcoma.	Endorex Corp. 900 North Shore Drive Lake Bluff, IL 60044 DD=06/10/1998
MN14 monoclonal antibody to carcinoembryonic antigen TN= CEA-CIDE	For the treatment of small cell lung cancer.	Immunomedics, Inc. 300 American Rd. Morris Plains, NJ 07950 DD=09/18/1998
MN14 monoclonal antibody to carcinoembryonic antigen TN= Cea-cide	Treatment of pancreatic cancer.	Immunomedics, Inc. 300 American Road Morris Plains, NJ 07950 DD=11/24/1998

Orphan Product Designations and Approvals List
January 1998 through December 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Mafenide acetate solution TN= Sulfamylon solution	For use as an adjunctive topical antimicrobial agent to control bacterial infection when used under moist dressings over meshed autografts on excised burn wounds.	Mylan Laboratories, Inc. 781 Chestnut Ridge Road P.O. Box 4310 Morgantown, WV 26504 DD=07/18/1990 MA=06/05/1998
Mecamylamine TN= Inversine	Treatment of Tourette's syndrome.	Layton Bioscience, Inc. 105 Reservoir Rd. Atherton, CA 94027 DD=10/14/1998
Methoxsalen TN= Uvadex	For use in conjunction with the UVAR photopheresis system to treat graft versus host disease.	Therakos, Inc. 437 Creamery Way Exton, PA 19431 DD=10/14/1998
Modafinil TN= Provigil	Treatment of excessive daytime sleepiness in narcolepsy.	Cephalon, Inc. 145 Brandywine Parkway West Chester, PA 19380 DD=03/15/1993 MA=12/24/1998
Murine MAb (Lym-1) and Iodine 131-I radiolabeled murine MAb (Lym-1) to human B-cell lymphoma TN= Oncolym	Treatment of B-cell non-Hodgkin's lymphoma.	Techniclone Corporation 14282 Franklin Ave. Tustin, CA 92780 DD=11/27/1998

Orphan Product Designations and Approvals List
January 1998 through December 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Octreotide TN= Sandostatin LAR	Treatment of acromegaly.	Novartis Pharmaceuticals Corporation 59 Route 10 East Hanover, NJ 07936 DD=08/24/1998 MA=11/25/1998
Octreotide TN= Sandostatin LAR	Treatment of severe diarrhea and flushing associated with malignant carcinoid tumors.	Novartis Pharmaceuticals Corporation 59 Route 10 East Hanover, NJ 07936 DD=08/24/1998 MA=11/25/1998
Octreotide TN= Sandostatin LAR	Treatment of diarrhea associated with vasoactive intestinal peptide tumors (VIPoma).	Novartis Pharmaceuticals Corporation 59 Route 10 East Hanover, NJ 07936 DD=08/24/1998 MA=11/25/1998
Oxypurinol TN=	Treatment of hyperuricemia in patients intolerant to allopurinol.	ILEX Oncology, Inc. 11550 IH-10 West, Suite 300 San Antonio, TX 78230 DD=11/09/1998
P1, P4-Di(uridine 5'-tetraphosphate), tetrasodium salt TN=	Treatment of cystic fibrosis.	Inspire Pharmaceuticals, Inc. 4222 Emperor Blvd., Suite 470 Durham, NC 27703 DD=10/27/1998

Orphan Product Designations and Approvals List
January 1998 through December 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
PEGASYS TN=	Treatment of renal cell carcinoma.	Hoffman-La Roche Inc. 340 Kingsland St. Nutley, NJ 07110 DD=07/13/1998
Papain, trypsin, and chymotrypsin TN= Wobe-Mugos	Treatment of multiple myeloma.	Marlyn Nutraceuticals, Inc. 14851 N. Scottsdale Rd. Scottsdale, AZ 85254 DD=12/21/1998
Pentostatin TN=	Treatment of cutaneous T-cell lymphoma.	SuperGen, Inc. Two Annbel Lane, Suite 220 San Ramon, CA 94583 DD=03/27/1998
Phenylacetate TN=	For use as an adjunct to surgery, radiation therapy and chemotherapy for the treatment of patients with primary or recurrent malignant glioma.	Targon Corporation 307 College Road East Princeton, NJ 08540 DD=03/06/1998
Pilocarpine HCl TN= Salagen	Treatment of xerostomia and keratoconjunctivitis sicca in Sjogren's syndrome patients.	MGI Pharma, Inc. 9900 Bren Road East Suite 300E Minneapolis, MN 55343 DD=02/28/1992 MA=02/11/1998
Polyethylene glycol-modified uricase TN= Zurase	Treatment of tumor lysis syndrome in cancer patients undergoing chemotherapy.	Phoenix Pharmacologics, Inc. 115 John Robert Thomas Dr. Exton, PA 19341 DD=12/21/1998
Prostaglandin E1 enol ester (AS-013) TN=	Treatment of Fontaine Stage IV chronic critical limb ischemia.	Alpha Therapeutic Corp. 5555 Valley Blvd. Los Angeles, CA 90032 DD=06/12/1998

Orphan Product Designations and Approvals List
January 1998 through December 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Radiolabeled monoclonal antibody to CD22 antigen on B-cells TN= LymphoCIDE	Treatment of non-Hodgkin's lymphoma.	Immunomedics, Inc. 300 American Rd. Morris Plains, NJ 07950 DD=07/13/1998
Recombinant bactericidal/permeability-increasing protein TN= Neuprex	Treatment of severe meningococcal disease.	Xoma Corporation 2910 Seventh Street Berkeley, CA 94710 DD=06/22/1998
Recombinant human Clara Cell 10kDa protein TN=	Prevention of neonatal bronchopulmonary dysplasia in premature neonates with respiratory distress syndrome.	Claragen, Inc. 335 Paint Branch Drive College Park, MD 20742 DD=07/13/1998
Recombinant human tumor necrosis factor receptor fusion protein TN= Enbrel	Treatment of juvenile rheumatoid arthritis.	Immunex Corporation 51 University St. Seattle, WA 98101 DD=10/27/1998
Recombinant humanized MAb 5c8 TN=	Prevention and treatment of Factor VIII/Factor IX inhibitors in patients with hemophilia A or B.	Biogen, Inc. 14 Cambridge Center Cambridge, MA 02142 DD=10/14/1998
Recombinant humanized monclonal antibody 5c8 TN=	Treatment of immune thrombocytopenic purpura.	Biogen, Inc. 14 Cambridge Center Cambridge, MA 02142 DD=02/03/1998

Orphan Product Designations and Approvals List
January 1998 through December 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Recombinant humanized monoclonal antibody 5c8 TN=	Treatment of systemic lupus erythematosus.	Biogen, Inc. 14 Cambridge Center Cambridge, MA 02142 DD=02/18/1998
Rifapentine TN= Priftin	Treatment of pulmonary tuberculosis.	Hoechst Marion Roussel P.O. Box 9627 Mail Station: H3-M2516 Kansas City, MO 64134 DD=06/09/1995 MA=06/22/1998
Rifaximin TN= Normix	Treatment of hepatic encephalopathy.	Salix Pharmaceuticals, Inc. 3600 W. Bayshore Road Palo Alto, CA 94303 DD=02/10/1998
S-adenosylmethionine TN=	Treatment of AIDS-myelopathy.	Di Rocco, Alessandro M.D. Beth Israel Medical Center, Phillips Ambulatory Care Center Philips Building, Suite 2Q; 10 Union Square East New York, NY 10003 DD=04/30/1998
Sacrosidase TN= Sucraid	Treatment of congenital sucrase-isomaltase deficiency.	Orphan Medical, Inc. 13911 Ridgedale Drive Suite 475 Minnetonka, MN 55305 DD=12/10/1993 MA=04/09/1998
Sodium phenylbutyrate TN=	For use as an adjuct to surgery, radiation therapy and chemotherapy for the treatment of patients with primary or recurrent malignant glioma.	Targon Corporation 307 College Road East Princeton, NJ 08540 DD=04/24/1998

Orphan Product Designations and Approvals List
January 1998 through December 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
TAK-603 TN=	Treatment of Crohn's disease.	TAP Holdings Inc. 2355 Waukegan Road Deerfield, IL 60015 DD=05/13/1998
Tacrolimus TN= Prograf	Prophylaxis of graft-versus-host-disease.	Fujisawa USA, Inc. 3 Parkway North Center Deerfield, IL 60015 DD=04/06/1998
Temozolomide TN= Temodal	Treatment of recurrent malignant glioma.	Shering-Plough Research Institute 2000 Galloping Hill Rd. Kenilworth, NJ 07033 DD=10/05/1998
Temozolomide TN= Temodal	Treatment of advanced metastatic melanoma.	Schering-Plough Research Institute 2000 Galloping Hill Rd. Kenilworth, NJ 07033 DD=10/14/1998
Tetrabenazine TN=	Treatment of moderate/severe tardive dyskinesia.	Lifehealth Limited Richmond House, Old Brewery Court, Sandyford Road Newcastle upon Tyne NE2 1XG England DD=05/12/1998
Thalidomide TN= Thalomid	Treatment of erythema nodosum leprosum.	Celgene Corporation P.O. Box 4914 7 Powder Horn Drive Warren, NJ 07059 DD=07/26/1995 MA=07/16/1998
Thalidomide TN=	Treatment of primary brain malignancies.	EntreMed, Inc. 9610 Medical Center Drive, Suite 200 Rockville, MD 20850 DD=02/27/1998

Orphan Product Designations and Approvals List
January 1998 through December 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Thalidomide TN=	Treatment of Kaposi's sarcoma.	EntreMed, Inc. 9610 Medical Center Dr., Suite 200 Rockville, MD 20850 DD=07/29/1998
Thalidomide TN= Thalomid	Treatment of multiple myeloma.	Celgene Corporation 7 Powder Horn Dr. Warren, NJ 07059 DD=10/14/1998
Thymalfasin TN= Zadaxin	Treatment of DiGeorge anomaly with immune defects.	SciClone Pharmaceuticals, Inc. 901 Mariner's Island Blvd. San Mateo, CA 94404 DD=01/08/1998
Thyrotropin alpha TN= Thyrogen	As an adjunct in the diagnosis of thyroid cancer.	Genzyme Corporation One Kendall Square Cambridge, MA 02139 DD=02/24/1992 MA=11/30/1998
Tiapride TN=	Treatment of Tourette's syndrome.	Synthelabo Research, Inc. 400 Plaza Drive Secaucus, NJ 07094 DD=04/21/1998
Transgenic human alpha 1 antitrypsin TN=	Treatment of cystic fibrosis.	PPL Therapeutics (Scotland) Limited Roslin, Edinburgh EH25 9PP Scotland U.K., DD=03/06/1998

Orphan Product Designations and Approvals List
January 1998 through December 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Valrubicin TN= Valstar	Treatment of carcinoma in situ of the urinary bladder.	Anthra Pharmaceuticals, Inc. 103 Carnegie Center, Suite 102 Princeton, NJ 08540 DD=05/23/1994 MA=09/25/1998
Xenogeneic hepatocytes TN= HepatAssist Liver Assist System	Treatment of severe liver failure.	Circe Biomedical, Inc. 99 Hayden Ave. Lexington, MA 02421 DD=11/27/1998

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO DECEMBER 1998 ADDITIONS

PATENT AND EXCLUSIVITY TERMS PATENT AND EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE PATENT AND EXCLUSIVITY COLUMNS, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 18TH EDITION FOR A FULL LISTING OF PATENT AND EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). ONLY NEW CODES WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

ABBREVIATIONS

PED	**PEDIATRIC EXCLUSIVITY**

REFERENCES

NEW DOSING *SCHEDULE*

D-38	**CONTINUOUS INFUSION AS AN ALTERNATE METHOD OF ADMINISTRATION**
D-39	**CHANGE IN TIME TO TAKE THE DRUG PRIOR TO A MEAL TO PREVENT MEAL-INDUCED HEARTBURN SYMPTOMS FROM " ...1/2-1 HOUR BEFORE EATING..." TO "...RIGHT BEFORE EATING OR UP TO 60 MIN BEFORE CONSUMING..."**
D-40	**ONCE-A-DAY DOSING REGIMEN**
D-41	**DRUG MAY BE DOSED RIGHT BEFORE A MEAL OR ANY TIME UP TO 30 MIN BEFORE EATING OR DRINKING FOOD AND BEVERAGES THAT WOULD BE EXPECTED TO CAUSE SYMPTOMS**
D-42	**TEN DAY DOSING REGIMEN FOR TRIPLE THERAPY, PREVACID IN COMBINATION WITH CLARITHROMYCIN AND AMOXICCLIN, FOR THE ERADICATION OF H. PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE**
D-43	**INITIATION OF TREATMENT WITH 900MG/DAY BY DELETION OF THE REQUIREMENT TO TITRATE TO 900MG/DAY OVER A 3-DAY PERIOD**
D-44	**IN A CLINICAL TRIAL, FEWER DISCONTINUATIONS DUE TO ADVERSE EVENTS, ESPECIALLY DIZZINESS AND VERTIGO, WERE OBSERVED WHEN TITRATING THE DOSE IN INCREMENTS OF 50MG/DAY EVERY THREE DAYS UNTIL AN EFFECTIVE DOSE (NOT EXCEEDING 400MG/DAY) WAS REACHED**
D-45	**ONCE DAILY DOSING FOR MAINTENANCE ONLY**
D-46	**NEW DOSING REGIMEN OF 80MG DAILY**
D-47	**TAKE DRUG "15 MINUTES TO 1 HOUR" PRIOR TO A MEAL TO PREVENT MEAL-INDUCED HEARTBURN**
D-48	**ADMINISTRATION OF CISATRICURIUM, A NEUROMUSCULAR BLOCKING AGENT AT DOSES OF 3 AND 4X THE ED95 OF CISATRICUNIUM FOLLOWING INDUCTION WITH THIOPENTAL**
D-49	**PEDIATRIC DOSING GUIDELINES**

NEW INDICATION

I-212	**TREATMENT OF SYMPTOMS OF DRY MOUTH IN PATIENTS WITH SJOGREN'S SYNDROME**
I-213	**TEMPORARY RELIEF OF PAIN AND PHOTOPHOBIA IN PATIENTS UNDERGOING CORNEAL REFRACTIVE SURGERY**
I-214	**TREATMENT OF OSTEOPOROSIS**
I-215	**PRE-PROCEDURAL APPLICATION TO ADULT MALE GENITAL SKIN PRIOR TO SITE-SPECIFIC SUBCUTANEOUS INFILTRATION WITH LIDOCAINE FOR THE REMOVAL OF GENITAL WARTS**
I-216	**FOR THE LONG-TERM TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA**
I-217	**PREVENTION (DURING AND FOLLOWING HOSPITALIZATION) OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY**
I-218	**USE OF LIPITOR AS AN ADJUNCTIVE THERAPY TO DIET FOR THE TREATMENT OF PATIENTS WITH ELEVATED SERUM TRIGLYCERIDE LEVELS (FREDERICKSON TYPE IV)**

PATENT AND EXCLUSIVITY TERMS

NEW INDICATION

I-219	USE OF LIPITOR BY PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDERICKSON TYPE III) WHO DO NOT RESPOND ADEQUATELY TO DIET
I-220	TREATMENT OF EPISODIC HEARTBURN, ACID INDIGESTION AND SOUR STOMACH
I-221	TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) IN MEN WITH AN ENLARGED PROSTATE TO IMPROVE SYMPTOMS, REDUCE THE RISK OF ACUTE URINARY RETENTION AND REDUCE THE RISK OF THE NEED OF SURGERY
I-222	PREVENTION OF ISCHEMIC COMPLICATIONS OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION, WHEN CONCURRENTLY ADMINISTERED WITH ASPIRIN
I-223	USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOICATED WITH ALLERGIC AND NONALLERGIC PERENNIAL RHINITIS IN CHILDREN AGE 6-11 YEARS
I-224	FOR THE USE IN PEDIATRIC PATIENTS 4 TO 11 YEARS OF AGE FOR THE MANAGEMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS
I-225	USE IN PATIENTS WITH PREVIOUS MI AND NORMAL CHOLESTEROL LEVELS, TO REDUCE RISK OF RECURRENT MI, MYOCARDIAL REVASCULARIZATION, AND CEREBROVASCULAR DISEASE EVENTS
I-226	FIRST-LINE THERAPY FOR THE TREATMENT OF ADVANCED CARCINOMA OF THE OVARY IN COMBINATION WITH CISPLATIN
I-227	SHORT-TERM TREATMENT OF SYMPTOMATIC GASTROESOPHAGEAL REFLUX DISEASE (GERD)
I-228	PREVENTION OF MEAL INDUCED HEARTBURN AT A DOSE OF 75MG TAKEN 30-60 MIN PRIOR TO A MEAL
I-229	PRILOSEC (OMEPRAZOLE), AMOXICILLIN AND CLARITHROMYCIN FOR THE ERADICATION OF H. PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE
I-230	IN COMBINATION WITH CISPLATIN, FOR THE FIRST-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN PATIENTS WHO ARE NOT CANDIDATES FOR POTENTIALLY CURATIVE SURGERY AND/OR RADIATION
I-231	TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR CHEMOTHERAPY
I-232	TREATMENT OF RECURRENT MUCOCUTANEOUS HERPES SIMPLEX INFECTIONS IN HIV-AFFECTED PATIENTS AT A DOSE OF 500MG TWICE DAILY
I-233	PROPHYLACTIC USE TO REDUCE PERIOPERATIVE BLOOD LOSS AND THE NEED FOR BLOOD TRANSFUSION IN PATIENTS UNDERGOING CARDIOPULMONARY BYPASS IN THE COURSE OF CORONARY ARTERY BYPASS GRAFT SURGERY
I-234	FOR USE IN COMBINATION WITH CISPLATIN FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED (STAGE IIIA OR IIIB) OR METASTATIC (STAGE IV) NON-SMALL CELL LUNG CANCER
I-235	PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 12 YEARS OF AGE AND OLDER
I-236	PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER
I-237	MAINTENANCE TREATMENT OF ASTHMA AND PREVENTION OF BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER
I-238	ADJUNCTIVE TREATMENT OF LENNOX-GASTAUT SYNDROME IN PEDIATRIC AND ADULT PATIENTS
I-239	TREATMENT OF PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
I-240	MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM AND RESULTANT METABOLIC BONE DISEASE IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL FAILURE (Ccr 15 TO 55ML MIN) NOT YET ON DIALYSIS
I-241	USE IN PHOTODYNAMIC THERAPY (PDT) FOR REDUCTION OF OBSTRUCTION AND PALLIATION OF SYMPTOMS IN PATIENTS WITH COMPLETELY OR PARTIALLY OBSTRUCTING ENDOBRONCHIAL NONSMALL CELL LUNG CANCER
I-242	TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE AND IN THE TREATMENT OF VULVAR AND VAGINAL ATROPHY IN WOMEN WITH AN INTACT UTERUS
I-243	USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH THE COMMON COLD IN CHILDREN AGE 5 TO 11 YEARS
I-244	REDUCE THE INCIDENCE OF BREAST CANCER IN WOMEN AT HIGH RISK FOR BREAST CANCER
I-245	TREATMENT OF ACUTE SINUSITIS
I-246	TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS
I-247	USE IN CONVERSION TO MONOTHERAPY IN ADULTS WITH PARTIAL SEIZURES WHO ARE RECEIVING TREATMENT WITH A SINGLE ENZYME-INDUCING ANTIEPILEPTIC DRUG

PATENT AND EXCLUSIVITY TERMS

NEW INDICATION

I-248	INPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITH/WITHOUT PULMONARY EMBOLISM WHEN ADMIN IN CONJUNCTION WITH WARFARIN SODIUM AND OUTPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCITON WITH WARFARIN SODIUM
I-249	TREATMENT OF CHRONIC HEPATITIS C IN PATIENTS WITH COMPENSATED LIVER DISEASE PREVIOUSLY UNTREATED WITH ALPHA INTERFERON THERAPY

PATENT USE CODE

U-215	TREATMENT OF EPILEPSY TWICE DAILY. TREATING A PATIENT BY ADMINISTERING CARBAMAZEPINE IN A DOSAGE FORM CAPABLE OF MAINTAINING BLOOD CONCENTRATION FROM 4-12MCG/ML OVER 12 HOURS
U-216	TREATMENT OF ADENOCARCINOMA, INCLUDING STAGE B2-C, BY ADMINISTERING AN AGONIST OF LR-RH AND FLUTAMIDE
U-217	METHOD OF PRODUCING ANESTHESIA
U-218	METHOD FOR LIMITING THE POTENTIAL FOR MICROBIAL GROWTH IN THE DRUG PRODUCT
U-219	TREATMENT OF PARKISON'S DISEASE
U-220	METHOD OF DIAGNOSIS
U-221	SELECTIVE VASODILATION BY CONTINUOUS ADENOSINE INFUSION
U-222	METHOD OF TREATING PAGETS DISEASE USING ACTONEL
U-223	TREATMENT OF BACTERIAL CONJUNCTIVITIS CAUSED BY SUSCEPTIBLE STRAINS OF MICROORGANISMS
U-224	CONTROLLING INTRAOCULAR PRESSURE
U-225	METHOD FOR DELIVERY
U-226	METHOD OF ENHANCING THE DISSOLUTION PROFILE OF A PHARMACEUTICAL FROM A SOLID DOSAGE FORM CONTAINING THE PHARMACEUTICAL AND SIMETHICONE
U-227	NASAL ADMINISTRATION
U-228	ASTHMA
U-229	CARDIAC INSUFFICIENCY (CONGESTIVE HEART FAILURE)
U-230	PREVENTION OF ACUTE CARDIAC ISCHEMIC EVENTS
U-231	USE IN PARKINSON'S DISEASE
U-232	METHOD OF TREATING MIGRAINE
U-233	DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE
U-234	METHOD OF USING RIBAVIRIN TO TREAT VIRAL INFECTIONS IN MAMMALS
U-235	METHOD OF MODULATING TH1 AND TH2 RESPONSE IN ACTIVATED T CELLS OF A HUMAN COMPRISING ADMINISTERING RIBAVIRIN TO THE T CELLS IN A DOSAGE WHICH PROMOTES THE TH1 RESPONSE AND SUPPRESSES THE TH2 RESPONSE
U-236	TREATING MALE PATTERN BALDNESS WITH 0.05 TO 3 MG/DAY
U-237	METHOD OF PERFORMING NMR IMAGING WITH A PATIENT COMPRISING ADMINISTERING TO THE PATIENT AN EFFECTIVE AMOUNT OF CONTRAST AGENT DISCLOSED IN THE CLAIMS
U-238	IMAGING A BODY TISSUE AND SUBJECTING TO NMR TOMOGRAPHY, ADMINISTERING AN AMOUNT OF PHARMACEUTICAL AGENT FOR AFFECTING THE RELAXATION TIMES OF ATOMS IN BODY TISSUES UNDERGOING NMR DIAGNOSIS, WHEREBY THE IMAGE CONTRAST IN ENHANCED....
U-239	TREATING OR CONTROLLING OCULAR INFLAMMATION WHICH COMPRISES TOPICALLY ADMINISTERING TO THE AFFECTED EYE A COMPOSITION COMPRISING A NSAID, A POLYMERIC QUATERNARY AMMONIUM COMPOUND AND BORIC ACID
U-240	TREATMENT OF ACUTE MIGRAINE ATTACKS

PATENT AND EXCLUSIVITY TERMS

PATENT USE CODE

U-241	FOR SHORT-TERM TREATMENT ACTIVE DUODENAL ULCER, MAINTENANCE THERAPY FOR DUODENAL ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING OF ACTIVE ULCER, SHORT-TERM TREATMENT ACTIVE BENIGN GASTRIC ULCER & GERD, PATHOLOGICAL HYPERSECRETORY CONDITIONS
U-242	USE OF FOLLITROPIN ALPHA ALONE IN IN-VITRO FERTILIZATION
U-243	TOPICAL ADMINISTRATION
U-244	PLATELET AGGREGATION INHIBITORS
U-245	TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS
U-246	PHOSPHATE BINDING
U-247	TREATMENT OF RHEUMATOID ARTHRITIS
U-248	TREATMENT OF HIV
U-249	METHOD OF TREATING ALLERGIC OR NON-ALLERGIC RHINITIS IN PATIENTS BY ADMINISTERING AEROSOLIZED PARTICLES OF MOMETASONE FUROATE
U-250	TREATMENT OF HEPATITIS B INFECTION
U-251	USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS IN THE TREATMENT OF TYPE II DIABETES
U-252	METHOD OF TREATING A HUMAN SUBJECT HAVING GAUCHER'S DISEASE
U-253	ORAL TRANSMUCOSAL USE

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020977	001	ABACAVIR SULFATE;ZIAGEN	5089500	JUN 26, 2009	U-248	PED	JUN 17, 2004
				5089500*PED	DEC 26, 2009	U-248	NCE	DEC 17, 2003
				5034394	JUN 26, 2009			
				5034394*PED	DEC 26, 2009			
	020978	001	ABACAVIR SULFATE;ZIAGEN	5089500	JUN 26, 2009	U-248	PED	JUN 17, 2004
				5089500*PED	DEC 26, 2009	U-248	NCE	DEC 17, 2003
				5034394	JUN 26, 2009			
				5034394*PED	DEC 26, 2009			
	020482	004	ACARBOSE;PRECOSE	4904769	FEB 27, 2007		NCE	SEP 06, 2000
	020802	001	ACETAMINOPHEN;EXCEDRIN (MIGRAINE)				NP	JAN 14, 2001
	020059	001	ADENOSINE;ADENOSCAN	5070877	DEC 10, 2008	U-116		
				5731296	MAR 24, 2015	U-221		
	020503	001	ALBUTEROL SULFATE;PROVENTIL-HFA	5766573	JUN 16, 2015		I-235	SEP 23, 2001
>ADD>	020560	001	ALENDRONATE SODIUM;FOSAMAX	5849726	JUN 06, 2015			
				5804570	FEB 17, 2015			
>ADD>	020560	002	ALENDRONATE SODIUM;FOSAMAX	5849726	JUN 06, 2015			
				5804570	FEB 17, 2015			
>ADD>	020560	003	ALENDRONATE SODIUM;FOSAMAX	5849726	JUN 06, 2015			
				5804570	FEB 17, 2015			
	020511	001	AMLEXANOX;APHTHASOL	5362737	NOV 08, 2011	U-243		
	019787	001	AMLODIPINE BESYLATE;NORVASC	4572909	JUL 31, 2006			
	019787	002	AMLODIPINE BESYLATE;NORVASC	4572909	JUL 31, 2006			
	019787	003	AMLODIPINE BESYLATE;NORVASC	4572909	JUL 31, 2006			
	050740	001	AMPHOTERICIN B;AMBISOME				ODE	AUG 11, 2004
	020304	001	APROTININ BOVINE;TRASYLOL				I-233	AUG 28, 2001
	020420	001	ARBUTAMINE HYDROCHLORIDE;GENESA	5108363	APR 28, 2009	U-220		
				5234404	AUG 10, 2010	U-220		
				5395970	MAR 07, 2012			
	020702	001	ATORVASTATIN CALCIUM;LIPITOR	4681893	SEP 24, 2009	U-161	I-218	JUL 10, 2001
							I-219	JUL 10, 2001
	020702	002	ATORVASTATIN CALCIUM;LIPITOR	4681893	SEP 24, 2009	U-161	I-218	JUL 10, 2001
							I-219	JUL 10, 2001
	020702	003	ATORVASTATIN CALCIUM;LIPITOR	4681893	SEP 24, 2009	U-161	I-218	JUL 10, 2001
							I-219	JUL 10, 2001
	020114	001	AZELASTINE HYDROCHLORIDE;ASTELIN	5164194	OCT 16, 2011	U-207		
	018521	001	BECLOMETHASONE DIPROPIONATE;VANCENASE	4364923	DEC 21, 1999			
	017573	001	BECLOMETHASONE DIPROPIONATE;VANCERIL	4364923	DEC 21, 1999			
	020486	001	BECLOMETHASONE DIPROPIONATE;VANCERIL DOUBLE STRENGTH	4364923	DEC 21, 1999			
	019408	001	BETAMETHASONE DIPROPIONATE;DIPROLENE	4489070	MAY 13, 2003			
	020816	001	BRINZOLAMIDE;AZOPT	5240923	AUG 31, 2010	U-224	NCE	APR 01, 2003
				5378703	AUG 31, 2010	U-224		
				5461081	OCT 24, 2012	U-225		
	020441	002	BUDESONIDE;PULMICORT				D-45	OCT 08, 2001
	020358	001	BUPROPION HYDROCHLORIDE;WELLBUTRIN	5763493	AUG 12, 2013			
				5731000	AUG 12, 2013			
	020358	002	BUPROPION HYDROCHLORIDE;WELLBUTRIN	5763493	AUG 12, 2013			
				5731000	AUG 12, 2013			
	020358	003	BUPROPION HYDROCHLORIDE;WELLBUTRIN	5731000	AUG 12, 2013			
				5763493	AUG 12, 2013			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020711	002	BUPROPION HYDROCHLORIDE;ZYBAN	5731000	AUG 12, 2013			
020711	003	BUPROPION HYDROCHLORIDE;ZYBAN	5731000	AUG 12, 2013			
020524	001	BUTENAFINE HYDROCHLORIDE;MENTAX	5021458	OCT 18, 2010	U-177		
020554	001	CALCIPOTRIENE;DOVONEX	4866048	DEC 29, 2007			
020611	001	CALCIPOTRIENE;DOVONEX	4866048	DEC 29, 2007			
020313	002	CALCITONIN, SALMON;MIACALCIN	5733569	MAR 31, 2015	U-227		
018044	001	CALCITRIOL;ROCALTROL				I-240	NOV 20, 2001
021068	001	CALCITRIOL;ROCALTROL				NDF	NOV 20, 2001
						I-240	NOV 20, 2001
020521	001	CALFACTANT;INFASURF PRESERVATIVE FREE				NCE	JUL 01, 2003
020838	001	CANDESARTAN CILEXETIL;ATACAND	5196444	APR 18, 2011	U-3	NCE	JUN 04, 2003
			5534534	JUL 09, 2013			
			5703110	APR 18, 2011			
			5705517	APR 18, 2011			
020838	002	CANDESARTAN CILEXETIL;ATACAND	5196444	APR 18, 2011	U-3	NCE	JUN 04, 2003
			5534534	JUL 09, 2013			
			5703110	APR 18, 2011			
			5705517	APR 18, 2011			
020838	003	CANDESARTAN CILEXETIL;ATACAND	5196444	APR 18, 2011	U-3	NCE	JUN 04, 2003
			5534534	JUL 09, 2013			
			5703110	APR 18, 2011			
			5705517	APR 18, 2011			
020838	004	CANDESARTAN CILEXETIL;ATACAND	5196444	APR 18, 2011	U-3	NCE	JUN 04, 2003
			5534534	JUL 09, 2013			
			5703110	APR 18, 2011			
			5705517	APR 18, 2011			
020896	001	CAPECITABINE;XELODA				NCE	APR 30, 2003
020896	002	CAPECITABINE;XELODA				NCE	APR 30, 2003
020712	001	CARBAMAZEPINE;CARBATROL	5326570	JUL 05, 2011	U-215		
020712	002	CARBAMAZEPINE;CARBATROL	5326570	JUL 05, 2011	U-215		
019972	001	CARTEOLOL HYDROCHLORIDE;OCUPRESS	4309432	JAN 02, 2000			
020297	001	CARVEDILOL;COREG	4503067	MAR 05, 2007	U-3		
			5760069	JUN 07, 2015	U-233		
020297	002	CARVEDILOL;COREG	4503067	MAR 05, 2007	U-3		
			5760069	JUN 07, 2015	U-233		
020297	003	CARVEDILOL;COREG	4503067	MAR 05, 2007	U-3		
			5760069	JUN 07, 2015	U-233		
020297	004	CARVEDILOL;COREG	4503067	MAR 05, 2007	U-3		
			5760069	JUN 07, 2015	U-233		
020998	001	CELECOXIB;CELEBREX				NCE	DEC 31, 2003
020998	002	CELECOXIB;CELEBREX				NCE	DEC 31, 2003
020774	001	CHLORHEXIDINE GLUCONATE;PERIOCHIP				NP	MAY 15, 2001
020238	002	CIMETIDINE;TAGAMET HB				D-41	JUN 05, 2001
020369	001	CIPROFLOXACIN HYDROCHLORIDE;CILOXAN	4670444	JUN 02, 2004	U-223	NDF	MAR 30, 2001
020805	001	CIPROFLOXACIN HYDROCHLORIDE;CIPRO HC	4670444	DEC 09, 2003		NC	FEB 10, 2001
			4844902	FEB 11, 2008			
019847	001	CIPROFLOXACIN;CIPRO				I-164	SEP 11, 1999
						I-245	JUN 03, 2000
020780	001	CIPROFLOXACIN;CIPRO	4670444	DEC 09, 2003			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020780	002	CIPROFLOXACIN;CIPRO	4670444	DEC 09, 2003			
	019857	001	CIPROFLOXACIN;CIPRO IN DEXTROSE 5%				I-164	SEP 11, 1999
							I-245	JUN 03, 2000
	019858	001	CIPROFLOXACIN;CIPRO IN SODIUM CHLORIDE 0.9%				I-164	SEP 11, 1999
							I-245	JUN 03, 2000
	020551	001	CISATRACURIUM BESYLATE;NIMBEX				D-48	OCT 15, 2001
	020551	002	CISATRACURIUM BESYLATE;NIMBEX PRESERVATIVE FREE				D-48	OCT 15, 2001
	020551	003	CISATRACURIUM BESYLATE;NIMBEX PRESERVATIVE FREE				D-48	OCT 15, 2001
	020822	002	CITALOPRAM HYDROBROMIDE;CELEXA				NCE	JUL 17, 2003
	020822	003	CITALOPRAM HYDROBROMIDE;CELEXA				NCE	JUL 17, 2003
	020822	004	CITALOPRAM HYDROBROMIDE;CELEXA				NCE	JUL 17, 2003
	020839	001	CLOPIDOGREL BISULFATE;PLAVIX	4529596	JUL 05, 2003			
				4847265	FEB 12, 2008			
				5576328	JAN 31, 2014			
	020574	001	CLOTRIMAZOLE;GYNE-LOTRIMIN 3				NP	NOV 24, 2001
	017922	001	DESMOPRESSIN ACETATE;DDAVP	5763407	DEC 23, 2013			
	017922	002	DESMOPRESSIN ACETATE;DDAVP	5763407	DEC 23, 2013			
	017922	003	DESMOPRESSIN ACETATE;DDAVP	5763407	DEC 23, 2013			
	018938	001	DESMOPRESSIN ACETATE;DDAVP	5763407	DEC 23, 2013			
	018938	002	DESMOPRESSIN ACETATE;DDAVP	5763407	DEC 23, 2013			
	019955	001	DESMOPRESSIN ACETATE;DDAVP	5763407	DEC 23, 2013		I-40	MAR 25, 2001
	019955	002	DESMOPRESSIN ACETATE;DDAVP	5763407	DEC 23, 2013		I-40	MAR 25, 2001
	020713	001	DESOGESTREL;MIRCETTE				NP	APR 22, 2001
	020344	001	DEXFENFLURAMINE HYDROCHLORIDE;REDUX	4309445	FEB 19, 2004	U-133		
	020809	001	DICLOFENAC SODIUM;DICLOFENAC SODIUM	5603929	NOV 16, 2014	U-239		
				5653972	NOV 16, 2014	U-239		
	020037	001	DICLOFENAC SODIUM;VOLTAREN				I-213	FEB 25, 2001
	020148	001	DIHYDROERGOTAMINE MESYLATE;MIGRANAL	4758423	JUL 31, 2001			
				4462983	JUL 31, 2001	U-227		
				5169849	DEC 08, 2009			
						U-227		
	020401	001	DILTIAZEM HYDROCHLORIDE;TIAZAC				I-133	JAN 30, 2001
	020401	002	DILTIAZEM HYDROCHLORIDE;TIAZAC				I-133	JAN 30, 2001
	020401	003	DILTIAZEM HYDROCHLORIDE;TIAZAC				I-133	JAN 30, 2001
	020401	004	DILTIAZEM HYDROCHLORIDE;TIAZAC				I-133	JAN 30, 2001
	020401	005	DILTIAZEM HYDROCHLORIDE;TIAZAC				I-133	JAN 30, 2001
	020449	001	DOCETAXEL;TAXOTERE				I-231	JUN 22, 2001
	020690	001	DONEPEZIL HYDROCHLORIDE;ARICEPT	4895841	NOV 25, 2010			
	020690	002	DONEPEZIL HYDROCHLORIDE;ARICEPT	4895841	NOV 25, 2010			
	020869	001	DORZOLAMIDE HYDROCHLORIDE;COSOPT				NC	APR 07, 2001
>ADD>	020408	001	DORZOLAMIDE HYDROCHLORIDE;TRUSOPT	4797413	APR 28, 2008	U-103		
	020972	001	EFAVIRENZ;SUSTIVA				NCE	SEP 17, 2003
	020972	002	EFAVIRENZ;SUSTIVA				NCE	SEP 17, 2003
	020972	003	EFAVIRENZ;SUSTIVA				NCE	SEP 17, 2003
	020164	001	ENOXAPARIN SODIUM;LOVENOX				I-248	DEC 31, 2001
							I-217	JAN 30, 2001
							I-222	MAR 27, 2001
	020164	002	ENOXAPARIN SODIUM;LOVENOX				I-248	DEC 31, 2001
							I-222	MAR 27, 2001
							I-217	JAN 30, 2001

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020164	003	ENOXAPARIN SODIUM;LOVENOX				I-248	DEC 31, 2001
	020164	004	ENOXAPARIN SODIUM;LOVENOX				I-248	DEC 31, 2001
	020164	005	ENOXAPARIN SODIUM;LOVENOX				I-248	DEC 31, 2001
	020738	004	EPROSARTAN MESYLATE;TEVETEN	5185351	FEB 09, 2010	U-3	D-40	OCT 28, 2001
	020738	005	EPROSARTAN MESYLATE;TEVETEN	5185351	FEB 09, 2010	U-3	D-40	OCT 28, 2001
	020718	001	EPTIFIBATIDE;INTEGRILIN	5756451	NOV 11, 2014		NCE	MAY 18, 2003
				5686570	NOV 11, 2014			
				5807825	SEP 15, 2015	U-244		
	020718	002	EPTIFIBATIDE;INTEGRILIN	5756451	NOV 11, 2014		NCE	MAY 18, 2003
				5686570	NOV 11, 2014			
				5807825	SEP 15, 2015	U-244		
	020907	001	ESTRADIOL;ACTIVELLE				NC	NOV 18, 2001
							I-242	NOV 18, 2001
	020375	003	ESTRADIOL;CLIMARA	5223261	JUN 29, 2010			
	020870	001	ESTRADIOL;COMBIPATCH				NP	AUG 07, 2001
	020870	002	ESTRADIOL;COMBIPATCH				NP	AUG 07, 2001
	020847	001	ESTRADIOL;ESCLIM	4842864	MAR 25, 2008			
	020847	002	ESTRADIOL;ESCLIM	4842864	MAR 25, 2008			
	020847	003	ESTRADIOL;ESCLIM	4842864	MAR 25, 2008			
	020847	004	ESTRADIOL;ESCLIM	4842864	MAR 25, 2008			
	020847	005	ESTRADIOL;ESCLIM	4842864	MAR 25, 2008			
	020527	002	ESTROGENS, CONJUGATED;PREMPHASE 14/14	5547948	JAN 17, 2015			
	020527	001	ESTROGENS, CONJUGATED;PREMPRO 14/14	5547948	JAN 17, 2015			
	083209	001	ESTROGENS, ESTERIFIED;ESTRATAB				I-214	MAR 10, 2001
	086715	001	ESTROGENS, ESTERIFIED;ESTRATAB				I-214	MAR 10, 2001
	020363	001	FAMCICLOVIR;FAMVIR				NCE	JUN 29, 1999
							I-232	JUN 12, 2001
	020363	002	FAMCICLOVIR;FAMVIR				I-232	JUN 12, 2001
	020363	003	FAMCICLOVIR;FAMVIR				I-232	JUN 12, 2001
>ADD>	020325	001	FAMOTIDINE;PEPCID AC	5854267	DEC 29, 2015		D-47	NOV 09, 2001
>ADD>	020801	001	FAMOTIDINE;PEPCID AC	5677794	MAY 02, 2015			
>ADD>				4283408	OCT 15, 2000			
>ADD>				5854267	DEC 29, 2015			
	019510	004	FAMOTIDINE;PEPCID PRESERVATIVE FREE	4283408	OCT 15, 2000			
	020752	001	FAMOTIDINE;PEPCID RPD	4283408	OCT 15, 2000			
				4305502	DEC 15, 1998			
				4371516	JAN 31, 2000	U-241		
	020752	002	FAMOTIDINE;PEPCID RPD	4283408	OCT 15, 2000			
				4305502	DEC 15, 1998			
				4371516	JAN 31, 2000	U-241		
>ADD>	020747	001	FENTANYL CITRATE;ACTIQ	4671953	MAY 01, 2005	U-253		
>ADD>	020747	002	FENTANYL CITRATE;ACTIQ	4671953	MAY 01, 2005	U-253		
>ADD>	020747	003	FENTANYL CITRATE;ACTIQ	4671953	MAY 01, 2005	U-253		
>ADD>	020747	004	FENTANYL CITRATE;ACTIQ	4671953	MAY 01, 2005	U-253		
>ADD>	020747	005	FENTANYL CITRATE;ACTIQ	4671953	MAY 01, 2005	U-253		
>ADD>	020747	006	FENTANYL CITRATE;ACTIQ	4671953	MAY 01, 2005	U-253		
	020625	001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	4254129	FEB 18, 2001	U-139		
	020786	001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA-D	4254129	FEB 18, 2001		NCE	JUL 25, 2001
				5375693	AUG 03, 2012			
				5578610	NOV 26, 2013			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020788	001	FINASTERIDE;PROPECIA	5547957	OCT 15, 2013	U-236		
020180	001	FINASTERIDE;PROSCAR				I-221	MAR 20, 2001
018830	001	FLECAINIDE ACETATE;TAMBOCOR	4642384	FEB 10, 2004			
018830	002	FLECAINIDE ACETATE;TAMBOCOR	4642384	FEB 10, 2004			
018830	003	FLECAINIDE ACETATE;TAMBOCOR	4642384	FEB 10, 2004			
018830	004	FLECAINIDE ACETATE;TAMBOCOR	4642384	FEB 10, 2004			
018554	001	FLUTAMIDE;EULEXIN	4472382	SEP 18, 2001	U-24		
			5712251	SEP 18, 2001	U-216		
020121	001	FLUTICASONE PROPIONATE;FLONASE				I-224	OCT 31, 2000
020378	001	FOLLITROPIN ALFA/BETA;GONAL-F	4589402	JUL 26, 2004	U-242		
			5767251	JUN 16, 2015			
020378	002	FOLLITROPIN ALFA/BETA;GONAL-F	4589402	JUL 26, 2004	U-242		
			5767251	JUN 16, 2015			
020961	001	FOMIVIRSEN SODIUM;VITRAVENE PRESERVATIVE FREE				NCE	AUG 26, 2003
020450	001	FOSPHENYTOIN SODIUM;CEREBYX	4260769	APR 07, 2003			
020235	001	GABAPENTIN;NEURONTIN				D-43	SEP 29, 2001
020235	002	GABAPENTIN;NEURONTIN				D-43	SEP 29, 2001
020235	003	GABAPENTIN;NEURONTIN				D-43	SEP 29, 2001
020882	001	GABAPENTIN;NEURONTIN	4087544	JAN 16, 2000			
			4894476	MAY 02, 2008			
			5084479	JAN 02, 2010			
020882	002	GABAPENTIN;NEURONTIN	4087544	JAN 16, 2000			
			4894476	MAY 02, 2008			
			5084479	JAN 02, 2010			
019596	001	GADOPENTETATE DIMEGLUMINE;MAGNEVIST	5560903	OCT 01, 2013			
020460	001	GANCICLOVIR;CYTOVENE	4423050	MAY 21, 2001	U-64		
			4642346	JUN 24, 2005			
			4507305	MAY 12, 2001	U-64		
020509	001	GEMCITABINE HYDROCHLORIDE;GEMZAR				I-234	AUG 26, 2001
020509	002	GEMCITABINE HYDROCHLORIDE;GEMZAR				I-234	AUG 26, 2001
020695	001	GREPAFLOXACIN HYDROCHLORIDE;RAXAR	5563138	OCT 08, 2013			
020818	001	HYDROCHLOROTHIAZIDE;DIOVAN HCT	5399578	MAR 21, 2012	U-3	NCE	DEC 23, 2001
						NC	MAR 06, 2001
020818	002	HYDROCHLOROTHIAZIDE;DIOVAN HCT	5399578	MAR 21, 2012	U-3	NCE	DEC 23, 2001
						NC	MAR 06, 2001
020716	001	HYDROCODONE BITARTRATE;VICOPROFEN	4587252	DEC 18, 2004	U-55		
016295	002	HYDROXYUREA;DROXIA				ODE	FEB 25, 2005
016295	003	HYDROXYUREA;DROXIA				ODE	FEB 25, 2005
016295	004	HYDROXYUREA;DROXIA				ODE	FEB 25, 2005
019771	001	IBUPROFEN;ADVIL COLD AND SINUS	4552899	NOV 12, 2002			
			4552899*PED	MAY 12, 2003			
019833	002	IBUPROFEN;CHILDREN'S ADVIL	4788220	NOV 29, 2005			
			4788220*PED	MAY 29, 2006			
020589	001	IBUPROFEN;CHILDREN'S ADVIL	4788220	JUL 08, 2007		NP	JUN 16, 1998
			4788220*PED	JAN 08, 2008		PED	DEC 16, 1998
020944	001	IBUPROFEN;CHILDREN'S ADVIL				NP	NOV 15, 1999
020516	001	IBUPROFEN;CHILDREN'S MOTRIN	5374659	DEC 20, 2011		NP	JUN 16, 1998
			5374659*PED	JUN 20, 2012		PED	DEC 16, 1998
020601	001	IBUPROFEN;CHILDREN'S MOTRIN	5215755	JUN 01, 2010		NP	NOV 15, 1999
			5215755*PED	DEC 01, 2010		PED	MAY 15, 2000

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020603	001	IBUPROFEN;CHILDREN'S MOTRIN	5374659	DEC 20, 2011		NP	JUN 16, 1998
				5374659*PED	JUN 20, 2012		PED	DEC 16, 1998
	020267	002	IBUPROFEN;JUNIOR STRENGTH ADVIL				NP	JUN 16, 1998
							PED	DEC 16, 1998
	020944	002	IBUPROFEN;JUNIOR STRENGTH ADVIL				NP	NOV 15, 1999
	020601	003	IBUPROFEN;JUNIOR STRENGTH MOTRIN	5215755	JUN 01, 2010		NP	NOV 15, 1999
				5215755*PED	DEC 01, 2010		PED	MAY 15, 2000
	020602	001	IBUPROFEN;JUNIOR STRENGTH MOTRIN				NP	JUN 16, 1998
							PED	DEC 16, 1998
	019842	001	IBUPROFEN;MOTRIN	5374659	DEC 20, 2011			
				5374659*PED	JUN 20, 2012			
	020135	001	IBUPROFEN;MOTRIN	5215755	JUN 01, 2010			
				5320855	JUN 14, 2011			
				5215755*PED	DEC 01, 2010			
				5320855*PED	DEC 14, 2011			
	020135	002	IBUPROFEN;MOTRIN	5215755	JUN 01, 2010			
				5320855	JUN 14, 2011			
				5215755*PED	DEC 01, 2010			
				5320855*PED	DEC 14, 2011			
	020812	001	IBUPROFEN;PEDIATRIC ADVIL				NP	JUN 16, 1998
							PED	DEC 16, 1998
>ADD>	019763	001	IFOSFAMIDE;IFEX	4882452	MAR 03, 2008			
>ADD>	019763	002	IFOSFAMIDE;IFEX	4882452	MAR 03, 2008			
>ADD>	019763	003	IFOSFAMIDE;IFEX/MESNEX KIT	4882452	MAR 03, 2008			
>ADD>	019763	004	IFOSFAMIDE;IFEX/MESNEX KIT	4882452	MAR 03, 2008			
>ADD>	020367	001	IMIGLUCERASE;CEREZYME	5236838	AUG 17, 2010			
>ADD>				5549892	AUG 27, 2013	U-252		
	020923	001	IOVERSOL;OPTIRAY 240	4396598	DEC 30, 2002			
	020923	002	IOVERSOL;OPTIRAY 320	4396598	DEC 30, 2002			
	020923	003	IOVERSOL;OPTIRAY 350	4396598	DEC 30, 2002			
>ADD>	020316	001	IOXILAN;OXILAN-300	4954348	DEC 21, 2009			
>ADD>	020316	002	IOXILAN;OXILAN-350	4954348	DEC 21, 2009			
	020393	001	IPRATROPIUM BROMIDE;ATROVENT				I-223	APR 01, 2001
	020394	001	IPRATROPIUM BROMIDE;ATROVENT				I-243	NOV 09, 2001
	020571	001	IRINOTECAN HYDROCHLORIDE;CAMPTOSAR	4604463	AUG 20, 2007			
	020083	001	ITRACONAZOLE;SPORANOX	5633015	MAY 27, 2014			
	020657	001	ITRACONAZOLE;SPORANOX	4267179	JUN 23, 2000			
				5707975	JAN 13, 2015			
				4727064	FEB 23, 2005			
	019927	001	KETOCONAZOLE;NIZORAL	4942162	FEB 11, 2003			
	020310	001	KETOCONAZOLE;NIZORAL A-D	4942162	FEB 11, 2003	U-245		
				4335125	JUN 15, 1999			
				5456851	APR 07, 2014			
>ADD>	020857	001	LAMIVUDINE;COMBIVIR	5859021	MAY 15, 2012	U-248		
>ADD>	021003	001	LAMIVUDINE;EPIVIR-HBV	5047407	FEB 08, 2009			
>ADD>				5532246	JUL 02, 2013	U-250		
>ADD>	021004	001	LAMIVUDINE;EPIVIR-HBV	5047407	FEB 08, 2009			
>ADD>				5532246	JUL 02, 2013	U-250		
	020241	001	LAMOTRIGINE;LAMICTAL				I-247	DEC 14, 2001
							ODE	AUG 24, 2005
							I-238	AUG 24, 2001

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020241	002	LAMOTRIGINE;LAMICTAL				I-247	DEC 14, 2001
						ODE	AUG 24, 2005
						I-238	AUG 24, 2001
020241	003	LAMOTRIGINE;LAMICTAL				I-247	DEC 14, 2001
						ODE	AUG 24, 2005
						I-238	AUG 24, 2001
020241	004	LAMOTRIGINE;LAMICTAL				I-247	DEC 14, 2001
						ODE	AUG 24, 2005
						I-238	AUG 24, 2001
020241	005	LAMOTRIGINE;LAMICTAL				I-247	DEC 14, 2001
						ODE	AUG 24, 2005
						I-238	AUG 24, 2001
020241	006	LAMOTRIGINE;LAMICTAL				I-247	DEC 14, 2001
						ODE	AUG 24, 2005
						I-238	AUG 24, 2001
020764	001	LAMOTRIGINE;LAMICTAL CD	5698226	JAN 29, 2012		ODE	AUG 24, 2005
			4602017	JUL 22, 2008	U-106	I-238	AUG 24, 2001
020764	002	LAMOTRIGINE;LAMICTAL CD	5698226	JAN 29, 2012		ODE	AUG 24, 2005
			4602017	JUL 22, 2008	U-106	I-238	AUG 24, 2001
020764	003	LAMOTRIGINE;LAMICTAL CD	5698226	JAN 29, 2012		ODE	AUG 24, 2005
			4602017	JUL 22, 2008	U-106	I-238	AUG 24, 2001
020406	001	LANSOPRAZOLE;PREVACID				I-227	MAR 12, 2001
						D-42	JUL 20, 2001
020406	002	LANSOPRAZOLE;PREVACID				I-227	MAR 12, 2001
						D-42	JUL 20, 2001
020905	001	LEFLUNOMIDE;ARAVA	4284786	DEC 13, 1999	U-247	NCE	SEP 10, 2003
			4351841	DEC 13, 1999	U-247		
			5679709	OCT 21, 2014	U-247		
020905	002	LEFLUNOMIDE;ARAVA	4284786	DEC 13, 1999	U-247	NCE	SEP 10, 2003
			4351841	DEC 13, 1999	U-247		
			5679709	OCT 21, 2014	U-247		
020905	003	LEFLUNOMIDE;ARAVA	4284786	DEC 13, 1999	U-247	NCE	SEP 10, 2003
			4351841	DEC 13, 1999	U-247		
			5679709	OCT 21, 2014	U-247		
020807	001	LEPIRUDIN;REFLUDAN	5180668	JAN 19, 2010		ODE	MAR 06, 2005
						NCE	MAR 06, 2003
019732	001	LEUPROLIDE ACETATE;LUPRON DEPOT	5716640	SEP 02, 2013			
020011	001	LEUPROLIDE ACETATE;LUPRON DEPOT	5716640	SEP 02, 2013			
020517	001	LEUPROLIDE ACETATE;LUPRON DEPOT	5716640	SEP 02, 2013			
020263	002	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5716640	SEP 02, 2013			
020263	003	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5716640	SEP 02, 2013			
020263	004	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5716640	SEP 02, 2013			
020263	005	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5716640	SEP 02, 2013			
020263	006	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5716640	SEP 02, 2013			
020708	001	LEUPROLIDE ACETATE;LUPRON DEPOT-3	5716640	SEP 02, 2013			
020517	002	LEUPROLIDE ACETATE;LUPRON DEPOT-4	5716640	SEP 02, 2013			
020634	001	LEVOFLOXACIN;LEVAQUIN				I-246	DEC 17, 2001
020634	002	LEVOFLOXACIN;LEVAQUIN				I-246	DEC 17, 2001
020635	001	LEVOFLOXACIN;LEVAQUIN				I-246	DEC 17, 2001

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020635	002	LEVOFLOXACIN;LEVAQUIN IN DEXTROSE 5%				I-246	DEC 17, 2001
	020635	003	LEVOFLOXACIN;LEVAQUIN IN DEXTROSE 5%				I-246	DEC 17, 2001
	019941	001	LIDOCAINE;EMLA				I-215	FEB 04, 2001
	020962	001	LIDOCAINE;EMLA				NP	FEB 04, 2001
	020606	001	LOPERAMIDE HYDROCHLORIDE;IMODIUM ADVANCED	5716641	MAY 21, 2012	U-226		
	020803	001	LOTEPREDNOL ETABONATE;ALREX	4996335	FEB 26, 2008		NCE	MAR 09, 2003
				5540930	OCT 25, 2013			
	020583	001	LOTEPREDNOL ETABONATE;LOTEMAX	4996335	FEB 26, 2008		NCE	MAR 09, 2003
				5540930	OCT 25, 2013			
	020841	001	LOTEPREDNOL ETABONATE;LOTEMAX	4996335	FEB 26, 2008		NCE	MAR 09, 2003
				5540930	OCT 25, 2013			
	019832	003	MAFENIDE ACETATE;SULFAMYLON				NDF	JUN 05, 2001
							ODE	JUN 05, 2005
	020652	001	MANGAFODIPIR TRISODIUM;TESLASCAN	4933456	JUN 12, 2007			
				4992554	FEB 12, 2008			
				5091169	FEB 25, 2009			
				5223243	JUN 29, 2010	U-237		
				4647447	MAR 03, 2004	U-238		
	019618	001	MESALAMINE;ROWASA	4657900	APR 14, 2004			
				RE33239	MAY 12, 2004			
	020208	001	METRONIDAZOLE;METROGEL-VAGINAL				D-40	MAY 16, 2000
	020901	001	METRONIDAZOLE;METROLOTION				NDF	NOV 24, 2001
	020827	001	MICONAZOLE NITRATE;MONISTAT 3				NP	MAR 30, 2001
	018654	001	MIDAZOLAM HYDROCHLORIDE;VERSED	4280957	DEC 20, 1999			
				4280957*PED	JUN 20, 2000			
	018654	002	MIDAZOLAM HYDROCHLORIDE;VERSED	4280957	DEC 20, 1999			
				4280957*PED	JUN 20, 2000			
	020942	001	MIDAZOLAM HYDROCHLORIDE;VERSED	4280957	DEC 20, 1999		PED	APR 15, 2002
				4280957*PED	JUN 20, 2000		NDF	OCT 15, 2001
	020415	003	MIRTAZAPINE;REMERON				NCE	JUN 14, 2001
	020717	001	MODAFINIL;PROVIGIL				ODE	DEC 24, 2005
							NCE	DEC 24, 2003
	020717	002	MODAFINIL;PROVIGIL				ODE	DEC 24, 2005
							NCE	DEC 24, 2003
	020762	001	MOMETASONE FUROATE MONOHYDRATE;NASONEX	4472393	SEP 18, 2001			
				5837699	JAN 27, 2014	U-249		
	020829	002	MONTELUKAST SODIUM;SINGULAIR	5565473	NOV 30, 2010	U-228	NCE	FEB 20, 2003
	020830	001	MONTELUKAST SODIUM;SINGULAIR	5565473	NOV 30, 2010	U-228	NCE	FEB 20, 2003
>ADD>	020763	001	NARATRIPTAN HYDROCHLORIDE;AMERGE	4997841	AUG 12, 2008	U-232	NCE	FEB 10, 2003
>ADD>	020763	002	NARATRIPTAN HYDROCHLORIDE;AMERGE	4997841	AUG 12, 2008	U-232	NCE	FEB 10, 2003
	020636	001	NEVIRAPINE;VIRAMUNE				D-49	SEP 11, 2001
	020933	001	NEVIRAPINE;VIRAMUNE				NDF	SEP 11, 2001
							NCE	JUN 21, 2001
	020536	001	NICOTINE;NICOTROL	4915950	FEB 12, 2008			
	020555	001	NIZATIDINE;AXID AR				I-220	APR 01, 2001
							D-39	APR 01, 2001
	020799	001	OFLOXACIN;FLOXIN				NDF	DEC 16, 2000
	020688	001	OLOPATADINE HYDROCHLORIDE;PATANOL	5116863	DEC 18, 2010			
	019810	001	OMEPRAZOLE;PRILOSEC				I-229	JUN 29, 2001

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	019810	002	OMEPRAZOLE;PRILOSEC	4786505	APR 20, 2007	U-108	I-229	JUN 29, 2001
>ADD>				4255431	APR 05, 2001	U-108		
>ADD>				4853230	APR 20, 2007	U-108		
>ADD>				4636499	MAY 30, 2005			
>ADD>				5093342	FEB 02, 2010	U-166		
>ADD>				5599794	FEB 04, 2014	U-166		
>ADD>				5629305	FEB 04, 2014	U-188		
	020932	002	OXYCODONE HYDROCHLORIDE;ROXICODONE				NS	OCT 26, 2001
							NP	OCT 26, 2001
	020262	001	PACLITAXEL;TAXOL				I-226	APR 09, 2001
>ADD>							I-230	JAN 08, 2002
	020819	001	PARICALCITOL;ZEMPLAR				NCE	APR 17, 2003
	020710	001	PAROXETINE HYDROCHLORIDE;PAXIL	5811436	SEP 22, 2015			
	020237	001	PILOCARPINE HYDROCHLORIDE;SALAGEN				ODE	FEB 11, 2005
							I-212	FEB 11, 2001
	020451	001	PORFIMER SODIUM;PHOTOFRIN	5145863	DEC 15, 2009	U-129	I-241	DEC 22, 2001
	020667	001	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	DEC 12, 2006			
				4843086	JUN 27, 2006	U-231		
	020667	002	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	DEC 12, 2006			
				4843086	JUN 27, 2006	U-231		
	020667	003	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	DEC 12, 2006			
				4843086	JUN 27, 2006	U-231		
	020667	004	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	DEC 12, 2006			
				4843086	JUN 27, 2006	U-231		
	020667	005	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	DEC 12, 2006			
				4843086	JUN 27, 2006	U-231		
	019898	002	PRAVASTATIN SODIUM;PRAVACHOL				I-225	MAR 27, 2001
	019898	003	PRAVASTATIN SODIUM;PRAVACHOL				I-225	MAR 27, 2001
	019898	004	PRAVASTATIN SODIUM;PRAVACHOL				I-225	MAR 27, 2001
	019781	001	PROGESTERONE;PROMETRIUM				NP	MAY 14, 2001
	019627	002	PROPOFOL;DIPRIVAN	5731355	MAR 22, 2015	U-217		
				5731356	MAR 22, 2015	U-218		
>ADD>	019885	001	QUINAPRIL HYDROCHLORIDE;ACCUPRIL	5747504	APR 10, 2005	U-210		
>ADD>	019885	002	QUINAPRIL HYDROCHLORIDE;ACCUPRIL	5747504	APR 10, 2005	U-210		
>ADD>	019885	003	QUINAPRIL HYDROCHLORIDE;ACCUPRIL	5747504	APR 10, 2005	U-210		
>ADD>	019885	004	QUINAPRIL HYDROCHLORIDE;ACCUPRIL	5747504	APR 10, 2005	U-210		
	020815	001	RALOXIFENE HYDROCHLORIDE;EVISTA	4418068	APR 03, 2001			
				5393763	JUL 28, 2012	U-114		
				5457117	JUL 28, 2012	U-114		
				5478847	MAR 02, 2014	U-114		
	019090	001	RANITIDINE HYDROCHLORIDE;ZANTAC	4585790	MAY 11, 2004			
				4521431	JUN 04, 2002			
				4521431*PED	DEC 04, 2002			
				4585790*PED	NOV 11, 2004			
	019593	001	RANITIDINE HYDROCHLORIDE;ZANTAC	4585790	MAY 11, 2004			
				4521431	JUN 04, 2002	U-121		
				4585790*PED	NOV 11, 2001			
				4521431*PED	DEC 04, 2002			
	019593	002	RANITIDINE HYDROCHLORIDE;ZANTAC	4585790	MAY 11, 2004			
				4521431	JUN 04, 2002	U-121		
				4585790*PED	NOV 11, 2004			
				4521431*PED	DEC 04, 2002			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	019675	001	RANITIDINE HYDROCHLORIDE;ZANTAC	4585790	MAY 11, 2004			
				4521431	JUN 04, 2002			
				5068249	NOV 26, 2008			
				5068249*PED	MAY 26, 2009			
				4521431*PED	DEC 04, 2002			
				4585790*PED	NOV 11, 2004			
	018703	001	RANITIDINE HYDROCHLORIDE;ZANTAC 150	4880636	MAY 13, 2008			
				4521431	JUN 04, 2002			
				4521431*PED	DEC 04, 2002			
				4880636*PED	NOV 13, 2008			
	020095	001	RANITIDINE HYDROCHLORIDE;ZANTAC 150	5028432	FEB 22, 2010			
				4521431	JUN 04, 2002			
				4521431*PED	DEC 04, 2002			
				5028432*PED	AUG 22, 2010			
	020251	001	RANITIDINE HYDROCHLORIDE;ZANTAC 150	5102665	JUN 23, 2009			
				4521431	JUN 04, 2002			
				4521431*PED	DEC 04, 2002			
				5102665*PED	DEC 23, 2009			
	020251	002	RANITIDINE HYDROCHLORIDE;ZANTAC 150	5102665	JUN 23, 2009			
				4521431	JUN 04, 2002			
				4521431*PED	DEC 04, 2002			
				5102665*PED	DEC 23, 2009			
	018703	002	RANITIDINE HYDROCHLORIDE;ZANTAC 300	4880636	MAY 13, 2008			
				4521431	JUN 04, 2002			
				4521431*PED	DEC 04, 2002			
				4880636*PED	NOV 13, 2008			
	020095	002	RANITIDINE HYDROCHLORIDE;ZANTAC 300	5028432	FEB 22, 2010			
				4521431	JUN 04, 2002			
				4521431*PED	DEC 04, 2002			
				5028432*PED	AUG 22, 2010			
	020520	001	RANITIDINE HYDROCHLORIDE;ZANTAC 75	4521431	JUN 04, 2002		I-228	JUN 08, 2001
				4880636	MAY 13, 2008		PED	JUN 19, 1999
				4880636*PED	NOV 13, 2008		PED	DEC 08, 2001
				4521431*PED	DEC 04, 2002			
	020903	001	RIBAVIRIN;REBETOL	4530901	JUL 23, 2002		I-249	DEC 09, 2001
				4211771	JUL 08, 1999	U-234	NP	JUN 03, 2001
				5767097	JAN 23, 2016	U-235		
	021024	001	RIFAPENTINE;PRIFTIN				NCE	JUN 22, 2003
							ODE	JUN 22, 2005
	020835	001	RISEDRONATE SODIUM;ACTONEL	5583122	DEC 10, 2013	U-222	NCE	MAR 27, 2003
	020272	005	RISPERIDONE;RISPERDAL	5158952	OCT 27, 2009		D-37	OCT 17, 2000
	020659	001	RITONAVIR;NORVIR	5846987	DEC 29, 2012	U-190		
	020680	001	RITONAVIR;NORVIR	5846987	DEC 29, 2012	U-190		
>ADD>	020864	001	RIZATRIPTAN BENZOATE;MAXALT	5602162	FEB 11, 2014	U-240	NCE	JUN 29, 2003
				5298520	JAN 28, 2012	U-240		
>ADD>	020864	002	RIZATRIPTAN BENZOATE;MAXALT	5602162	FEB 11, 2014	U-240	NCE	JUN 29, 2003
				5298520	JAN 28, 2012	U-240		
>ADD>	020865	001	RIZATRIPTAN BENZOATE;MAXALT-MLT	5602162	FEB 11, 2014	U-240	NCE	JUN 29, 2003
				4305502	DEC 15, 1998			
				5298520	JAN 28, 2012	U-240		
				4758598	DEC 15, 1998			
				4371516	FEB 01, 2000			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020865	002	RIZATRIPTAN BENZOATE;MAXALT-MLT	5602162	FEB 11, 2014	U-240	NCE	JUN 29, 2003
				4305502	DEC 15, 1998			
				5298520	JAN 28, 2012	U-240		
				4758598	DEC 15, 1998			
				4371516	FEB 01, 2000			
	020533	001	ROPIVACAINE HYDROCHLORIDE MONOHYDRATE;NAROPIN	4870086	JUL 28, 2010			
	020533	003	ROPIVACAINE HYDROCHLORIDE MONOHYDRATE;NAROPIN	4870086	JUL 28, 2010			
	020533	004	ROPIVACAINE HYDROCHLORIDE MONOHYDRATE;NAROPIN	4870086	JUL 28, 2010			
	020533	005	ROPIVACAINE HYDROCHLORIDE MONOHYDRATE;NAROPIN	4870086	JUL 28, 2010			
	020772	001	SACROSIDASE;SUCRAID				ODE	APR 09, 2005
							NCE	APR 09, 2003
	020236	001	SALMETEROL XINAFOATE;SEREVENT	5126375	FEB 12, 2008		I-216	FEB 05, 2001
	020692	001	SALMETEROL XINAFOATE;SEREVENT	5225445	FEB 12, 2008	U-211	I-237	SEP 25, 2001
				5380922	JAN 10, 2012		I-236	SEP 25, 2001
				5590645	MAR 01, 2011			
				5126375	FEB 12, 2008			
				D342994	JAN 04, 2008			
	020828	001	SAQUINAVIR;FORTOVASE	5196438	NOV 19, 2012			
	020443	001	SERMORELIN ACETATE;GEREF	4517181	MAY 14, 2002			
				4703035	DEC 28, 2004			
	020443	002	SERMORELIN ACETATE;GEREF	4517181	MAY 14, 2002			
				4703035	DEC 28, 2004			
	020926	001	SEVELAMER HYDROCHLORIDE;RENAGEL	5496545	AUG 11, 2013	U-246	NCE	OCT 30, 2003
				5667775	SEP 16, 2014	U-246		
	020895	001	SILDENAFIL CITRATE;VIAGRA	5250534	JUN 18, 2011		NCE	MAR 27, 2003
	020895	002	SILDENAFIL CITRATE;VIAGRA	5250534	JUN 18, 2011		NCE	MAR 27, 2003
	020895	003	SILDENAFIL CITRATE;VIAGRA	5250534	JUN 18, 2011		NCE	MAR 27, 2003
	020773	001	SIMETHICONE-CELLULOSE;SONORX				NP	OCT 29, 2001
	019766	001	SIMVASTATIN;ZOCOR	4444784	DEC 23, 2005	U-59	D-46	JUL 10, 2001
							I-239	JUL 10, 2001
	019766	002	SIMVASTATIN;ZOCOR	4444784	DEC 23, 2005	U-59	D-46	JUL 10, 2001
							I-239	JUL 10, 2001
	019766	003	SIMVASTATIN;ZOCOR	4444784	DEC 23, 2005	U-59	D-46	JUL 10, 2001
							I-239	JUL 10, 2001
	019766	004	SIMVASTATIN;ZOCOR	4444784	DEC 23, 2005	U-59	D-46	JUL 10, 2001
							I-239	JUL 10, 2001
>ADD>	019766	005	SIMVASTATIN;ZOCOR	4444784	DEC 23, 2005	U-59	NS	JUL 10, 2001
							I-239	JUL 10, 2001
							D-46	JUL 10, 2001
	019676	001	SOMATROPIN, BIOSYNTHETIC;NUTROPIN				ODE	OCT 29, 2004
	019676	002	SOMATROPIN, BIOSYNTHETIC;NUTROPIN				ODE	OCT 29, 2004
	020181	001	SOYBEAN OIL;LIPOSYN III 30%				NP	JAN 13, 2001
	020626	001	SUMATRIPTAN;IMITREX	5037845	AUG 06, 2008			
				5307953	DEC 02, 2012			
				5554639	SEP 10, 2013	U-232		
				5705520	DEC 10, 2011	U-232		
	020626	002	SUMATRIPTAN;IMITREX	5037845	AUG 06, 2008			
				5307953	DEC 02, 2012			
				5554639	SEP 10, 2013	U-232		
				5705520	DEC 10, 2011	U-232		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020626	003	SUMATRIPTAN;IMITREX	5037845	AUG 06, 2008			
				5307953	DEC 02, 2012			
				5554639	SEP 10, 2013	U-232		
				5705520	DEC 10, 2011	U-232		
	017970	001	TAMOXIFEN CITRATE;NOLVADEX				I-244	OCT 29, 2001
	017970	002	TAMOXIFEN CITRATE;NOLVADEX				I-244	OCT 29, 2001
	020887	001	TECHNETIUM TC-99M APCITIDE;ACUTECT	5508020	APR 16, 2013		NCE	SEP 14, 2003
				5645815	JUL 08, 2014			
				5443815	AUG 22, 2012			
>ADD>	020850	001	TELMISARTAN;MICARDIS	5591762	JAN 07, 2014	U-3	NCE	NOV 10, 2003
>ADD>	020850	002	TELMISARTAN;MICARDIS	5591762	JAN 07, 2014	U-3	NCE	NOV 10, 2003
	020791	001	TESTOSTERONE;TESTODERM	4379454	FEB 17, 2001			
	020785	001	THALIDOMIDE;THALOMID				NCE	JUL 16, 2003
							ODE	JUL 16, 2005
	020898	001	THYROTROPIN ALFA;THYROGEN				ODE	NOV 30, 2005
							NCE	NOV 30, 2003
	020912	001	TIROFIBAN HYDROCHLORIDE;AGGRASTAT	5292756	MAR 08, 2011	U-230	NCE	MAY 14, 2003
				5658929	MAR 08, 2011			
				5733919	OCT 23, 2016			
	020913	001	TIROFIBAN HYDROCHLORIDE;AGGRASTAT	5292756	MAR 08, 2011	U-230	NCE	MAY 14, 2003
				5658929	MAR 08, 2011			
				5733919	OCT 23, 2016			
	020697	001	TOLCAPONE;TASMAR	5236952	AUG 17, 2010		NCE	JAN 29, 2003
				5476875	DEC 19, 2012	U-219		
	020697	002	TOLCAPONE;TASMAR	5236952	AUG 17, 2010		NCE	JAN 29, 2003
				5476875	DEC 19, 2012	U-219		
	020771	001	TOLTERODINE TARTRATE;DETROL	5382600	JAN 17, 2012		NCE	MAR 25, 2003
	020771	002	TOLTERODINE TARTRATE;DETROL	5382600	JAN 17, 2012		NCE	MAR 25, 2003
>ADD>	020505	001	TOPIRAMATE;TOPAMAX	4513006	SEP 26, 2003			
>ADD>	020505	002	TOPIRAMATE;TOPAMAX	4513006	SEP 26, 2003			
>ADD>	020505	003	TOPIRAMATE;TOPAMAX	4513006	SEP 26, 2003			
>ADD>	020505	004	TOPIRAMATE;TOPAMAX	4513006	SEP 26, 2003			
>ADD>	020505	005	TOPIRAMATE;TOPAMAX	4513006	SEP 26, 2003			
>ADD>	020505	006	TOPIRAMATE;TOPAMAX	4513006	SEP 26, 2003		NCE	DEC 24, 2001
>ADD>	020844	001	TOPIRAMATE;TOPAMAX SPRINKLE	4513006	SEP 26, 2003		NCE	DEC 24, 2001
>ADD>	020844	002	TOPIRAMATE;TOPAMAX SPRINKLE	4513006	SEP 26, 2003		NCE	DEC 24, 2001
>ADD>	020844	003	TOPIRAMATE;TOPAMAX SPRINKLE	4513006	SEP 26, 2003		NCE	DEC 24, 2001
	020671	001	TOPOTECAN HYDROCHLORIDE;HYCAMTIN	5004758	MAY 28, 2010			
	020137	002	TORSEMIDE;DEMADEX				D-38	FEB 13, 2001
	020281	001	TRAMADOL HYDROCHLORIDE;ULTRAM				D-44	AUG 21, 2001
	020281	002	TRAMADOL HYDROCHLORIDE;ULTRAM				D-44	AUG 21, 2001
	020528	001	TRANDOLAPRIL;MAVIK	5744496	APR 28, 2015	U-229		
	020528	002	TRANDOLAPRIL;MAVIK	5744496	APR 28, 2015	U-229		
	020528	003	TRANDOLAPRIL;MAVIK	5744496	APR 28, 2015	U-229		
>ADD>	020719	001	TROGLITAZONE;PRELAY	5859037	NOV 13, 2017	U-251		
				4572912	NOV 09, 2008			
>ADD>	020719	002	TROGLITAZONE;PRELAY	5859037	NOV 13, 2017	U-251		
				4572912	NOV 09, 2008			
>ADD>	020719	003	TROGLITAZONE;PRELAY	5859037	NOV 13, 2017	U-251		
				4572912	NOV 09, 2008			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020720	001	TROGLITAZONE;REZULIN	5859037	NOV 13, 2017	U-251		
				4572912	NOV 09, 2008			
>ADD>	020720	002	TROGLITAZONE;REZULIN	5859037	NOV 13, 2017	U-251		
				4572912	NOV 09, 2008			
>ADD>	020720	003	TROGLITAZONE;REZULIN	5859037	NOV 13, 2017	U-251		
				4572912	NOV 09, 2008			
	020586	001	UREA, C-13;MERETEK UBT KIT (W/ PRANACTIN)	4830010	OCT 27, 2009	U-147		
	020675	001	URSODIOL;URSO	4859660	AUG 22, 2006			
	020892	001	VALRUBICIN;VALSTAR PRESERVATIVE FREE				NCE	SEP 25, 2003
							ODE	SEP 25, 2005
	020699	001	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	4535186	DEC 13, 2007			
	020699	002	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	4535186	DEC 13, 2007			
	020699	003	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	4535186	DEC 13, 2007			
	020699	004	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	4535186	DEC 13, 2007			
	020943	001	VERAPAMIL HYDROCHLORIDE;VERELAN PM				NP	NOV 25, 2001
	020943	002	VERAPAMIL HYDROCHLORIDE;VERELAN PM				NP	NOV 25, 2001
	020943	003	VERAPAMIL HYDROCHLORIDE;VERELAN PM				NP	NOV 25, 2001
	020388	001	VINORELBINE TARTRATE;NAVELBINE	4307100	JUL 08, 2002			
	020547	001	ZAFIRLUKAST;ACCOLATE	4859692	SEP 27, 2010			
>ADD>	020518	002	ZIDOVUDINE;RETROVIR	4724232	SEP 17, 2005			
>ADD>				4818538	SEP 17, 2005			
>ADD>				4833130	SEP 17, 2005			
>ADD>				4828838	SEP 17, 2005			
>ADD>				4837208	SEP 17, 2005			
	020471	001	ZILEUTON;ZYFLO	4873259	DEC 10, 2010	U-168		
	020471	003	ZILEUTON;ZYFLO	4873259	DEC 10, 2010	U-168		
>ADD>	020768	001	ZOLMITRIPTAN;ZOMIG	5863935	NOV 14, 2012			
>ADD>	020768	002	ZOLMITRIPTAN;ZOMIG	5863935	NOV 14, 2012			

*U.S. Government Printing Office: 1999 — 454-723/00006

New 19th Edition



APPROVED DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

19TH EDITION

Superintendent of Documents Subscription Order Form

Order Processing Code
* 8240

Charge your order. It's easy!

MasterCard VISA

☐ **Yes,** enter my subscription as follows:

__ subscriptions of **APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS**, ADP, and the monthly Cumulative Supplements, for $78.00 per year.

The total cost of my order is $_____. Price includes regular shipping and handling and is subject to change. International customers please add 25%.

For privacy protection, check the box below:

☐ Do not make my name available to other mailers.

Please choose method of payment:

☐ Check payable to Superintendent of Documents
☐ GPO Deposit Account ☐☐☐☐☐☐☐☐–☐☐
☐ VISA or MasterCard
☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐

_____
(Credit card expiration date)

Thank you for your order!

_____
(Authorizing Signature)

(10/98)

_____
Company or personal name

_____
Additional address/attention line

_____
Street address

_____
City, State, ZIP Code

(_____)_____
Daytime phone including area code

_____
Purchase Order No. (optional)

Mail To: Superintendent of Documents, Government Printing Office, P.O. Box 371954 Pittsburgh, PA 15250-7954
To **FAX** your charge order, call (202) 512-2250.
To charge your subscription call (202) 512-1800.